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Abstract
Arginine methylation is catalyzed by the protein arginine methyltransferase
(PRMT) family of enzymes, which transfer a methyl group from S-adenosylmethionine
(SAM) to the guanidinium group of an arginine residue. This reaction first produces
monomethylated arginine (MMA) that can then be further methylated to produce either
asymmetrically dimethylated arginine (ADMA) or symmetrically dimethylated arginine
(SDMA). There are nine PRMT family members described to date, with PRMT1 as the
predominant member, suggested to be responsible for ~85% of asymmetric
dimethylation. In addition, PRMT1-dependent methylation likely plays a significant role
in a plethora of diseases (e.g., cancer, heart disease, and ALS). These observations
render it imperative that the isozyme be more thoroughly characterized and suggests that
potent and selective inhibitors may be useful as therapeutics.
Herein we describe our efforts to decode PRMT1-dependent methylation by
investigating the catalytic mechanism, the effects of post-translational modifications and
protein-protein interactions on activity, the development of potent and selective inhibitors
and inactivators, as well as examining crosstalk between arginine methylation and
phosphorylation.

Using site-directed mutagenesis and unnatural amino acid

incorporation, we have identified key active site residues that are critical for catalysis
and/or substrate binding, and have determined the effects of phosphorylation, if any, on
enzyme activity. In vitro assays with known interacting proteins has increased our

vi

knowledge of the regulation of PRMT1 activity by protein-protein interactions. The use
of MS/MS analysis aided in the identification of the site of modification for a potent
inactivator of the isozyme, C21, and has led to the design of new inhibitors and
inactivators that will likely be more potent and selective for not only PRMT1, but
PRMT5 as well. Finally, using a peptide based model, we began to investigate crosstalk
between arginine methylation and serine/threonine phosphorylation within kinase
consensus sequences and hypothesize that it is an important means of regulation in
regards to cell signaling. Overall, the results presented in the following chapters have
enhanced our understanding of PRMT1-dependent methylation and have opened doors
for future studies involving the regulation of the enzyme and inhibitor design.
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CHAPTER 1
Introduction
1.1 Post-Translational Modifications
Post-translational modifications (PTMs) of proteins are well-known for the
variety of roles they play in controlling cellular functions. With over 400 different
experimentally determined types (Khoury et al. 2011), PTMs add to the diversity of the
already complex nature of the proteome by influencing protein-protein interactions, the
cellular location of proteins, and protein stability through alterations to the size, charge,
and hydrogen bonding capabilities of the parent residues (Figure 1.1). These processes
are the basis for a plethora of cellular functions (e.g., transcription and signal
transduction) that are vital to the maintenance, growth, and survival of healthy cells. Due
to their fundamental roles in the cell, the dysregulation of various PTMs has been
associated with a wide range of diseases (e.g., cancer and autoimmune diseases), thus
making the responsible enzymes attractive drug targets.
1.2 Modification of Histones
The most notable and well-studied group of modified proteins are the histones.
In the nucleus, two of each of the four core histones (i.e., H2A, H2B, H3, and H4) come
together as an octamer around which DNA is wrapped and held in place by histone H1 to
form a complex known as the nucleosome. Nucleosomes are further packaged into
chromatin, and it is the state of the chromatin (i.e., decondensed vs. condensed) that
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Figure 1.1 Selected post-translational modiﬁcations of arginine, lysine, serine,
threonine, and tyrosine. (A) Arginine residues can be mono- and dimethylated by the
PRMTs to form ω-MMA, ADMA, or SDMA. They can also be converted to
citrulline by the PADs. (B) Lysine residues can be mono-, di-, and trimethylated by
KMTs, acetylated by KATs, or ubiquitinated by ubiquitin ligases. (C) Serine,
threonine, and tyrosine residues can be phosphorylated by kinases.
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dictates whether genes are transcribed. PTMs on the unstructured N-terminal tails of
histones are responsible for switching the transcription of genes on and off using what
has been termed the histone code (Figure 1.2). For example, specific modifications can

Figure 1.2 Post-translational modifications of histones.
cause the destabilization of chromatin via the disruption of key interactions between
DNA and histones (i.e., electrostatic interactions), such as in the case of acetylation of
lysine 16 on histone H4 and the inhibition of heterochromatin formation (Shogren-Knaak
et al. 2006 & Bannister et al. 2011). They can also aid in the recruitment of the
transcriptional machinery through protein domains that are capable of binding such
PTMs (e.g., bromo-, chromo-, tudor-, and pleckstrin-homology (PH) domains (reviewed
in Kouzarides et al. 2007). In terms of blocking transcription, a modification can also
recruit a particular protein that stabilizes chromatin and silences genes, as in the case of
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tri-methylated lysine 9 of histone H3 and its recruitment of heterochromatin protein 1
(HP1) (Canzio et al. 2011).
1.3 Crosstalk Between Post-Translational Modifications1
Over the last decade there have been several examples of crosstalk between two
or more different post-translational modifications (PTMs), with many of these being
observed within the context of histones. Generally, this crosstalk is thought to modulate
and fine-tune cell signaling cascades such that a desired outcome is achieved e.g.,
transcription of a particular gene or, alternatively, activation of one gene under the
control of a transcription factor and repression of another. Although crosstalk between
two or more PTMs has predominantly been studied within the context of chromatin
biology (Suganuma et al. 2008 and Lee et al. 2010), as one would expect, this type of
regulatory mechanism extends to non-histone proteins as well. Several models have been
proposed for histone crosstalk (Fischle 2003 et al., Schreiber et al. 2002, Fischle et al.
2008), and they are readily applied to non-histone proteins as well (Figure 1.3). For
example, cis crosstalk refers to communication between modifications on the same
protein (Figure 1.3A). Within cis crosstalk lies the possibility for adjacent crosstalk (i.e.,
between residues that are close to one another in both the primary and tertiary structures)
or distal crosstalk (i.e., between residues that are far apart in both the primary and tertiary
structures) (Figure 1.3A).

Trans crosstalk is also possible and occurs between

modifications on two different proteins (Figure 1.3B). Functionally, direct crosstalk
refers to one PTM directly affecting the modification of a second residue (e.g.,
modification of one residue prevents the modification of another residue) (Figure 1.3C).
1

Adapted with permission from Rust, H.L.; Thompson, P.R., Kinase consensus sequences: a breeding
ground for crosstalk. ACS chemical biology 2011, 6 (9), 881-892. Copyright 2013 American Chemical
Society.
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Figure 1.3 Crosstalk scenarios. (A) The cis-eﬀect refers to crosstalk
between two or more modiﬁcations located on the same protein.
Within the same protein there can be adjacent (i.e., between residues
that are close in both primary and tertiary structures) or distal (i.e.,
between residues that are separated in primary and tertiary structures)
crosstalk. (B) The trans-eﬀect refers to crosstalk between two
modiﬁcations located on two diﬀerent proteins. Functionally,
crosstalk can be (C) direct (i.e., one modiﬁcation inhibits or enhances
the subsequent modiﬁcation of the same or a diﬀerent residue) or (D)
indirect (i.e., a speciﬁc modiﬁcation inhibits or enhances proteinprotein interactions leading to altered downstream eﬀects). Note that
while this ﬁgure depicts crosstalk involving histones, the same
explanations can be applied to non-histone proteins. Adapted from
Fischle et al. 2008.
5

Indirect crosstalk involves modulating a protein-protein interaction via the presence,
or lack, of a PTM (e.g., a PTM enhances the binding of a transcription factor leading to
the recruitment of other coactivators) (Figure 1.3D). An early example of direct cis
crosstalk (Figure 1.3A) from the histone field involves the phosphorylation of H3S10 and
the acetylation of H3K14.

Here, stimulation of the Ras-MAPK (mitogen activated

protein kinase) pathway (Chadee et al. 1999) 1 results in the Rsk-2 (ribosomal S6 kinase)
dependent phosphorylation of H3S10 (Sassone-Corsi et al. 1999), which enhances the
acetylation of H3K14 by generating a better substrate for the histone acetyltransferase
Gcn5 (general control non-repressed 5) (Cheung et al. 2000, Clayton et al. 2000, and Lo
et al. 2000). Although this is only one example of crosstalk from the histone field, a
plethora of others have been published (reviewed in Suganuma et al. 2008, Lee et al.
2010, and Baek et al. 2011), including several papers that describe crosstalk in nonhistone proteins, with a particular set of crosstalk examples involving serine/threonine
phosphorylation and the modification of neighboring arginine residues; and these
examples will be discussed later in Chapter 6.
1.4 Arginine Modifications
Arginine residues within proteins can undergo several different types of PTMs,
some of which are more prevalent and well-studied than others. These modifications
include enzyme mediated modifications, i.e., citrullination, methylation, phosphorylation,
and ADP-ribosylation, as well as non-enzymatic modifications, i.e., advanced glycation
end-products (AGE) and carbonylation (reviewed in Slade et al. 2013).
relevant modifications to this thesis are discussed in greater detail below.

6

The most

1.4.1 Citrullination
Citrullination, also known as deimination, is catalyzed by the protein arginine
deiminase (PAD) family of enzymes, which is comprised of PADs1-4 and PAD6. These
isozymes catalyze the conversion of the guanidium moiety of arginine to an ureido
moiety via a calcium dependent hydrolytic mechanism (Kearney et al. 2005). This PTM
alters electrostatic interactions by changing a positively charged residue to a neutral
residue (Figure 1.4). In regards to histones, the in vivo sites of citrullination have been
determined to be H2 Arg 3 (Hagiwara et al. 2005), H3 Arg 2, Arg 8, Arg 17 (Cuthbert et
al. 2004), and Arg 26 (Cuthbert et al. 2004 & Zhang et al. 2012), and H4 Arg 3 (Wang et
al. 2004). Citrullination of these sites correlate with either transcriptional repression
(e.g., citrullination of H3 Arg 17 at the pS2 promoter) (Cuthbert et al. 2004, Wang et al.
2004) or activation (e.g., citrullination of H3 Arg 26 at ERα target genes) (Zhang et al.
2012), depending upon the specific histone and residue.

Figure 1.4 PAD catalyzed reaction. PADs catalyze the
conversion of the guanidinium moiety of an arginine
residue to an ureido moiety via a calcium dependent
hydrolytic mechanism.
In addition to its role in transcription, histone citrullination, specifically histone
H3 by PAD4, is essential for neutrophil extracellular trap (NET) formation, a component
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of the innate immune response. NETs are comprised of decondensed chromatin, with the
DNA and histones acting as traps for pathogens (Figure 1.5) (Neeli 2008 et al., Wang et
al. 2009, Li et al. 2010). Non-histone proteins, such as myelin basic protein (MPB)
(Wood et al. 2008) and antithrombin (Chang et al. 2005), are also citrullinated by
members of the PAD family, thus demonstrating the versatility of these isozymes.
Citrullination has become an increasingly important PTM because of its apparent roles in
diseases such as Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), ulcerative colitis,
Alzheimers Disease (AD), and cancer (reviewed in Jones et al. 2009). In fact, Clamidine, a pan-PAD inhibitor, was found to decrease disease severity in animal models
of spinal cord injury (Lange et al. 2011), collagen-induced arthritis (CIA) (Willis et al.
2011), ulcerative colitis (Chumanevich et al. 2011), and cancer (McElwee et al. 2012).
Pathogen
(e.g. bacteria)

Condensed
Chromatin

Neutrophils

Decondensed
Chromatin

PAD4

NETs

Figure 1.5 Role of PAD4 in NET formation.
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1.4.2 Methylation
Methylation of arginine residues is catalyzed by the protein arginine
methyltransferase (PRMT) family of enzymes. These isozymes transfer a methyl group
from S-adenosylmethionine (SAM) to the guanidinium moiety of arginine residues in
proteins, but not free arginine. This reaction ﬁrst produces an ω-monomethylarginine
residue (ω-MMA), which in most cases is further methylated to produce either an
asymmetrically dimethylated arginine residue (ADMA) or a symmetrically dimethylated
arginine (SDMA) residue (Figure 1.6). The addition of one or two methyl groups does

Figure 1.6 PRMT catalyzed reactions. PRMTs catalyze the transfer of a methyl
group from S-adenosylmethionine (SAM) to the guanidinium group of an arginine
residue. Type I PRMTs produce asymmetric dimethyl arginine (ADMA), Type II
PRMTs produce symmetric dimethyl arginine (SDMA), and Type III PRMTs only
produce ω-monomethylarginine (ω-MMA).
not alter the charge of the residue; however, it decreases the number of potential
hydrogen bond donors, thus leaving the possibility of decreased intra- or intermolecular
interactions. Unlike lysine methylation, this modification appears to be irreversible, as an
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arginine demethylase has yet to be discovered. Some have suggested the possibility that
PAD4 may catalyze a demethylimination reaction that would convert methylated arginine
to citrulline. This conversion would not truly reverse the modification but may have a
similar function. There is conflicting evidence in vitro and in vivo however, as to
whether this reaction actually occurs in the cell, with more evidence supporting the
notion that it does not take place (reviewed in Thompson et al. 2006).
1.5 Protein Arginine Methyltransferase Family
In humans, there are nine PRMT family members including: PRMT1, -2, -3, -4, 6, and -8 (Yang et al. 2013), which are type I PRMTs that produce ADMA; PRMT5,
which is a deﬁnitive type II PRMT and produces SDMA (Yang et al. 2013); and PRMT7,
which is a type III PRMT and generates only ω-MMA (Miranda et al. 2004 & ZuritaLopez et al. 2012) (Figure 1.6). Note that enzymatic activity has yet to be demonstrated
for PRMT9. All PRMTs possess a highly conserved ~310 amino acid catalytic core that
is responsible for methyltransferase activity.

This core consists of a SAM binding

domain that contains a Rossmann type fold typical of Class I methyltransferases, a unique
β-barrel domain, and a dimerization arm. All family members possess an N-terminal
extension and several also contain C-terminal extensions (Figure 1.7) (reviewed in Yang
et al. 2013).
1.5.1 PRMT1
PRMT1 is the most prevalent PRMT isozyme and it is thought to be responsible
for ~85% of the asymmetrically dimethylated arginine residues in vivo (Tang et al. 2000
& Pawlak et al. 2000). The PRMT1 gene, located at 19q13.3 in humans (Scorilas et al.
2000), is highly conserved with ~50% sequence identity between humans and S.
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Figure 1.7 Structure of PRMT family members. PRMT family members have four common
motifs in their SAM binding domain and one motif in their unique PRMT domain. Each
isozyme has a distinct N-terminus with some containing common protein domains such as a
SH3 or a Zn finger domain. Adapted from Yang et al. 2013.
cerevisiae and over 90% between mammals, zebrafish, and Xenopus (Zhang et al. 2003).
This isozyme was originally discovered as an interacting partner of the immediate-early
gene TIS21 (Lin et al. 1996), leukemia-associated BTG1 (Lin et al. 1996), and interferonα receptor (IFNAR1) (Abramovich et al. 1997), as well as via sequence homology to a
yeast homolog (Scott et al. 1998). PRMT1 is the smallest member of the PRMT family
and has three major human splice variants (i.e., PRMT1v1-v3) (Scott et al. 1998 &
Goulet et al. 2007), that translate into proteins ranging from 353-371 amino acids in
length (Scott et al. 1998 & Pawlak et al. 2000), and four minor variants (i.e., PRMT1v4v6 (Zhang et al. 2003 & Goulet et al. 2007) and v7 (Goulet et al. 2007)). Although we
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NH2----------------------MKSSSGVAVSCGQAESSEKPNAEDMTSKDYYFDSYAHFGIHEEMLKDE
NH2-----------------------------MVSCGQAESSEKPNAEDMTSKDYYFDSYAHFGIHEEMLKDE
NH2----------------------------------------------MTSKDYYFDSYAHFGIHEEMLKDE
NH2-MAAAEAANCIME---------------------------------MTSKDYYFDSYAHFGIHEEMLKDE

Figure 1.8 PRMT1 splice variants. The NES of PRMT1v2 is highlighted in green.
are only beginning to understand the differences between these splice variants, the
variation of which lies within the N-terminus (Figure 1.8), these variants
show different tissue expression patterns and have effects on subcellular localization. For
example, PRMT1 is expressed in all tissues studied thus far (Scott et al. 1998, Tang et al.
1998, Lin et al. 1996, Pawlak et al. 2000), with PRMT1v1 and –v2 found in several
tissues, -v4 only in the heart, -v5 predominately in the pancrease, no detection of –v6,
and -v7 mostly in the heart and skeletal muscles (Goulet et al. 2007). In regards to
subcellular localization, PRMT1 as a whole is located in both the nucleus and the
cytoplasm (Tang et al. 1998, Cote et al. 2003, Frankel et al. 2002, Goulet et al. 2007).
More specifically, PRMT1v3, -v4, -v5, and –v6 are diffuse throughout the cell (Goulet et
al. 2007), whereas PRMT1v1 and –v7 are more nuclear (Goulet et al. 2007) and
PRMT1v2 is primarily cytoplasmic (Herrmann et al. 2005 and Goulet et al. 2007). In
fact, PRMT1v2 is the only variant that contains a nuclear export signal (Goulet et al.
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2007) and was found to translocate from the nucleus, contingent on substrate methylation
status (Herrmann et al. 2005) and catalytic activity of the enzyme (Herrmann et al. 2009).
Interestingly, these different N-terminal tails are also important for the substrate
specificities of PRMT1, as demonstrated by the different methylation profiles observed
for each of the variants. For example, known PRMT substrates such as SmB and Sam68
were methylated to a greater extent by PRMT1v1 and –v2, but hnRNP A1 was a better
substrate for PRMT1v5 and -6 (Goulet et al. 2007). In addition, incubation of purified
PRMT1 variants with extracts prepared from mouse embryonic stem cell yielded distinct
visual differences in the proteins methylated by PRMT1v1 and –v2 (Goulet et al. 2007).
Similar results were also observed with purified mouse PRMT1v1 and –v2 and mouse
embryonic stem cell extracts (Pawlak et al. 2002). Surprisingly, the addition of Nterminal His6 tags to the two main variants abolished the differences in substrate
specificity (Pawlak et al. 2002), thus demonstrating the uniqueness of the N-termini of
PRMT1. It is hypothesized that the unstructured N-terminal tail of the enzyme folds back
and interacts with its substrates, which would account for the differences in observed
substrate specificity (Goulet et al. 2007).
Although vital for early postimplantation development, PRMT1 is not essential
for cell viability (Pawlak et al. 2000).

This isozyme is involved in transcriptional

regulation through both its methylation of Histone H4 at arginine 3 (Strahl et al. 2001 &
Wang et al. 2001) and other proteins involved in transcription (e.g., transcription factors
(Yamagata et al. 2008 & Jobert et al. 2009), coactivators (Teyssier et al. 2005),
elongation factors (Kwak et al. 2003)), and RNA binding proteins (Cote et al. 2003,
Ostareck-Lederer et al. 2006, Chiou et al. 2007).
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It primarily acts as a coactivator for

nuclear receptors (Koh et al. 2001) and transcription factors (i.e., YY1 (Rezai-Zadeh et
al. 2003), p53 (An et al. 2004), STAT5 (Kleinschmidt et al. 2008), and AE9a (Shia et al.
2012)), however, there are instances in which PRMT1 represses transcription
(Kleinschmidt et al. 2008). Interestingly, it was determined that methylation of arginine
3 of Histone H4 enhances acetylation of lysine residues on both Histone H3 (Huang et al.
2005) and Histone H4 (Wang et al. 2001 & Huang et al. 2005), but prior acetylation
prevents methylation (Huang et al. 2005). PRMT1 also plays a variety of other roles in
the cell.

More specifically, it is involved in insulin signaling (Iwasaki et al.2007),

estrogen signaling (Le Romancer et al. 2008), and interferon signaling (Abramovich et al.
1997), as well as, DNA damage response pathways through methylation of MRE11
(Boisvert et al. 2005, Dery et al. 2008, Yu et al. 2009) and 53BP1 (Boisvert et al. 2005).
1.5.2 PRMT2
PRMT2, the gene of which is located at 21q22.3, was discovered by Katsanis et
al. and contains 57% nucleotide sequence homology to PRMT1 (Katsanis et al. 1997).
The translated protein is 433 amino acids in length with an N-terminal extension that
distinguishes it from PRMT1 (Krause et al. 2007). This extension contains a SRC
Homology 3 (SH3) domain, which is known to facilitate protein-protein interactions
(Pawson et al. 1992, Mayer et al. 1993). Interestingly, the SH3 domain is required for
PRMT2’s interaction with E1B-AP5 (Kzhyshkowska et al. 2001) but not estrogen
receptor alpha (ERα) (Qi et al. 2002). Originally, methylatransferase activity for this
enzyme could not be detected directly (Kzhyshkowska et al. 2001, Qi et al. 2002, Ganesh
et al. 2006, Meyer et al. 2007). It was recently discovered, however, that PRMT2 is a
Type I PRMT (Lakowski et al. 2009) and is capable of methylating recombinant histone
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H4 in vitro (Lakowski et al. 2009) and histone H3R8 in Xenopus (Blythe et al. 2010).
PRMT2 appears to mainly play the role of a transcriptional co-activator for a number of
nuclear hormone receptors (e.g., androgen receptor, estrogen receptor) (Meyer et al.
2007, Qi et al. 2002), which is unexpected because it is a cytoplasmic protein. However,
evidence has shown that it can be transported into the nucleus with the androgen receptor
upon hormone stimulation (Meyer et al.2007).
1.5.3 PRMT3
PRMT3 is a Type I PRMT that was identified in a yeast two-hybrid screen for
PRMT1 interacting proteins (Tang et al. 1998). The gene is located at 11p15.1 and
encodes a 531 amino acid protein that contains an N-terminal zinc finger domain (Krause
et al. 2007). This zinc finger domain was found to dictate substrate specificity and is
vital for PRMT3’s interaction with RNA-associated proteins (Frankel et al. 2000).
PRMT3 is located in the cytoplasm and, although the crystal structure suggests that it can
form homodimers (Zhang et al. 2003), it was found as a monomer using gel filtration of
rat cell extracts (Tang et al. 1998). The major substrate of PRMT3 is the 40 S ribosomal
protein S2 (rpS2), thus suggesting that this enzyme may play roles in the regulation of
protein synthesis and or ribosome assembly (Swiercz et al. 2005).
1.5.4 PRMT4/CARM1
PRMT4, more commonly known as coactivator-associated methyltransferase 1
(CARM1), was discovered during a yeast two-hybrid screen for proteins that interact
with the AD2 domain of p160 coactivators (Chen et al. 1999). The gene is located at
19p13.2 and encodes a 608 amino acid protein in humans (Krause et al. 2007). Although
most PRMTs only contain a unique N-terminal extension, CARM1 contains both an N-
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and C-terminal extension.

Neither of these extensions are required for enzymatic

activity, homo-oligomerization, or p160 binding in vitro (Teyssier et al. 2002), however,
both of them are required for the isozyme’s transcriptional coactivator function. The Nterminus adopts a pleckstrin homology domain (PH) fold that is typically involved in the
formation of multiprotein complexes and the regulation of protein-protein interactions.
The role of that this fold plays in the function of this isozyme remains to be determined
(Troffer-Charlier et al. 2007). Importantly, it was demonstrated that CARM1 is essential
to life in that knockout mice die shortly after birth (Yadav et al. 2003). CARM1 is
known to methylate Histone H3 at arginine 2, 17, and 26 (Schurter et al. 2001), several
splicing factors (e.g., SmB and U1C) (Cheng et al. 2007), as well as transcriptional coactivators (e.g., SRC-3 (Feng et al. 2006), CBP (Xu et al. 2001 and Chevillard-Briet et al.
2002), and p300 (Chevillard-Briet et al. 2002). The identities of these CARM1 substrates
exemplify the role of this isozyme as a coactivator involved in transcriptional regulation
(Ma et al. 2001, Schurter et al. 2001, Chevillard-Briet et al. 2002, Feng et al. 2006).
1.5.5 PRMT5
Human PRMT5, originally known as Jak-binding protein 1 (JBP1), was identified
during a search for Janus kinase 2 (Jak2) interacting proteins (Pollack et al. 1999) and
was found to be a homologue of the previously reported Skb1 from Schizosaccaromyces
pombe (Gilbreth et al. 1996) and HSL7 from Saccharomyces cerevisiae (Ma et al. 1996).
It is the only known Type II PRMT and produces SDMA (Branscombe et al. 2001).
Located at 14q11.2, the PRMT5 gene encodes a 637 amino acid protein (Krause et al.
2007) with a large N-terminal extension that contains a TIM barrel domain (Antonysamy
et al. 2012). This TIM barrel domain is solely responsible for the interaction of this
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isozyme with its binding partner methylosome protein 50 (MEP50) (Antonysamy et al.
2012).

MEP50 is a WD40-repeat containing protein that is required for PRMT5

methyltransferase activity and aids in substrate recognition and interactions with other
proteins, as the isozyme shows minimal activity unless it is a part of a larger multiprotein
complex (Friesen et al. 2002). Located in the nucleus and the cytoplasm, PRMT5 plays
roles in a plethora of cellular processes such as transcriptional regulation (Pal et al. 2004,
Pal et al. 2007, Wang et al. 2008), differentiation (Dacwag et al. 2007, Dacwag et al.
2009, Mallappa et al. 2011), the synthesis of ribosomes (Ren et al. 2010), and cell
proliferation (Pal et al. 2007 & Wang et al. 2008). Similar to PRMT1, PRMT5 is
essential for both embryonic development and the derivation of embryonic stem cells
(Tee et al. 2010).
1.5.6 PRMT6
Discovered during a human genome search for PRMTs (Frankel et al. 2002), the
PRMT6 gene is located at 1p13.1 and encodes a 375 amino acid protein (Krause et al.
2007). A type I PRMT, this particular isozyme is located exclusively in the nucleus and
was the first PRMT discovered to be capable of automethylation (Frankel et al. 2002).
PRMT6 plays roles in transcriptional regulation, regulation of HIV replication, base
excision repair, and cell cycle progression via methylation of histone H2A arginine 3
(Hyllus et al. 2007) and arginine 29 (Waldmann et al. 2011), histone H3 arginine 2
(Hyllus et al. 2007, Guccione et al. 2007, Iberg et al. 2008), histone H4 arginine 3 (Hyllus
et al. 2007), HIV-1 Tat (Boulanger et al. 2005), HMGA1a/b (Miranda et al. 2005 and
Sgarra et al. 2006), DNA polymerase β (El-Andaloussi et al. 2006), and tumor suppressor
p16 (Wang et al. 2012). In addition, our lab recently determined the kinetic mechanism
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of PRMT6 to be a rapid equilibrium random mechanism with dead end EAP and EBQ
complexes (Obianyo et al. 2012).
1.5.7 PRMT7
The PRMT7 gene, which was also discovered from computational alignments of
potential PRMT genes (Miranda et al. 2004 and Lee et al. 2005), is located at 16q22.1
(Krause et al. 2007). The gene encodes a 692 amino acid protein (Krause et al. 2007) that
uniquely contains an additional but less conserved SAM binding domain at the Cterminus (Miranda et al. 2004). Surprisingly, the presence of both SAM binding domains
were found to be necessary for methyltransferase activity, although SAM could only
crosslink to the N-terminal SAM binding domain (Miranda et al. 2004), suggesting that
only the N-terminal half of the enzyme is active and the C-terminus acts as a regulatory
domain. Although originally there were conflicting results regarding the final product of
methylation, with one group suggesting a Type III enzyme and only the formation of ωMMA (Miranda et al. 2004) and another group suggesting a Type II enzyme and the
formation of both ω-MMA and SDMA (Lee et al. 2005), recent evidence has supported
the notion that it is a Type III enzyme with the latter result possibly being an artifact of
contamination by PRMT5 (Zurita-Lopez et al. 2012). Like PRMT1, PRMT7 is located in
both the nucleus and cytoplasm (Lee et al. 2005).

Although one of the lesser

characterized PRMTs, it has been suggested that this isozyme plays a role in cellular
differentiation (Buhr et al. 2008) and the DNA damage response (Gros et al. 2006 and
Verbiest et al. 2008).
1.5.8 PRMT8
Human PRMT8, located on chromosome 12p13.3 and encoding a 394 amino acid
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protein, was originally discovered due to its 80% sequence homology to PRMT1, with
the major variations located at the N-termini (Zhang et al. 2003). Despite the high
sequence homology between the two isozymes, PRMT8 expression is primarily restricted
to brain tissue (Lee et al. 2005, Taneda et al. 2007, Kousaka et al. 2009) and it is targeted
to the plasma membrane via myristoylation of its N-terminus at glycine-2 at its Nterminus (Lee et al. 2005). Interestingly, the N-terminus also plays a regulatory role in
enzymatic activity in that the full length recombinant protein displays significantly
decreased activity compared to a N-terminal truncated variation that more closely
resembles PRMT1 (Sayegh et al. 2007). The isozyme is also capable of automethylation
via the production of ADMA on arginine 73 and ω-MMA on arginine 58, however, it is
still uncertain as to whether this is an intra- or inter- molecular reaction, as PRMT8 is
capable of forming homodimers (Sayegh et al. 2007). Additionally, two proline rich
sequences on the N-terminus have been found to bind SH3 domains of proteins, including
the SH3 domain of PRMT2, however, the functional significance of these interactions is
unknown as no change in PRMT8 activity was observed in in vitro assays (Sayegh et al.
2007). Several PRMT8 interacting proteins (e.g., TET-family of RNA-binding proteins,
hnRNPs, and actin) were revealed via in vitro GST-pull down experiments with
recombinant GST-PRMT8 and hypomethylated cell extracts. Specifically, the isozyme
co-localizes with Ewing’s sarcoma (EWS), independent of the binding partner’s
methylation status (Pahlich et al. 2008). The function of PRMT8 in the cell remains to be
fully defined.
1.5.9 PRMT9
PRMT9, often denoted along with its chromosomal location (4q31), was
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identified by sequence homology with other PRMT family members (Lee et al. 2005).
No enzymatic activity has been reported and it has yet to be characterized. Sequence
analysis has shown that it is most closely related to PRMT7 in that it contains a second
SAM binding domain on the C-terminus. The N-terminus contains two tetratricopeptide
repeats, which based on the previously reported functions of this motif (Blatch et al.
1999), could potentially play a role in protein-protein interactions (Bedford et al. 2007).
A controversy remains in regards to a second PRMT9, PRMT9 (2p16), which is also
known as F-box only protein 11 (FBXO11). This enzyme was found to produce ωMMA, ADMA, and SDMA (Cook et al. 2006) despite being structurally different from
the PRMTs, which are a part of the Type I seven-β strand methyltransferase family (Katz
et al. 2003 & Bedford et al. 2009). A separate study demonstrated that this protein had
no methyltransferase activity (Fielenbach et al. 2007); the production of SDMA in the
original report may possibly be due to sample contamination by PRMT5 (Nishioka et al.
2003).

Therefore, the methyltransferase classification of this protein has yet to be

confirmed.
1.6 Role of PRMT1 in Disease
With the multitude and variety of roles that the PRMT isozymes play in the cell, it is
conceivable that their dysregulation would be involved in the pathogenesis of one or
more human diseases. Our research thus far has focused on PRMT1 because it is the
major Type I methyltransferase and would therefore logically play a greater role in the
onset and progression of diseases compared to the other isozymes.

The following

subsections will give an overview of the involvement of PRMT1 in various diseases.
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1.6.1 Cancer
A recent study of the expression levels of PRMT1 in tumors from various tissues
revealed that the isozyme, and in some cases select splice variants, is/are significantly
overexpressed in a variety of cancers (Yoshimatsu et al. 2011). The results of this study
are in agreement with several more specific studies that have shown that PRMT1 is
overexpressed in breast cancer (Goulet et al. 2007)(Baldwin et al. 2012), colon cancer
(Mathioudaki et al. 2008), gliomas (Wang et al. 2012), acute lymphoblastic leukemia
(ALL) (Zou et al. 2012). In addition, higher levels of serum ADMA is observed in
cancer patients, an observation that is the first of its kind (Yoshimatsu et al. 2011).
1.6.1.A Breast Cancer
Estrogen and its receptor, estrogen receptor α (ERα), are well-known for the
genomic roles that they play in breast cancer, demonstrated by the fact that 70% of breast
cancers are estrogen dependent and ERα positive (Le Romancer et al. 2008).
Surprisingly, evidence suggests that the role that PRMT1 plays in breast cancer is of
nongenomic origin. In the cytoplasm, the DNA binding domain of ERα is methylated by
PRMT1 at arginine 260, in response to estrogen. This methylation event leads to the
formation of a multiprotein complex involving the receptor itself, Src kinase,
phosphoinositide 3-kinase (PI3K), and focal adhesion kinase (FAK).

This complex

ultimately activates protein kinase B (Akt) and induces cell proliferation and survival
(Figure 1.9) (Le Romancer et al. 2008). Interestingly, in the same study, 55% of invasive
breast cancer tissues analyzed had high levels of methylated ERα and 45% had low levels
(Le Romancer et al. 2008), thus demonstrating a plausible nongenomic role for PRMT1
in breast cancer.
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Figure 1.9 Proposed model of an ERα-dependent role of PRMT1 in breast cancer.
A second nongenomic role for PRMT1 in breast cancer has also been revealed
(Figure 1.10). The authors of this study had previously shown that the different splice
variants of PRMT1 are overexpressed in breast cancer cells to varying degrees, with
PRMT1v2 having a more significant increase than the predominant PRMT1v1 (Goulet et
al. 2007), which led them to further investigate the contribution of this particular variant
to the disease. RNA interference was used to abolish PRMT1v2 expression and yielded
an increase in apoptosis and decreased cell invasion in an aggressive cell line.
Intriguingly, overexpression of this variant caused increased invasiveness in a known
non-aggressive cell line, that was not observed with the other PRMT variants. The role
of PRMT1v2 in cell motility and invasion is dependent on the localization and activity of
the enzyme as mutations to the NES and activity site abolish the effects.

Further

investigation into the role of this particular variant showed that it is likely involved in
regulating β-catenin degradation, a protein involved in cell-cell adhesion, as an increase
in phosphorylated β-catenin was observed in PRMT1v2 expressing cells (Baldwin et al.
2012) (Figure 1.10). This observation is in concordance with and in addition to another
study that demonstrated a role for PRMT1 in controlling β-catenin expression in the
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cytoplasm through regulation of Wnt signaling via methylation of Axin (Cha et al. 2011).

Figure 1.10 Proposed model of the role of PRMT1v2 in breast cancer. (A) In
the absence of PRMT1v2, the Wnt signaling pathway targets Axin to the
membrane, which allows β-catenin to enter the nucleus. (B) In the presence
of PRMT1v2, Axin is methylated, which leads to the phosphorylation of βcatenin and subsequent degradation (Cha et al. 2011 & Baldwin et al. 2012).
1.6.1.B Leukemia
The mixed lineage leukemia (MLL) gene is commonly associated with ALL and
AML in that chromosomal translocation of the gene forms fusion proteins that aberrantly
regulate and activate the expression of genes such as class I homeobox (HOX) (Daser et
al. 2005) and ultimately transform early myeloid progenitors and haematopoietic stem
cells (Cozzio et al. 2003 & So et al. 2003). PRMT1 was discovered to be a critical
component of the MLL transcriptional complex comprised of the SH3-domain containing
MLL-EEN oncogenic fusion protein, SAM68, an RNA-binding protein and substrate of
PRMT1, and CREB-binding protein (CBP), a histone acetyltransferase (Cheung et al.
2007). Results of several in vitro and in vivo experiments demonstrate that MLL-EEN
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binds SAM68 via its SH3-domain which leads to the recruitment of both PRMT1 and
CBP to downstream targets of the fusion protein, in this case Hoxa9a (Figure 1.11).
Methylation of histone H4 arginine 3 by PRMT1 leads to increased acetylation of histone
tails by CBP and activation of gene transcription (Cheung et al. 2007). This observation
is in agreement with another study demonstrating cooperativity between PRMT1 and
p300, a histone acetyltransferase related to CBP (An et al. 2004). Other studies have
shown that CBP interacts with wild type MLL (Ernst et al. 2001 & Daser et al. 2005) but
recruitment of CBP alone by another MLL fusion protein, MLL-AFX, did not induce

Figure 1.11 Proposed model of the role of PRMT1 in leukemia (Cheung et al. 2007).
cellular transformation (So et al. 2002), thus suggesting that other factors are necessary.
On the other hand, PRMT1 does not interact with wild type MLL, but the creation of a
MLL-PRMT1 fusion protein transformed primary myeloid progenitor cells, thus
demonstrating that the PRMT1 alone plays a key role in the MLL dependent leukemia
(Cheung et al. 2007).
In a separate but similar example, PRMT1 interacts with a splice form (AE9a) of
AML1-ETO, a transcription factor fusion protein associated with AML. This particular
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isoform was identified from patient samples and rapidly induces leukemia in a mouse
model (Shia et al. 2012). Recruitment of PRMT1 by AE9a to the promoters of target
genes yields activation of the genes by methylation of histone H4 and subsequent histone
acetylation (Shia et al. 2012), as observed in in the previous example.

To further

demonstrate the importance of PRMT1 in this pathway, knockdown of the enzyme
decreased proliferation of AE9a leukemic cells (Shia et al. 2012).
1.6.2 Heart Disease
Heart disease is the leading cause of death in the United States for both men and
women (Hoyert et al. 2012) and PRMT1 may be a contributing factor. In addition to the
observation that the enzyme is overexpressed in tissues of patients with this disease
(Chen et al. 2006), free MMA and ADMA, which are products of the degradation of
PRMT1 substrates, are competitive inhibitors of the nitric oxide synthases (NOSs), vital
enzymes responsible for the production of nitric oxide (NO) (Valance et al. 1992). Free
MMA and ADMA are normally converted to citrulline by dimethylarginine
dimethylaminohydrolase (DDAH) and can then be further broken down and used for
protein synthesis or excreted (Vallance et al. 2004) (Figure 1.12). An increase in PRMT1
expression coupled with dysfunction of DDAH can cause an increase in free MMA and
ADMA (Vallance et al. 2004) and research efforts have focused on ADMA because its
concentration is 10 times greater than MMA in human plasma (Vallance et al. 1992 &
Tran et al. 2003). Elevation of free ADMA levels causes vasoconstriction (Achan et al.
2003 & Vallance et al. 2004), due to a decrease in NO production, and its levels are
correlated with the severity of hypercholesterolemia and atherosclerosis, as well as the
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mortality of patients suffering from end stage renal disease (Tran et al. 2003, Vallance et
al. 2004, Leiper et al. 2002, Landim et al. 2009, Zoccali et al. 2001).

Figure 1.12 Proposed model of the role of PRMT1 in heart disease.
1.6.3 Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis is a progressive neurodegenerative disease that
affects the entire motor system and half of patients die within 3 years of onset (Mitchel et
al. 2007). In the familial form of ALS, which accounts for 10% of cases (Shaw et al.
1997), and more specifically termed ALS6, a gene fusion, i.e., fused in
sarcoma/translocated in liposarcoma (FUS/TLS), was found to be mutated (Kwiatkowski
et al. 2009 & Vance et al. 2009). FUS is normally involved in transcription, RNA
processing, and translation as a ribonuclear protein (Law 2006 et al. & Wang et al. 2008)
and plays a crucial role in neurons regarding the formation of dendritic spines (Fujii et al.
2005). Although WT FUS is found mostly in the nucleus, FUS mutants appear to be
localized in the cytoplasm (Kwiatkowski et al. 2009, Vance et al. 2009, Bosco et al.
2010, Dormann et al. 2010, Gal et al.2011, Ito et al. 2011, Kino et al. 2011) where they
have been observed to form inclusions and associate with stress granules (Dormann et al.
2010, Bosco et al. 2010, Gal et al. 2011, Ito et al. 2011, Kino et al. 2011). Two recent
studies have linked PRMT1 to ALS via FUS (Figure 1.13). Both WT (Yamaguchi et al.
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Figure 1.13 Proposed model of the role of PRMT1 in ALS. (A) In the absence and
presence of PRMT1, WT FUS localizes in the nucleus. (B) In the absence of PRMT1,
mutant FUS is capable of localizing in the nucleus, however, methylation of the mutant
by PRMT1 leads to aggregation and formation of inclusions in the cytoplasm
(Tradewell et al. 2012).
2012, Tradewell et al. 2012) and mutant FUS (Tradewell et al. 2012) are methylated by
PRMT1, however, methylation appears to predominantly affect the function of mutant
FUS, as demonstrated by a PRMT1 knockout model in mouse embryonic stem cells
(MES) and HEK293 cells, as well as methyltransferase inhibition in motor neurons. The
results revealed that PRMT1-dependent methylation appears to likely be a defining factor
in the localization of mutant FUS to the cytoplasm (Tradewell et al. 2012). Interestingly,
the ALS linked FUS mutations are present on the C-terminus of the protein where the
nuclear localization signal (NLS) is also located and it is hypothesized that the mutations
may affect nuclear-cytoplasmic shuttling. It remains unclear as to the exact role of the
PRMT1-dependent methylation, however, it may enhance protein-protein interactions
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that ultimately lead to aggregation of mutant FUS in the cytoplasm and the formation of
inclusions (Tradewell et al. 2012).
1.7 Conclusion
The involvement of PRMT1 in the aforementioned diseases demonstrates the
likelihood that this enzyme is a worthwhile drug target. The close structural relationship
between the PRMT family members presents a challenge in designing a selective
inhibitor towards a particular isozyme. In addition, the presence of PRMT1 splicevariants with different substrate specificities and functions creates an additional level of
difficulty. There is also a lack of knowledge at this time in regards to how enzyme
activity is regulated (e.g., PTMs or protein-protein interactions). Herein, we will discuss
mechanistic studies of PRMT1, potential methods of enzyme regulation, and the
development of selective inhibitors. We will also present evidence for possible crosstalk
between arginine methylation and phosphorylation.
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CHAPTER 2
Mechanistic Studies on PRMT12
2.1 Introduction
PRMT1 shows the widest tissue distribution and highest expression, and is
thought to be responsible for ~85% of the asymmetrically dimethylated arginine residues
in vivo (Tang et al. 2000 & Pawlak et al. 2000). It is located in both the nucleus and the
cytoplasm (Herrmann et al. 2005) and is active as a head-to-tail dimer, which is formed
by the interaction of the dimerization arm of one monomer with the SAM binding domain
of another monomer (Zhang et al. 2003).

Our research thus far has focused on

developing inhibitors that target this isozyme (Osborne et al. 2007, Osborne et al.2008,
Obianyo et al. 2010, Bicker et al. 2010) due to its involvement in several diseases (e.g.,
cancer, heart disease, ALS). Previously, we demonstrated that PRMT1 preferentially
methylates a 21 residue peptide based on the N-terminus of histone H4 with comparable
kinetics to the parent protein (Osborne et al. 2007).

Additionally, these studies

demonstrated that positively charged residues present in the C-terminus of this peptide,
which is denoted AcH4-21, are critical for the high rates of catalysis observed with this
substrate. We further demonstrated that PRMT1 catalyzes the methylation of the AcH421 substrate in a partially processive manner, i.e., PRMT1 can rebind SAM and

2

Adapted with permission from Rust, H.L.; Zurita-Lopez, C.I.; Clarke, S.; Thompson, P.R., Mechanistic
studies on transcriptional coactivator protein arginine methyltransferase 1. Biochemistry 2011, 50(16),
3332-45. Copyright 2013 American Chemical Society.
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subsequently produce ADMA before the first methylation product, w-MMA, is released
(Osborne et al. 2007). Because ADMA formation is not obligatory, we have suggested
that PRMT1 displays partial processivity. The partially processive nature of this reaction
is entirely consistent with the fact that PRMT1 uses a Rapid Equilibrium Random kinetic
mechanism with dead-end E•SAM•w-MMA and E•AcH4-21•SAH complexes, where the
E•SAM•w-MMA complex can undergo a second methyl transfer reaction to produce
ADMA (Obianyo et al. 2008).
To follow up on these studies and provide a mechanistic basis for the methylation
of an arginine residue, which is arguably a weak nucleophile, we examined the structure
of PRMT1 bound to SAH (Zhang et al. 2003). Based on this structure, there are a
number of highly conserved active site residues that likely play key roles in SAM
recognition, substrate binding, and catalysis (Figure 2.1). For example, in PRMT1 it has
been suggested that R54 and E100 are involved in SAM binding by hydrogen bonding
and forming electrostatic interactions with the carboxylate group and ribose moiety of
SAM, respectively (Zhang et al. 2000 & Zhang et al. 2003). The R54 residue also likely
hydrogen bonds with the side chain of E144 to orient the γ-carboxylate of this residue for
optimal electrostatic and hydrogen bond interactions with the Nη2 of a substrate arginine
residue. This interaction likely helps position Nη2 for attack on the methyl group of
SAM. The γ-carboxylate of E153 also likely contributes to the alignment of the substrate
guanidinium via electrostatic and two hydrogen bond interactions with Nη1 and Nδ
(Zhang et al. 2000 & Zhang et al. 2003), although, it should be noted that, in structures of
PRMT1, the position of this residue does not appear to be catalytically competent as it is
‘flipped’ out of the active site (Zhang et al. 2003). Examination of the crystal structure of
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CARM1 also identified Y154, a conserved tyrosine residue that corresponds to Y39 in
PRMT1, as potentially playing a role in PRMT catalysis. Although Y39 is not visible in
the crystal structure of PRMT1, the side chain phenol of this residue forms the top of the
SAM binding pocket and is likely important for cofactor binding. Additionally, based on
the CARM1 structure, the phenol appears to interact with E153 (PRMT1 numbering) and
help orient this residue, and, as a consequence, the substrate guanidinium to promote
catalysis (Yue et al. 2007 & Troffer-Charlier et al. 2007).
A

B

E153
H293
Y39
E144

E100

Y39

H293

R54

Y39

R54

SAH

M155

M155

E144

E100

A

B

Figure 2.1 Active site of PRMT1. (A) Structure of PRMT1 (white) highlighting key
residues in the active site believed to play roles in substrate binding and/or catalysis.
Note that the PRMT1 structure is overlaid with PRMT3 (teal) because electron density of
Y39 is not present in the crystal structure of PRMT1 and the positioning of E153 in
PRMT1 is different from PRMT3, which is likely due to the crystallization conditions.
This figure was prepared with UCSF Chimera using the coordinates from PRMT1
(PDBID 1ORI) and PRMT3 (PDBID 1F3L).
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Also present in the active site is M155. Although this residue is not thought to
play a direct role in rate acceleration, it has been suggested (Branscombe et al. 2001) that
M155 is responsible for the formation of ADMA as the end product of dimethylation, as
opposed to SDMA, due to steric hindrance that would prevent the transfer of a methyl
group to Nη1 after methylation of Nη2 (Zhang et al. 2000 & Branscombe et al. 2001).
This hypothesis is supported by the fact that PRMT5, a Type II PRMT, has a serine
residue in this position that presumably creates a more open pocket that enables
symmetric dimethylation (Branscombe et al. 2001).
Given that the guanidinium group is a relatively weak nucleophile, it has been
suggested that its interaction with E153 causes a redistribution of electrons that activates
Nη2 for an SN2-type nucleophilic attack on the methyl group of SAM (Figure 2.2) (Zhang
et al. 2000). This attack potentially results in the formation of a dication intermediate
that undergoes the loss of a proton to possibly E144 or via a proton wire to H293.
However because the formation of a dication intermediate is somewhat unfavorable, it

Figure 2.2 Proposed catalytic mechanism of PRMT1
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has been suggested that PRMT1 uses a stepwise or concerted mechanism in which the
proton is removed prior to or simultaneously with methyl transfer (Zhang et al. 2000).
Herein we describe our efforts to characterize the catalytic mechanism of PRMT1
using site directed mutagenesis on a number of highly conserved active site residues (i.e.,
Y39, R54, E100, E144, E153, M155, and H293), which are believed to play key roles in
SAM recognition, substrate binding, and catalysis, as well as pH rate profiles,
processivity studies, and the determination of Solvent Isotope Effects (SIEs).
2.2 Materials and Methods
2.2.1 Chemicals
Sodium

dodecyl

sulfate

(SDS), tris(hydroxymethyl)aminomethane

(TRIS),

tetramethylethylenediamine, acrylamide, and ammonium persulfate were purchased from
Bio-Rad (Hercules, CA). 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
Tricine, dithiothreitol (DTT) were purchased from RPI (Mt. Prospect, IL). Acetonitrile
and methanol were purchased from Fisher Scientific (Pittsburgh, PA). Sodium chloride
and dimethylformamide (DMF) were purchased from Alfa Aesar (Ward Hill, MA).
Piperidine was purchased from Sigma-Aldrich (St. Louis, MO). Fmoc protected amino
acids, (ethylenedinitrilo)tetraacetic acid (EDTA), and trifluoroacetic acid (TFA) were
purchased from EMD (Gibbstown, NJ).
Elmer and

14

14

C-labeled SAM was purchased from Perkin-

C-labeled BSA from Sigma-Aldrich. Mutagenic primers were purchased

from IDT Inc. (Coralville, IA).
2.2.2 Purification of PRMT1
The purification of PRMT1 has been described (Osborne et al. 2007). In brief, a
pET28b construct (Zhang et al. 2003) containing the PRMT1 gene and an N-terminal
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hexa-histidine tag was transformed into E. coli BL21(DE3) cells. One colony was used
to inoculate 5 mL of LB media containing 50 μg/mL kanamycin and incubated overnight
with shaking at 37 °C. Two liters of LB media were inoculated with 20 mL of overnight
culture containing 50 μg/mL kanamycin and grown at 37 °C and 250 rpm until OD600 =
0.4-0.6.

Protein expression was then induced with 0.4 mM isopropyl-β-D-

thiogalactopyranoside and the cells were incubated with shaking at 22 °C overnight. The
next day the cells were harvested by centrifugation at 5000 rpm (4400 g) for 10 min. The
pellet was resuspended in 30 mL of Lysis Buffer (20 mM HEPES pH 8, 100 mM NaCl, 5
mM imidazole pH 7.5, 0.5 mM PMSF, 5 mM 2-mercaptoethanol) and lysed using a
French pressure cell at 20,000 psi. The lysate was centrifuged at 13,000 rpm (20,250 g)
for 30 min and the supernatant was applied to a Ni2+ Chelating Sepharose Fast Flow
column. The protein was eluted using a 5 mM to 500 mM imidazole step gradient in 20
mM HEPES pH 8 and 100 mM NaCl. Fractions were screened on a 12% SDS-PAGE gel
and fractions containing protein were dialyzed overnight in 20 mM HEPES pH 8.0 and
50 mM NaCl. The next day the protein was additionally purified by FPLC using a Mono
Q anion exchange column (GE Healthcare). Fractions were screened on a 12% SDSPAGE gel and fractions containing protein were dialyzed overnight in 100 mM HEPES,
200 mM NaCl, 1 mM DTT, 2 mM EDTA, and 10% glycerol. The next day the protein
was concentrated using a 10 kDa Amicon Centriplus centrifugal filter and the
concentration was determined using a Bradford assay. The enzyme was flash frozen in
liquid nitrogen and stored at -80 °C.
2.2.3 Site-Directed Mutagenesis
PRMT1 mutants

were generated using the QuikChange Site-Directed
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Mutagenesis KitTM (Stratagene). The full open reading frame was sequenced for each
mutant to ensure that only the desired mutation had been incorporated.

DNA that

contained desired the mutation was then transformed into E. coli BL21(DE3) cells and
purified using our established protocol for wild type (WT) PRMT1 (described above).
2.2.4 Synthesis of Peptides
AcH4-21 and RGG3 peptides were synthesized as previously described on a
Rainin PS3 automatic peptide synthesizer using Fmoc chemistry on a Wang resin
(Osborne et al. 2007). The sequences of these peptides can be found in Table 2.1. The
peptides were cleaved from the resin with 95% TFA, 2.5% triisopropylsilane, and 2.5%
water, and then precipitated with diethyl ether. Peptides were purified by reverse phase
HPLC with a mobile phase of water/0.05% TFA and eluted with acetonitrile/0.05% TFA.
The masses were determined using a Bruker Ultraflex II MALDI-TOF mass
spectrometer.
2.2.5 Gel-Based Activity Assay
A previously described gel-based assay was used to determine the steady state
kinetic parameters of WT and PRMT1 mutants (Osborne et al. 2007). Assays were
performed in a reaction mixture of 50 mM HEPES pH 8.0, 1 mM EDTA, 50 mM NaCl,
0.5 mM dithiothreitol, 15 μM [14C]-labeled SAM, and a varying concentration of AcH421 (0-1000 μM final). Reactions were pre-incubated at 37 °C for 10 min and WT
PRMT1, or a PRMT1 mutant, was then added and the reaction was quenched after 15
min. For the assays varying SAM (0-39.7 μM final), the same reaction mixture was used
except the concentration of AcH4-21 was held constant at 100 μM. Each assay was done
in duplicate and the standard deviation of the duplicate raw data values agreed within ≤
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20%. The GraFit version 5.0.11 software (Leatherbarrow 2004) was used to fit the data
to eq 1 or eq 2 if substrate inhibition was observed,
υ = Vmax[S]/(Km+[S])

(1),

υ = Vmax[S]/[(Km+[S])(1+[S]/Ki)]

(2).

2.2.6 MALDI-MS Based Activity Assay
A previously described matrix assisted laser desorption/ionization (MALDI) MS
based assay was used to determine the processivity of WT and select PRMT1 mutants
(Osborne et al. 2007). Briefly, assays were performed in a reaction mixture of 50 mM
HEPES pH 8.0, 1 mM EDTA, 50 mM NaCl, 500 μM SAM, and 20 μM AcH4-21.
Reactions were then pre-incubated at 37 °C for 10 min. WT PRMT1 or a PRMT1 mutant
was then added and the reaction was quenched with 3 μL of 50% TFA in ddH2O after the
appropriate time period. Spectra were acquired on a Bruker Ultraflex II MALDI-TOF
MS or an Applied Biosystems 4800 Plus MALDI TOF/TOF MS and analyzed using Flex
Analysis software. The percent turnover was determined by dividing the intensity of the
modified peptide by the sum of the intensities of the unmodified and modified substrates
times 100%.
2.2.7 Chemical Analysis of Methylation Products
A reaction mixture of 10 μg of GST-GAR and 1.4 μM [3H]-SAM in 50 mM
HEPES at pH 7.5 was incubated with 2 μg of WT PRMT1 or a PRMT1 mutant for 2 h at
37 °C. The products were then precipitated with an equal volume of 50% trichloroacetic
acid, washed with acetone, and hydrolyzed for 20 h at 110 °C in 6 M HCl. The
hydrolysate was dried and mixed with standards of ADMA, SDMA, and w-MMA before
being fractionated on a high-resolution cation exchange column as described (Fisk et al.
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2009). One-tenth of the fractions were used for ninhydrin analysis of the standards, and
nine-tenths were counted.
2.2.8 Partial Proteolysis
Partial proteolysis assays were performed in a reaction mixture of 50 mM HEPES
pH 8.0, 1 mM EDTA, 50 mM NaCl, 0.5 mM dithiothreitol, and in the absence or
presence of 0.5 mM SAH and 0.75 μg/mL subtilisin on ice. WT PRMT1, or a PRMT1
mutant, was then added and the reaction was quenched after 60 min with 5 mM
phenylmethylsulfonyl fluoride. Protein fragments were separated by 12% SDS-PAGE
and visualized with Coomassie Brilliant Blue.
2.2.9 pH Profile
The steady state kinetic parameters for the WT enzyme as well as the Y39F and
H293A mutants were determined over a pH range of 6.0-9.25 using the gel-based activity
assay described above. Assays were performed in a reaction mixture of 50 mM Bis-Tris
(6.0-7.0), 50 mM HEPES (7.0-8.5), 50 mM Tricine (8.5-9.0), or CHES (8.75-9.25), 1
mM EDTA, 50 mM NaCl, and 0.5 mM dithiothreitol, with constant and varying
concentrations of [14C]-SAM (0-41 μM final) and RGG3 (0-1000 μM final). Each assay
was done in duplicate and the standard deviation of the duplicate raw data values agreed
within ≤20%. Note that, in order to make certain that the variances in kinetic parameters
were not the result of a buffer effect; an overlapping buffer method was utilized. The
kinetic parameters for the overlapping buffers were similar and thus the average was
used. In addition, time course assays were performed at each pH to demonstrate that
activity was not lost over time. The GraFit version 5.0.11 software (Leatherbarrow 2004)
was used to fit the data to eq 3 or eq 4,
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(3),
y = ((Lim1 + Lim2 x 10(pH-pKa1))/(10(pH-pKa1)+1) - (((Lim2 -Lim3) * 10(pH-pKa2))/(10(pHpKa2)

+1)))

y = ((Lim1 + Lim2 + 10(pH-pKa1))/(10(pH-pKa1)+1))

(4).

For eq 3 and eq 4, Lim 1 corresponds to the activity measured at low pH, Lim2
corresponds to the maximum activity measured at the optimum pH, and for eq 3, Lim3 is
equal to the activity measured at high pH.
2.2.10 Solvent Isotope Effect
SIEs were investigated by determining the steady state kinetic parameters for the
WT enzyme using the gel-based activity assay described above. The reaction mixture
consisted of 50 mM HEPES pH 8.0, 1 mM EDTA, 50 mM NaCl, 0.5 mM dithiothreitol,
15 μM [14C]-labeled SAM, and a varying concentration of AcH4-21 (0-1000 μM final) in
>92% D2O. The assay was done in duplicate and the standard deviation of the duplicate
raw data values agreed within ≤20%. The GraFit version 5.0.11 software (Leatherbarrow
2004) was used to fit the data to eq 1.
2.2.11 SAH Inhibition Studies
The inhibition constants for SAH were determined for the WT and mutant
enzymes using the gel-based activity assay described above.

The reaction mixture

consisted of 50 mM HEPES pH 8.0, 1 mM EDTA, 50 mM NaCl, 0.5 mM dithiothreitol,
15 μM [14C]-labeled SAM, 100 μM AcH4-21, and a varying concentration of SAH (0500 μM final). The assay was done in duplicate and the standard deviation of the
duplicate raw data values agreed within ≤ 20%. The GraFit version 5.0.11 software

38

(Leatherbarrow 2004) was used to fit the data to a Dixon plot of 1/υ versus SAH
concentration. The Ki was determined using eq 5,
slope = Km/(Vmax*Ki*[S])

(5).

2.2.12 pKa calculations
The structure of PRMT1 (PDB ID: 1ORI) was rebuilt using Amber topology
parameters and hydrogen atoms added to the structure. Atom partial charges and atomic
radii were assigned based on Amber99 force-field using the program AMBER. pKa value
were computed taking into account desolvation effects and intra-protein interactions,
including the proximity of neighboring functional groups.
2.3 Results and Discussion
To begin to investigate the catalytic mechanism of PRMT1, site directed
mutagenesis was used to probe the roles of Y39, R54, E100, S102, E144, E153, M155,
and H293. The mutant enzymes were purified and characterized according to described
procedures (Osborne et al. 2007). AcH4-21, a 21 amino acid peptide based on the Nterminus of histone H4, was used as a substrate for PRMT1 and mutants (Table 2.1). The
kinetic parameters of each mutant were determined for the AcH4-21 peptide as well as
SAM (Table 2.2 & 2.3). Note that similarly to other systems (Boehr et al. 2001 &
Knuckley et al. 2007) 2, partial proteolysis studies were performed to ensure that the loss
of activity associated with a particular mutation was not due to a gross structural
perturbation (data not shown).
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Table 2.1 Peptide Sequences
Peptide

Sequence

AcH4-21

1-Ac-SGRGKGGKGLGKGGAKRHRKV

RGG3

GGRGGFGGRGGFGGRGGFG

Table 2.2 Kinetic parameters of PRMT1 mutants for the AcH4-21 peptide
Mutant

Km
(µM)

Fold

kcat
(min-1)

Fold

kcat/Km
(M-1·min-1)

Fold

WTa

1.1 ± 0.5

-----

4.6 x 10-1 ± 2 x 10-2

-----

4.1 x 105

-----

Y39Fa

2.0 ± 0.7

1.8

4.2 x 10-2 ± 2 x 10-3

11

2.1 x 104

20

R54Ka

0.8 ± 0.6

0.7

1.09 x 10-2 ± 4 x 10-4

42

1.3 x 104

32

R54Aa

5±1

4.5

6.0 x 10-2 ± 3 x 10-3

7.7

1.3 x 104

32

E100Da

5±1

4.5

3.6 x 10-1 ± 1 x 10-2

1.3

7.6 x 104

5.4

E100Qa

6±2

5.5

2.5 x 10-1 ± 1 x 10-2

1.8

4.5 x 104

9.1

E100Aa

2.6 ± 0.9

2.4

1.85 x 10-1 ± 8 x 10-3

2.5

7.2 x 104

5.7

E144Da

1.7 ± 0.4

1.5

2.2 x 10-1 ± 1 x 10-2

2.0

1.3 x 105

3.2

E144Qa

2.0 ± 0.6

1.8

1.3 x 10-1 ± 4 x 10-3

3.5

6.7 x 104

6.1

E144Aa

0.3 ± 0.2

0.3

9.5 x 10-3 ± 2 x 10-4

50

3 x 104

14

E153Da

3.1 ± 0.5

2.8

2.65 x 10-2 ± 5 x 10-4

17

8.6 x 103

50

E153Qa

2.0 ± 0.8

1.8

7.7 x 10-3 ± 3 x 10-4

60

3.8 x 103

110

E153Aa

1.8 ± 0.6

1.6

3.8 x 10-3 ± 1 x 10-4

121

2.2 x 103

190

E144A/
E153Aa

3.0 ± 0.7

2.7

1.32 x 10-1 ± 4 x 10-3

3.5

4.4 x 104

9.3

M155La

0.6 ± 0.4

0.5

1.73 x 10-1 ± 5 x 10-3

2.7

3 x 105

1.4

M155Ab

1.8 ± 0.5

1.6

4.6 x 10-2 ± 1 x 10-3

10

2.6 x 104

16

H293Qa

2±2

1.8

7.6 x 10-3 ± 6 x 10-4

61

3.7 x 103

110

H293Aa

11.1 ± 0.6

10

1.81 x 10-2 ± 2 x 10-4

25

1.6 x 103

256

a

[SAM] = 15 μM. b[SAM] = 30 μM.
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Table 2.3 Kinetic parameters of PRMT1 mutants for SAM
Mutant

Km
(µM)

Fold

kcat
(min-1)

Fold

kcat/Km
(M-1·min-1)

Fold

WTa

6±1

-----

5.8 x 10-1 ± 3 x 10-2

-----

1 x 105

-----

Y39Fa

14 ± 3

2.3

7.0 x 10-2 ± 5 x 10-3

8.3

5.1 x 103

20

R54Ka

14 ± 1

2.3

3.3 x 10-2 ± 1 x 10-3

18

2.4 x 103

42

R54Aa

10 ± 1

1.7

9.5 x 10-2 ± 4 x 10-3

6.1

9.1 x 103

11

E100Da

6±2

1.0

4.8 x 10-1 ± 5 x 10-2

1.2

7.8 x 104

1.3

E100Qa

7±2

1.2

2.8 x 10-1 ± 2 x 10-2

2.1

3.8 x 104

2.6

E100Aa

5±2

0.8

1.6 x 10-1 ± 2 x 10-2

3.6

3.1 x 104

3.2

E144Da

4.0 ± 0.9

0.7

2.7 x 10-1 ± 2 x 10-2

2.1

6.8 x 104

1.5

E144Qa

8.3 ± 0.9

1.4

1.60 x 10-1 ± 7 x 10-3

3.6

1.9 x 104

5.3

E144Aa

3.1 ± 0.6

0.5

1.05 x 10-2 ± 4 x 10-4

55

3.4 x 103

29

E153Da

5±1

0.8

2.8 x 10-2 ± 2 x 103

21

5.8 x 103

17

E153Qa

17 ± 4

2.8

1.9 x 10-2 ± 2 x 10-3

31

1.1 x 103

91

E153Aa

9±3

1.5

4.1 x 10-3 ± 4 x 10-4

141

4 x 102

250

E144A/
E153Aa

10 ± 2

1.7

1.06 x 10-1 ± 6 x 10-3

5.5

1.1 x 104

9.1

M155La

10 ± 2

1.7

1.00 x 10-1 ± 8 x 10-3

5.8

1 x 104

10

M155Aa

110 ± 21

18

2.9 x 10-1 ± 4 x 10-2

2.0

2.8 x 103

36

H293Qa

17 ± 6

2.8

1.4 x 10-2 ± 2 x 10-3

41

8 x 102

125

H293Aa

37 ± 2

6.2

5.6 x 10-2 ± 1 x 10-3

10

2 x 103

50

a

[AcH4-21] = 100 μM.

2.3.1 Mutagenesis Studies of SAM Binding Mutants
2.3.1.1 R54 Mutants
R54 hydrogen bonds and/or forms an electrostatic interaction with E144, one of
the two key glutamate residues, and presumably orients this residue for the productive
recognition of the substrate guanidinium. Additionally, both Nη1 and Nη2 of this residue
interact with the carboxylate group on the methionine portion of SAM, which suggests
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that this residue could play a key role in SAM binding (Figure 2.2). Consistent with this
prediction is the 42-fold decrease in the kcat/Km value observed for SAM with the R54K
mutant. However, the effect on kcat/Km is primarily driven by a decrease in kcat and not
Km, suggesting that the lack of a more dramatic effect on the SAM Km reflects the multistep nature of the reaction, where Kd is not equal to Km; kcat/Km represents all steps up to
and including the first irreversible step of the reaction. To evaluate whether this was
indeed the case, we determined the dissociation constants, i.e., Ki, for SAH binding to
both the WT and R54A enzymes; SAH was used for these experiments as a proxy for
SAM to more accurately gauge the effects of a particular mutation on SAM binding. The
results of these studies confirm that R54 is not critical for SAM binding, as evidenced by
the fact that the Ki for SAH is similar to that obtained for the WT enzyme (Table 2.4).
Table 2.4: SAH Inhibition Studies
Enzyme
WT
Y39F
R54A
E100A
M155A

Ki (μM)
1.28 ± 0.06
26 ± 1
1.8 ± 0.2
1.9 ± 0.1
34 ± 6

With respect to the peptide substrate, large changes in both kcat(app) (42- and 7.7fold) and kcat/Km (32- and 32-fold) were observed for both the R54K and R54A mutants,
respectively. Although these effects are at least partially related to our inability to
completely saturate the enzyme with SAM in our radioactive methyltransferase assay,
which is why the term kcat(app) is used, their magnitude, particularly on kcat(app), is
consistent with a role for this residue in orienting the substrate guanidinium via E144 for
nucleophilic attack on the methyl group of SAM. Consistent with this notion is the fact
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that the kcat values obtained with SAM, where the peptide substrate is saturating, are
decreased by a similar order of magnitude.
2.3.1.2 E100 Mutants
E100 hydrogen bonds to the ribose moiety of SAM and thus would be expected to
play an important role in SAM binding. Three mutants, i.e., the E100D, E100Q, and
E100A mutants, were made to confirm this hypothesis. With respect to the kinetic
parameters determined for SAM, there is only a very small effect on kcat/Km.

For

example, the complete removal of the E100 carboxylate, as occurs in the E100A mutant,
decreases kcat/Km by only 3.2-fold.

The Ki for SAH with this mutant is similarly

unaffected, quite clearly demonstrating that this residue is not important for SAM binding
or catalysis. This result is especially surprising when one considers that the distances
between the ribose hydroxyls and the α-carboxylate of E100 in the PRMT1●SAH
complex are only 2.6-2.7 Å, which are distances typically associated with relatively
strong hydrogen bonds. Although the observed interactions may be an artifact of the
crystallization conditions (the enzyme was crystallized at pH ~4.7, which would favor
protonation of E100 and potentially promote hydrogen bond formation), similar distances
and orientations are observed in the crystal structures of the PRMT3●SAH and
CARM1●SAH complexes which were crystallized at pH 6.3 and pH 7, respectively
(Zhang et al. 2000, Troffer-Charlier et al. 2007).

Thus, such an explanation is

intellectually unsatisfying. Nevertheless, these results are at least partially consistent
with the fact that methylthioadenosine is a relatively poor PRMT1 inhibitor (Osborne et
al. 2007).
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With respect to the kinetic parameters determined for the AcH4-21 peptide, the
effects, while still small, are significantly larger than those observed with SAM. For
example, the fold decrease in kcat(app)/Km for the E100D, E100Q, and E100A mutants are
5.4-fold, 9.1-fold, and 5.7-fold, respectively. As the effects are largely driven by an
increase in Km, these results suggest that an interplay exists between the binding of both
substrates, or alternatively, a change in the kinetic mechanism.
2.3.1.3 M155 Mutants
To probe the importance of M155, the M155L and M155A mutants were
generated. With respect to the peptide substrate, the kinetic parameters for the M155L
mutant were similar to those obtained for the WT enzyme; the kcat(app) and kcat(app)/Km
values were only decreased by 2.7-fold and 1.4-fold, respectively. In contrast to these
relatively minor effects, 5.8- and 10-fold decreases in kcat and kcat/Km were observed when
SAM was tested as the varied substrate. These effects either represent an inability to
properly position the S-methyl group of SAM or, alternatively, an effect on SAM
binding. Given that M155 forms the bottom of the adenine portion of the SAM binding
pocket, these results are most consistent with the latter possibility because the structural
differences between a leucine and a methionine would be expected to alter SAM binding.
Similar effects on SAM binding are observed with the M155A mutant. For example, the
Km and kcat/Km values of the M155A mutant for SAM are increased by 18- and 36-fold,
respectively. Confirming that this residue is important for SAM binding is the fact that
the Ki for SAH is increased by 27-fold relative to WT. The large changes in Ki, Km and
kcat/Km likely reflect a loss of steric constraint within the SAM binding pocket, which
disfavors the binding of SAM in an orientation that is productive for catalysis. With
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respect to the peptide substrate, 10- and 16-fold reductions in kcat(app) and kcat(app)/Km were
observed. These effects are most likely due to our inability to completely saturate the
enzyme with SAM in our radioactive methyltransferase assay.
2.3.1.4 Role of M155 in ADMA Formation
Given the postulated role of M155 in directing the formation of ADMA, as opposed
to SDMA (Zhang et al. 2000 & Branscombe et al. 2001), we also investigated, in
collaboration with Cecilia Zurita-Lopez and Steve Clarke (UCLA), the contribution of
this residue to the regiospecific dimethylation of a substrate arginine residue. For these
studies, the M155A mutant was utilized because we hypothesized that this mutation
would relieve the steric constraint imposed by the methionine and thereby open up the
pocket and allow for SDMA formation. To investigate this possibility, the M155A
mutation, along with the WT control, was used to catalyze the 3H-SAM dependent
methylation of GST-GAR, a fusion protein that links GST to the N-terminus of human
fibrilarin (Figure 2.3). Subsequently, the reaction was hydrolyzed in 6 M HCl at 110°C,
and the extent of w-MMA, SDMA, and ADMA formed was quantified by high resolution
cation exchange chromatography. The results of these experiments indicate that the
M155A mutant catalyzes the exclusive formation of w-MMA and ADMA. Thus, despite
the fact that this mutation relieves the steric constraint thought to prevent SDMA
formation, our results indicate M155 is not responsible for the formation of ADMA over
SDMA.
Nevertheless, given that the mutation of this residue strongly impacts the kinetics of
the PRMT1 catalyzed reaction, particularly with respect to the Km for SAM, we reasoned
that it may play a role in the processivity of ADMA formation. To investigate this
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possibility, a previously established MALDI-MS assay (Osborne et al. 2007) was
utilized. Consistent with previous results with the WT enzyme, w-MMA and ADMA

Figure 2.3 Amino acid analysis of PRMT1-depedent methylation products.
(A) WT PRMT1 produces a mixture of w-MMA and ADMA as products of
methylation. (B) The M155A mutant also produces a mixture of w-MMA and
ADMA as products of methylation.
In each case, the position of the
standards was determined by ninhydrin assay (dotted lines); the position of the
[3H]-radiolabeled derivatives by counting (solid lines). The slightly earlier
elution position of the [3H]-ADMA and [3H]-w-MMA products compared to
the standards is due to the mass and pKa differences of amino acids with
tritium versus hydrogen-containing methyl groups (Fisk et al. 2009).
containing peptides were initially produced in equimolar amounts, followed by a decrease
in levels of w-MMA (Figure 2.4A).

As described previously, these results are

characteristic of an enzyme that has the ability to rebind SAM and subsequently produce
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Figure 2.4 Processivity of WT PRMT1 and M155 mutants. (A) WT PRMT1
uses a partially processive mechanism to catalyze the formation of ADMA. (B)
The M155L mutant uses a partially processive mechanism, however, formation
of ADMA is slower than with WT PRMT1. (C) The M155A mutant uses a
distributive mechanism to catalyze the formation of ADMA. The large percent
turnover of w-MMA suggests that w-MMA is released prior to the rebinding in
preparation for the second round of methylation.
ADMA before the first methylation product, w-MMA, is released (Osborne et al. 2007).
Because ADMA formation is not obligatory, we have suggested that PRMT1 displays
partial processivity. With respect to the M155L mutant, similar results were obtained,
however, the level of ADMA formed is significantly lower at the early time points
(Figure 2.4B).

This result indicates that the M155L mutant is significantly less

processive than the WT enzyme. For the M155A mutant, little to no ADMA is formed
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until the 20 min time point (Figure 2.4C), which suggests that w-MMA is released prior
to the rebinding of SAM and that this mutant utilizes a distributive mechanism. Note that
the concentration of SAM used in these assays was 500 µM; thus the loss of processivity
is not due to a failure to saturate the enzyme with SAM. In total, these results are
consistent with M155 playing a key role in SAM binding, as reduced affinity for SAM, as
occurs with both the M155L and M155A mutants, would be expected to decrease the
processivity of the enzyme because, for these mutants, the off rate for the
monomethylated peptide is larger than the rate constant for SAM binding.
2.3.2 Mutagenesis Studies of Catalytic Mutants
2.3.2.1 E144 Mutants
E144 appears to orient Nη2 of the substrate guanidinium group to facilitate
nucleophilic attack on the S-methyl group of SAM. In order to investigate this role, the
E144D, E144Q, and E144A mutants were generated. The kcat/Km values for the E144D
mutant were decreased by 3.2-fold and 1.5-fold for AcH4-21 and SAM, respectively.
The ability of aspartate to substitute for the glutamate indicates flexibility within the
active site and reveals that positioning of this residue is not critical for catalysis. For the
E144Q mutant, the effects on kcat/Km are slightly larger, with these values down 6.1-fold
and 5.3-fold for AcH4-21 and SAM, respectively. These data suggest that the charge of
this residue is significantly less important than its ability to hydrogen bond with both the
substrate guanidinium and R54, as opposed to modulating the nucleophilicity of that
group. Note that the calculated pKa of the E144 carboxylate is ~2.7; thus this residue is
likely deprotonated in the PRMT1 active site. Nevertheless, this residue is important for
catalysis, as illustrated by the 14-fold and 29-fold decrease in the kcat/Km values for
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AcH4-21 and SAM for the E144A mutant. Note the effects on kcat/Km are dominated by a
decreased kcat, suggesting that this residue is relatively unimportant for substrate binding.
These results are consistent with previous findings from mutagenesis studies that only
measured relative rates (Zhang et al. 2003). In total, the data suggest that the hydrogen
bonding characteristics, and to a lesser extent, the charge of E144, are important for
orienting the substrate guanidinium for nucleophilic attack on the S-methyl group of
SAM.
2.3.2.2 E153 Mutants
The carboxylate group of E153 is thought to play a crucial role in catalysis
through its electrostatic and hydrogen bonding interactions with Nη1 and Nδ of the
substrate guanidinium. To investigate the importance of both the size and charge of this
residue the E153D, E153Q, and E153A mutants were made and the kinetic parameters
determined. The results are consistent with this residue playing a key role in catalysis.
For example, the kcat values for the E153D, E153Q, and E153A mutants are decreased by
21-, 31-, and 140-fold, respectively. Given that the effects on kcat/Km mirror the effects
on kcat, these data indicate that both the charge and the position of E153 are more
important for catalysis than substrate binding. These results are also consistent with
previous findings from mutagenesis studies that only measured relative rates (Zhang et al.
2003). The fact that mutating E153 has a more dramatic effect than mutating E144 is
consistent with the notion that this residue plays an important role in redistributing
electron density within the guanidinium group to enhance its nucleophilicity.
2.3.3.3 E144A/E153A Mutant
Given the results obtained for the E144 and E153 single mutants, we expected
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that the E144A/E153A double mutant would likely yield negligible, if any, activity.
However, this was not the case, as kcat is decreased by only 5.5-fold and the kcat/Km values
are only decreased by 9.3- and 9.1-fold for AcH4-21 and SAM, respectively. The more
significant effect on the single mutants is most easily explained by the formation of a
strong salt bridge to the remaining glutamate. Such an interaction would be expected to
decrease activity by altering both the nucleophilicity of the guanidinium and its position
such that methyl transfer is suboptimal.

The fact that the double mutant retains

considerable activity is more difficult to rationalize. However, it is possible that the
removal of the two glutamate residues increases the hydrophobicity of the active site,
which would be expected to depress the pKa of the guanidinium, and thereby increase its
nucleophilicity. Although we cannot rule out such a possibility, the active site possesses
a number of other hydrophilic residues in close proximity (e.g., Y39, R54, and H293) that
should minimize any change in hydrophobicity.

An alternative explanation that is

equally supported by the data involves the PRMT1 catalyzed reaction being primarily
driven by bringing the substrate guanidinium into close proximity to the S-methyl group
of SAM.
2.3.3.4 H293 Mutants
H293 has been thought to play the role of a general base by accepting a proton
from Nη2, however, this residue is >6 Å from the approximate position of the substrate
guanidinium, a distance that is too far to directly remove the proton. Although a watermediated proton transfer mechanism is possible, the high basicity of the substrate
guanidinium makes this mechanism intellectually unsatisfying and we have suggested
(see above) that proton loss could occur prior to, concomitant with, or even after methyl
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transfer, and that H293 may not act as a general base. In order to probe this hypothesis,
the H293Q and H293A mutants were generated. For the H293Q mutant, the kcat is
decreased by 41-fold, whereas negligible changes in the Km values were observed,
indicating that the 110- and 125-fold decreases in the kcat/Km values for AcH4-21 and
SAM are driven by kcat. For the H293A mutant, the effects on kcat/Km are similar in
magnitude, with the kcat/Km values for AcH4-21 and SAM decreased by 256- and 50-fold,
respectively. Although these results indicate that H293 plays a critical role in catalysis,
and could be interpreted as being consistent with a role for H293 as the general base,
alternative explanations are also possible.

For example, in the structure of the

PRMT1●SAH complex, H293 appears to form a salt bridge with D51, a conserved
residue that is present on αY. Given the short distance between the side chains of H293
and D51 (i.e., 2.6 Å), this interaction likely plays a critical role in forming the two helix
boundary that separates the SAM and peptide binding portions of the active site (Figure
2.5).

As such, one would expect that disruption of this interaction would lead to

decreased activity via the inability to properly form the substrate and cofactor binding
pockets. This is especially likely when one considers that Y39, H45, M48, and R54 are
present on helix αY and αZ and likely play key roles in both PRMT1 catalysis (e.g., Y39
and R54) and forming the active site cleft (e.g., H45 and M48). Consistent with this
possible role for H293 is the fact that similar effects on kcat/Km are observed for both
SAM and the AcH4-21 peptide. This is the case because either the alanine or glutamine
mutations would not be expected to affect SAM binding, only kcat. Given that R54 is also
present on helix αY some of the effects of mutating this residue may also be due to the
destabilizing the formation of the PRMT1 substrate and cofactor binding pockets.
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D51
2.6 Å

H293

SAH

Figure 2.5 D51 and H293 interaction. The kinetic
effects of the H293 mutations can be explained by
the fact that a salt bridge likely forms between D51
and H293, which are only separated by 2.6 Å. A
disruption of this interaction could possibly prevent
the proper formation of the binding pockets. This
figure was prepared with UCSF Chimera using the
coordinates for PRMT1 (PDB 1ORI).
2.3.3.5 Y39 Mutant
In CARM1, Y154 appears to be important for both cofactor binding and orienting
E267 (Y154 and E267 correspond to Y39 and E153 in PRMT1) (Yue et al. 2007, TrofferCharlier et al. 2007, Feng et al. 2009). Although the Y154F mutant appears to abolish
CARM1 activity, this was a single point assay and only relative rates were measured
(Feng et al. 2009). Thus, to establish the role of the corresponding residue in PRMT1,
the Y39F mutant was generated and the kinetic parameters determined. Although this
mutation has only small, ~2-fold effects on the Km values for AcH4-21 and SAM, the Ki
for SAH is increased by ~20-fold (Table 2.4), thereby confirming that this residue is
important for cofactor binding; the lack of a more dramatic effect on the SAM Km reflects
the multi-step nature of the reaction, where Kd is not equal to Km. The importance of this
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residue was further illustrated by the 20-fold decrease in the kcat/Km value observed for
AcH4-21 and the 20-fold decrease seen with SAM. The position of this residue within
the PRMT1 active site and the fact that kcat is also decreased by 8.3 fold suggest that this
residue also plays an important role in rate enhancement; the specific role of this residue
in catalysis is described below (see pH studies).
2.4 pH Studies
In order to further increase our understanding of PRMT1 catalysis, pH rate
profiles were generated for the WT enzyme by determining kcat and kcat/Km values for both
SAM and the RGG3 peptide over a pH range of 6.0-9.25. The RGG3 peptide (Table 2.1)
was used in place of the AcH4-21 peptide to simplify the interpretation of the pH rate
profiles. This is the case because this peptide has comparable kinetic parameters to the
AcH4-21 peptide and, more importantly, because, with the exception of the N-terminus
(pKa ~ 8.0), this peptide lacks residues that typically ionize within the pH range under
study. Note that at all pH values enzyme activity was linear with respect to time,
indicating that the loss of activity at the pH extremes was not due to a non-specific effect
on enzyme structure. Also note that kcat/Km is the apparent second order rate constant for
the reaction of free substrate and free enzyme (or when one substrate (A) is saturating,
the EA complex), and therefore the pH-dependence of kcat/Km monitors the ionization
state of these entities. In contrast, effects on kcat are interpreted as being due to the
presence of important ionizable groups in the enzyme•substrate complex.
With SAM as the varied substrate, the plot of log kcat/Km versus pH is bell-shaped
and is consistent with the presence of two ionizable groups that are important for
substrate capture; pKa values of 6.2 ± 0.3 and 10.5 ± 0.4 were assigned to the ascending
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and descending limbs, respectively (Figure 2.6A). With respect to kcat, the rate of the
reaction increases with increasing pH until a limiting value is reached (Figure 2.6B).
Fitting the data to eq 4 yields a pKa value of 5.1 ± 0.8. Although it is difficult to
definitively assign an observed pKa to a particular residue, or functional group on a
substrate, the structures of PRMT1, SAM, and the RGG3 peptide suggest several possible
residues/functional groups whose ionization could alter substrate capture or kcat. With
respect to the ascending limb, protonation of the SAM carboxylate (pKa ~ 2 in solution),
D51, E100, E144, and E153 could explain the loss in activity as the pH decreases.
However, most of these groups are readily ruled out. For example, the pKa of the SAM
carboxylate is significantly lower than the pKa for the ascending limb of the kcat/Km versus
pH-rate profile. Consistent with this notion is the fact that the R54A mutation does not
affect the Ki for SAM. Although protonation of D51, which is the residue that interacts
with H293, could also explain the loss of activity at low pH, the fact that the pH rate
profiles obtained for the H293A mutant show a similar loss of activity at low pH (vide
infra) argues against this possibility. Protonation of E100 could also potentially explain
the loss of activity at low pH. However, the fact that little to no effect on the kinetic
parameters were observed when this residue was mutated to alanine makes this
suggestion unlikely. Of the remaining two residues, i.e., E144 and E153, the residue
most likely responsible for the loss of activity at low pH is E153. We surmise that this is
the case because the E144Q mutant retains considerable activity; thus, the ionization of
this residue would also be expected to minimally impact the reaction rate. In contrast, the
activity of the E153Q mutant is significantly decreased and similar to that obtained for
the E153A mutant, thereby suggesting that protonation of the E153 carboxylate would
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Figure 2.6. pH profiles of WT PRMT1 with SAM. (A) The log kcat/Km versus
pH plot is used to determine the pKa of ionizable groups on the enzyme or
substrate. (B) The log kcat versus pH plot is used to determine the pKa of
ionizable groups in the ES complex.
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have a profound negative impact on rate acceleration. Also consistent with the ionization
of this residue corresponding to the ascending limb is the fact that the pKa of a glutamate
residue in solution is typically in the range of 4-5. In total, these data suggest that E153
must be deprotonated for optimal PRMT1 activity.
With respect to the descending limb, deprotonation of the amino group on SAM
(pKa ~ 9.5 in solution), the N-terminal amino group on the RGG3 peptide (pKa ~ 8 in
solution), Y39, and H293 could explain the loss in activity as the pH increases. Given
the similarities in the pKa values of these functional groups, it is more difficult to
definitively assign the pKa of the descending limb. Nevertheless, the fact that the pKa of
the N-terminal amine on the RGG3 peptide is significantly lower than the pKa of the
descending limb argues against the notion that the ionization of this group is responsible
for the decreased activity at high pH. Note also that the pKa of an arginine residue is 12.5
and is significantly higher than the pKa observed for the descending limb, arguing against
the idea that ionization of these residues in the RGG3 peptide is responsible for the loss
in activity.

The fact that the concentration of the RGG3 peptide is fixed in these

experiments further argues against these possibilities because, here, kcat/Km is the second
order rate constant for the reaction of SAM with the E•RGG3 complex, and thus, kcat/Km
monitors the ionization state of these entities and not the RGG3 peptide. The fact that the
calculated pKa of H293 (7.9) is significantly lower than the pKa observed for the
descending limb suggests that this residue is also not responsible for the loss in activity at
high pH. Of the two remaining functional groups/residues, i.e., the amino group on SAM
and the Y39 phenol, deprotonation of either one could be responsible for the loss in
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activity at high pH, as the pKa values of these groups (i.e., 9.5 and 10.5, respectively) are
similar to that obtained for the descending limb.
When the RGG3 peptide is used as the varied substrate, the plot of log kcat/Km
versus pH is also bell-shaped with an ascending limb pKa of 5.2 ± 0.2 and a descending
limb pKa of 10.0 ± 0.3 (Figure 2.7A). For the same reasons described above, these pKa
values likely correspond to the protonation states of E153 and Y39, respectively. Note
that the assignment of the descending limb to the amino group on SAM can be at least
partially ruled out because the concentration of SAM is fixed in these experiments; thus,
kcat/Km is the second order rate constant for the reaction of the RGG3 peptide with the
E•SAM complex, and, as such kcat/Km monitors the ionization state of these entities, and
not SAM. Interestingly, and in contrast to the data presented for SAM, the plot of the log
kcat values versus pH is relatively flat, thereby indicating that when the peptide is the
varied substrate the turnover number is not influenced by pH (Figure 2.7B).

This

difference most likely reflects a change in the rate determining step for the reaction.
Given that PRMT1 methylates its substrates in a partially processive fashion, this data is
most consistent with product release being rate limiting when the peptide is the varied
substrate, as opposed to the case when the concentration of SAM is varied and chemistry,
a conformational change, or SAM binding is potentially rate-limiting.
pH-rate profiles were also generated for the H293A and Y39F mutants using the
RGG3 peptide as the varied substrate (Figure 2.7). Note that we focused on these
mutants because of their putative roles as the general base and because the tyrosine
residue possesses an ionizable group that potentially corresponds to the basic limb of the
WT pH-rate profile. Also note that we only generated profiles for the RGG3 peptide
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Figure 2.7. pH profiles of WT PRMT1 and mutants with the RGG3
peptide. (A) The log kcat/Km versus pH plot is used to determine the pKa
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because we envisioned that this data would provide greater insights into the factors that
are important for promoting methyl transfer to the peptide substrate. For the H293A and
Y39F mutants, the plots of log kcat versus pH are sigmoidal, with the rates increasing as a
function of pH to a limiting value (Figure 2.7B). Fitting the data to eq 4 identified pKa
values of 4.8 ± 0.4 and 5.1 ± 0.8 for the H293A and Y39F mutants, respectively.
Interestingly, these data differ substantially from that obtained with the WT enzyme,
where changes in pH did not affect kcat. This difference likely reflects a change in the
rate limiting step. Consistent with this possibility is the fact that the mutation of either
residue decreases kcat by ≥11-fold; thus, chemistry is potentially rate limiting for both the
H293A and Y39F mutants.

In total, these data indicate that both residues play an

important role in rate enhancement.
With respect to kcat/Km, the plots of log kcat/Km versus pH for both the WT and
H293A are similarly bell-shaped, and the pKa values obtained with the H293A mutant
(i.e., 5.2 ± 1.6 and 10.1 ± 0.9) are nearly identical to those obtained for the WT enzyme
(Figure 2.7A). Conversely, only the ascending limb is evident in the Y39F kcat/Km versus
pH plot, which suggests that the phenolic side chain of this residue corresponds to the
descending limb of the kcat/Km versus pH rate profile. These results suggest that Y39
must be protonated for optimal activity and that deprotonation of the phenol leads to a
decrease in activity either by the loss of a key hydrogen bond between Y39 and E153 or
electrostatic repulsion between these two residues that leads to a decrease in enzyme
activity. In contrast, it is interesting to note that the lack of an effect of mutating H293 on
the shape of the pH-rate profiles, suggests that the general acid/base properties of this
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residue are not important for rate enhancement. As such, these data suggest that H293
does not act as the general base that deprotonates the substrate guanidinium.
2.4 Solvent Isotope Effects
To further probe the catalytic mechanism of PRMT1, we also determined the
steady state kinetic parameters for the PRMT1 catalyzed reaction in D2O, using the
AcH4-21 peptide as the varied substrate. For these experiments, the rates of the reaction
were measured in ≥92% D2O and compared to those obtained in H2O at the
corresponding pL. For the WT enzyme, a small inverse SIE (0.9) is apparent on kcat/Km
when the peptide is the varied substrate (Table 2.5). Although this result could be
Table 2.5 Solvent Isotope Effects (SIE) and Solvent Viscosity Effects (SVE)
Mutant

SIE

kcat

SVE

kcat

SIE

kcat/Km

SVE

kcat/Km

WT

1.0

0.7

0.9

0.9

E144A/E153A

0.8

0.7

0.4

0.6

Y39F

0.4

0.4

0.3

1.8

R54A

1.2

1.3

0.6

1.7

H293A

0.1

1.2

0.1

1.6

interpreted as being consistent with general base catalysis being unimportant for rate
enhancement (a normal SIE would be expected if general base catalysis plays a
prominent role in rate enhancement), the fact that chemistry is unlikely to be rate limiting
for the peptide substrate with the wild type enzyme (see above), could suggest that the
lack of an effect is due to the fact that product release is insensitive to the identity of the
solvent.

Given this possibility, we also determined SIEs for the Y39F, R54A,

E144A/E153A, and H293A mutants, because the large decreases in kcat (~5- to 20-fold)
suggest that chemistry is rate limiting for these enzymes. To help to confirm this
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Figure 2.8 Processivity of WT PRMT1 and mutants. (A) WT PRMT1 uses a partially
processive mechanism to catalyze the formation of ADMA. (B-D) TheY39F, R54A,
and H293A mutants uses a distributive mechanism to catalyze the formation of
ADMA in which ω-MMA is released prior to rebinding in preparation for the second
round of methylation. (E) The E144A/E153A mutant uses a partially processive
mechanism, however, the formation of ADMA is slower than WT.

61

possibility, we examined the processivity of the above described mutant enzymes. The
results of these studies (Figure 2.8) indicated that the Y39F, R54A, E144A/E153A, and
H293A mutants do not methylate the AcH4-21 peptide in a partially processive fashion,
further suggesting that chemistry is rate-limiting for at least a subset of these mutant
enzymes. Note that for the majority of the mutants examined, relatively small inverse
SIEs (SIEkcat and SIEkcat/Km ~ 0.6 to 0.9) were observed on both kcat and kcat/Km (Table 2.5).
The two exceptions are the cases of the R54A and H293A mutants. For the R54A
mutant, the

SIE

kcat is small and normal (SIEkcat = 1.2), whereas for the H293A mutant the

SIE on both kcat and kcat/Km is large and inverse (SIEkcat and

SIE

kcat/Km = 0.1). Note that

these experiments were performed in parallel and that representative data from one of at
least two independent experiments is reported in Table 2.5.
Inverse SIEs are often attributed to medium effects, the dissociation of a metal
chelated water, viscosity effects, or effects on thiol ionization (Karsten et al. 1995).
Although medium effects are difficult to exclude, they are typically small and normally
ignored (Karsten et al. 1995). Additionally, the lack of a requirement for metal ions or
the presence of a thiol within the active site of PRMT1 suggests that the observed inverse
SIE is not due to either of these possibilities. To control for the effect of the increased
viscosity of D2O, the kinetic parameters were determined in the presence of 10%
glycerol, a concentration of glycerol that closely mimics the viscosity of D2O (Table 2.5).
The results of these solvent viscosity experiments (SVEs) indicate that, with the
exception of the R54A and H293A mutants, the kcat values for the WT and mutant
enzymes were accelerated in the presence of 10% glycerol, suggesting that for these
mutants the inverse SIE on kcat can be attributed to a viscosity effect. With respect to
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kcat/Km, inverse SVEs were detected for only the WT and E144A/E153A double mutant,
suggesting again that for these mutants the inverse SIE on kcat/Km can be attributed to a
viscosity effect. However, normal SVEs were observed for the Y39F, R54A, and H293A
mutants, indicating that the inverse SIEs are due to a direct effect of D2O on the PRMT1
catalyzed reaction. Although it is difficult to speculate on the molecular basis for the
inverse SIEs, there are at least two possible explanations. First, given that deuterium
atoms are known to form stronger hydrogen bonds, D2O may stabilize the structure of
PRMT1 and thereby enhance the rate of the reaction. This may be particularly true for
the H293A mutant, where a very large, and likely unprecedented, inverse SIE was
observed (SIE = 0.1). As mentioned previously, the disruption of the salt bridge between
H293 and D51, which would be caused by the alanine mutation, likely prevents the
proper formation of the substrate and cofactor binding pockets. However, when the
H293A mutant is assayed in D2O, this solvent stabilizes the structure of PRMT1 and
compensates for the loss of the interaction between H293 and D51. As kcat/Km reports on
all steps up to including the first irreversible step of the reaction, which for PRMT1 is
likely methyl transfer, the observed inverse SIEs for the mutant enzymes may,
alternatively, be reporting on the formation of the dication intermediate because
rehybridization of the ω-nitrogen from sp2 to sp3 would be expected to yield an inverse
isotope effect. Regardless of the nature of the inverse SIE, the lack of a normal SIE for
WT PRMT1, and all of the catalytically impaired mutants, suggests that general base
catalysis is unimportant for the PRMT1 catalyzed reaction, and, more specifically,
suggest that H293 does not act as a general base.
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2.4 Conclusions
PRMT1 activity impacts a number of important cell signaling pathways (e.g.,
gene transcription), and is dysregulated in a number of human diseases including heart
disease and cancer.

Given its role in these diseases, PRMT1 represents a novel

therapeutic target, and, as such, we have been focused on developing inhibitors targeting
this isozyme (Osborne et al. 2007, Osborne et al. 2008, Obianyo et al. 2010, Bicker et al.
2010). In order to gain insights that could guide the design of inhibitors with increased
potency and selectivity, we used a combination of site directed mutagenesis, pH rate
profiles, and SIEs to begin to characterize the catalytic mechanism of PRMT1. For the
mutagenesis studies, we focused our efforts on examining the contribution of eight
residues lining the active site pocket of PRMT1, including Y39, R54, E100, S102, E144,
E153, M155, and H293, which, based on structures of PRMT family members, have been
hypothesized to be important for SAM binding (i.e., Y39, R54, E100), the regiospecific
generation of ADMA (i.e., M155), the regulation of CARM1 (i.e., S102 and Y39),
general base catalysis (i.e., H293), and modulating the nucleophilicity of the substrate
guanidinium (i.e., E144 and E153).
The results of the mutagenesis studies indicate that while R54 and E100 form
hydrogen bonds and electrostatic interactions with the SAM carboxylate and the ribose
moiety, respectively, neither residue is important for SAM binding. However, the fact
that the R54 mutations negatively impact the kinetic parameters obtained for the peptide
substrate, helps to confirm that the observed hydrogen bond or electrostatic interaction
between the R54 guanidinium and the E144 carboxylate is important for rate
enhancement; this interaction likely orients E144 such that it can properly position Nη2
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for nucleophilic attack on the S-methyl group of SAM. In contrast to R54 and E100,
M155 is important for SAM binding, as evidenced by the 26-fold increase in the Ki for
SAH when this residue is mutated to alanine. The kcat/Km obtained for SAM is similarly
affected. As M155 forms the bottom of the adenine portion of the SAM binding pocket,
the loss of hydrophobic interactions between M155 and the adenine ring, as occurs both
the M155L and M155A mutants, likely results in both a loss of affinity and an inability to
properly position the cofactor for methyl transfer.

M155 is also important for the

processivity, but not the regiospecificity of the PRMT1 catalyzed reaction, i.e., this
residue does not direct the formation of ADMA over SDMA, as has previously been
suggested.
E144 and E153 have previously been suggested to orient the substrate
guanidinium and modulate its nucleophilicity to promote methyl transfer (Zhang et al.
2000). Consistent with previous mutagenesis studies that only measured relative rates
(Zhang et al. 2000), our results indicate that both residues are important for PRMT1
catalysis. Interestingly, however, the charge and position of E144 appear to be relatively
unimportant for rate enhancement as both the E144D and E144Q mutants retain
considerable activity. These results suggest that the hydrogen bond between E144 and
the substrate guanidinium is most important, and that this interaction likely orients Nη2
for nucleophilic attack on the S-methyl group of SAM. In contrast, both the charge and
position of E153 are important for rate enhancement, and the results are consistent with
the previous suggestion that this residue modulates the nucleophilicity of the guanidinium
group by redistributing electron density toward Nη1 and Nδ.
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With respect to Y39, in addition to being important for SAM binding (due to its
position at the top of the SAM binding pocket), this residue appears to be important for
rate enhancement. This is apparent from the 20-fold decrease in kcat/Km when the peptide
is the varied substrate. This result indicates that the phenolic hydroxyl group enhances
the rate of catalysis. Based on structures of PRMT1 family members, this residue likely
hydrogen bonds to E153, and this interaction is important for positioning the E153
carboxylate such that it can modulate the nucleophilicity of the substrate guanidinium.
This hypothesis is supported by the fact that PRMT1 loses activity at high pH, where the
deprotonated form of Y39 would be expected to predominate and the resultant
electrostatic repulsions between this residue and the E153 carboxylate would lead to a
loss in activity. This latter observation is further supported by the loss of the high pKa
when this residue is mutated to phenylalanine.
The results obtained for the H293A mutant are particularly interesting. Although
this residue has been suggested to act as general base to deprotonate the substrate
guanidinium and thereby enhance the nucleophilicity of this group, our results do not
support such a hypothesis despite the fact that mutation of this residue decreases kcat/Km
by ≥ 50-fold. This is the case because effects are observed on both the kinetic parameters
determined for SAM and the peptide substrate.

Additionally, the pH rate profiles

obtained for the H293A mutant are similar to those obtained for the WT enzyme, which
indicates that the ionization of this residue does not contribute to either the rate limiting
step of the reaction or substrate capture. Although the contribution of this residue to rate
enhancement may not be apparent in the pH rate profiles, because this residue is
unimportant for substrate capture or the rate-limiting step of the reaction, we deem this
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possibility unlikely and suggest that the decreased activity observed when this residue is
mutated is due to the loss of a critical salt bridge between this residue and D51. The loss
of this salt bridge would be expected to destabilize the two N-terminal helices and impact
cofactor and peptide binding, both of which occur when this residue is mutated. The SIE
data also do not support a role for this residue as a general base, as a large and inverse
SIE was observed for the H293A mutant. Further support for the idea that H293 is not a
general base comes from the structure of PRMT1, which shows that this residue is ≥6 Å
distal from the approximate site of the substrate guanidinium, a distance that is too great
for this residue to play such a role.
In total, the data described above support a mechanism in which SAM and a
protein, or peptide, substrate bind to the enzyme in a random fashion to form a ternary
complex (Figure 2.2). E153 then likely redistributes the electron density towards either
Nη1 or Nδ, or even both, which enhances the nucleophilicity of Nη2. The methyl group of
SAM is then transferred to the protonated guanidinium of the substrate arginine to form a
dication intermediate.

Although such an intermediate is to our knowledge

unprecedented, dianionic carboxylate intermediates have been proposed for several
enzymes. Rehybridization of the guanidinium destabilizes the dication intermediate,
thereby facilitating the loss of the extra proton to water or an unknown general base.
While E144 could serve such a role, this seems unlikely when one considers that the
effect of mutating this residue to glutamine has only a small impact on kcat/Km. Further
support for the notion that methyl transfer precedes proton transfer comes from the lack
of a normal SIE on both the wild type enzyme as well as several catalytically impaired
mutants; a normal SIE would be expected if proton abstraction was rate-limiting. Given
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that Hedstrom and colleagues (Guillen Schlippe et al. 2005) have noted that in several
enzymes arginine residues can act as general bases and that the pKa of those residues is
potentially modulated by slight structural perturbations to the normally planar
guanidinium, we cannot completely rule out the possibility that E144 and E153 depress
the pKa of the substrate arginine and thereby enhance its nucleophilicity, via such a
mechanism. However, it is difficult to rationalize such a mechanism with our findings
that the E144A/E153A double mutant possesses considerably more activity than either of
the single mutations alone. Thus, we favor the mechanism proposed above where the
methyl group is transferred to the protonated guanidinium. In summary, our results
suggest that the PRMT1-catalyzed reaction is primarily driven by bringing the substrate
and cofactor into the proximity of each other and that the prior deprotonation of the
substrate guanidinium is not required for methyl transfer.
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CHAPTER 3
Regulation of PRMT1 by Post-translational Modifications
3.1 Introduction
Post-translational modifications play a pivotal role in the cell by adding an
additional level of functional regulation.

For example, the methylation of arginine

residues within proteins, which is catalyzed by the PRMT family of enzymes, has been
found to affect gene transcription, RNA splicing, signal transduction, and cell
proliferation (Bedford et al. 2005, Bedford et al. 2007, Bedford et al. 2009, Wolf et al.
2009, and Di Lorenzo et al. 2011). Due to its numerous and various roles in cellular
processes, it is only logical that arginine methylation itself would be regulated. One such
method of regulation of the PRMT family is that of PTMs.
In fact, the activity of both CARM1 and PRMT5 has been found to be regulated
by phosphorylation. In CARM1, three different serine residues, i.e., S217, S228, and
S448, have been demonstrated to be phosphorylated in vivo (Feng et al. 2009,
Higashimoto et al. 2007, Carascossa et al. 2010).

S217 was identified by mass

spectrometry on immunoprecipitated CARM1 from MCF-7 cells and this residue is
conserved amongst Type I PRMTs. Phosphorylation of this residue diminishes the
methyltransferase activity of the enzyme in vitro and abrogates its coactivator function in
vivo.

Additionally, this PTM causes the mainly nuclear enzyme to localize in the
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cytoplasm. Based on the structure of CARM1, this change in activity is presumably due
to the addition of a phosphate group to the side chain hydroxyl of S217, disrupting the
hydrogen bond to the backbone carbonyl of Y154 (Feng et al. 2009). As a result, the
enzyme cannot bind SAM. Additionally, this PTM could affect the position of Y154
(Y39 in PRMT1) (Feng et al. 2009), which has been suggested to interact with the ribose
and sulfur atom of SAM, as well as with E267, a residue important for catalysis (Yue et
al. 2007, Troffer-Charlier et al. 2007, & Rust et al. 2011). S228, which is conserved
among different species (but not among different PRMT family members), was also
identified by mass spectrometry on immunoprecipitated CARM1 from HELA and MCF7 cells. Mutation of S228 to glutamate inhibited methyltransferase activity in vitro and
abrogated its coactivator function in vivo. These results are likely due to the disruption of
dimer formation (Higashimoto et al. 2007). Finally, S448 was identified from MCF-7
cells using an antibody against a PKA substrate consensus motif and verified by sitedirected mutagenesis. Interestingly, unlike the previous two sites that were involved in
regulating methyltransferase acitivty, phosphorylation of this residue mediates the
interaction between CARM1 and apo-ERα and plays a role in ligand independent
activation of the receptor by cAMP (Carascossa et al. 2010).
PRMT5 is also phosphorylated in vivo at three tyrosine residues (i.e., Y297,
Y304, and Y307) that are conserved amongst species. Phosphorylation greatly decreases
the methyltransferase activity of the enzyme in vitro against histones H2A and H4 and
inhibits its association in vivo with MEP50, a known interacting partner that is critical for
activity. Intriguingly, the responsible kinases are constitutively active mutants of Janus
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kinase 2 (JAK2), i.e., JAK2V617F and JAKK539L, and the phosphorylation of PRMT5
by these mutants likely promotes myeloproliferative neoplasms (Liu et al. 2011).
In addition to phosphorylation, automethylation has been detected in select PRMT
family members (i.e., CARM1 (Kuhn et al. 2011), PRMT6 (Frankel et al. 2002), and
PRMT8 (Sayegh et al. 2007)).

Although the in vitro methyltransferase activity of

CARM1 is not affected by automethylation of R551 in its C-terminal domain (CTD), as
determined using an arginine to lysine mutant, this modification appears to down regulate
its roles in mRNA splicing and transcriptional activation (Kuhn et al. 2011). PRMT8 is
monomethylated at R58 and dimethylated at R73 of its N-terminal tail. Interestingly, full
length PRMT8 has very limited activity; however, a truncation mutant lacking the first 60
residues is significantly more active. The effect of automethylation on this isozyme
remains to be determined, but it is speculated that it might alter substrate recognition
(Sayegh et al. 2007). Finally, the effect of automethylation on PRMT6 is unknown at this
time (Frankel et al. 2002).
As mentioned previously, our research is concentrated on PRMT1 because it is
the dominant Type I PRMT and plays a role in a variety of diseases (e.g., cancer, heart
disease, and ALS).

We have been focused thus far on the kinetic and catalytic

mechanisms of the enzyme, as well as the development of potent inhibitors, while other
groups have mainly focused on determining the functional roles of PRMT1.

The

mechanisms (i.e., PTMs and protein-protein interactions) by which this otherwise
constitutively active enzyme is regulated, however, have yet to be fully investigated. In
fact, knowledge of the regulation of PRMT1 by post-translational modifications is
extremely limited. PhosphoSitePlus® (www.phosphosite.org) (Hornbeck et al. 2012), a
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curated

source

for

experimentally

determined

PTMs,

lists

phosphorylation,

ubiquitylation, and acetylation as observed modifications to a variety of PRMT1 residues
(Table 3.1). Interestingly, the data for most, if not all, of the discovered PTMs arose
from cancer cell lines such as K-562, AMO-1, and KMS-27 (Hornbeck et al. 2012),
which would argue for a role for PRMT1 in disease. These results, however, are only
based on high throughput mass spectrometry data, with no site specific methods such as
the use of site-directed mutagenesis or specific antibodies, to verity the existence and/or
importance of this modification.
Tab3. Table 3.1 Observed modifications of PRMT1a
# of records

a

Modification

Residue

Sequence

1

Phosphorylation

Y34

EDMTSKDyyFDSYAH

1

Phosphorylation

Y35

EDMTSKDyyFDSYAH

22

Ubiquitination

K113

DYAVKIVkANkLDHV

10

Ubiquitination

K116

DYAVKIVkANkLDHV

1

Ubiquitination

K125

DHVVTIIkGKVEEVE

1

Ubiquitination

K165

TVLYARDkWLAPDGL

12

Ubiquitination

K215

CIKDVAIkEPLVDVV

1

Ubiquitination

K225

LDVVDPkQlVTNAC

3

Phosphorylation

S289

GFSTSPEsPyTHWkQ

127

Phosphorylation

Y291

STSPEsPytHWkQtV

5

Phosphorylation

T292

TSPEsPytHWkQtVF

1

Acetylation

K295

EsPytHWkQtVFYME

6

Ubiquitination

K295

EsPytHWkQtVFYME

1

Phosphorylation

T297

PytHWkQtVFYMEDY

29

Ubiquitination

K324

IGMRPNAkNNRDLDF

Adapted from (Hornbeck et al. 2012)
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A

B

C
Y39

S102

S217

Y154

SAH

SAH

Figure 3.1 Structural comparisons between the PRMTs and contrast between amino acid
side chains. (A) The hydroxyl of S217 of CARM1 hydrogen bonds to the backbone
carbonyl of Y154 and is critical for activity. (B) The hydroxyl of S102 of PRMT1 (white)
potentially hydrogen bonds to the backbone carbonyl of Y39. Note that because Y39 is
not visible in the crystal structure of PRMT1, an overlay of PRMT3 (tan) was used to
demonstrate its approximate location. (C) S102 was mutated to a glutamate and alanine
residue to probe its function. This figure was prepared with UCSF Chimera using the
coordinates from CARM1 (PDBID 3B3F), PRMT1 (PDBID 1ORI), and PRMT3
(PDBID 1F3L).
To address this issue in PRMT1, we set out to investigate the effect of
phosphorylating S102 and Y291 on PRMT1 activity. As described above, S217 of
CARM1 (S102 in PRMT1 numbering) is conserved amongst the Type I PRMTs and
phosphorylation of this residue abolishes the methyltransferase activity of CARM1.
Examination of the crystal structures of CARM1 and PRMT1 (with PRMT3 overlay
because the N-terminal tail residues are absent in the PRMT1 structure) revealed the
possibility that phosphorylation of this residue may be a common regulatory mechanism
between both enzymes due to their similar positions (Figure 3.1A-B).

In order to

determine if phosphorylation of S102 in PRMT1 would yield the same effect as it does in
CARM1, a S102E mutant was created, to mimic phosphorylation of the residue, and a
S102A mutant, to probe the general importance of the hydroxyl group (Figure 3.1C).
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Figure 3.2 Structure of PRMT1 and structural contrast of amino acid side chains. (A)
Results of previous studies involving mutation of H293 suggest that the addition of a
phosphate to Y291 would likely negatively affect methyltransferase activity. (B)
Structural contrast of tyrosine and phosphorylated tyrosine clearly shows that the addition
of a phosphate group adds both bulk and charge to the residue. Mutation to a
phenylalanine can reveal the importance of the hydroxyl group, whereas, a glutamate
mutant is often used to determine the effect of the addition of a negative charge.
However, due to the large difference in overall size between phosphotyrosine and
glutamate, the incorporation of p-carboxymethyl L-phenylalanine is a better overall
mimic. This figure was prepared with UCSF Chimera using the coordinates from
PRMT1 (PDBID 1ORI).
Y291 was specifically chosen for this investigation because it has the largest
number of curated mass spectrometry hits according to PhosphoSitePlus® (Hornbeck et
al. 2012).

Based on the position of this residue in the structure of PRMT1, we

hypothesized that phosphorylation would impact methyltransferase activity and/or
protein-protein interactions (Figure 3.2A). This prediction was based on previous studies
that showed that H293 is important for catalysis, possibly due to the formation of a salt
bridge with D51 (Rust et al. 2011). Although hydrogen bond formation between Y291
and E47 can be ruled out due to the 5.0 Å distance between the two, the addition of a
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negatively charged phosphate group would likely cause repulsion and consequently open
up the SAM binding pocket, as well as destabilize residues that are important for
catalysis, similar to the case with H293. Although glutamate mutations are often used as
a mimic of phosphotyrosine, comparison of the two structures clearly demonstrates that
there is a difference in both size and electronics. In order to overcome this problem, pcarboxymethyl-L-phenylalanine (pCMF) (Figure 3.2), a previously reported stable mimic
of phoshotyrosine (Xie et al. 2007), was installed at this position using an established
method of unnatural amino acid (UAA) incorporation that utilizes an orthogonal amber
suppressor tRNA/aminoacyl-tRNA synthetase pair developed by the Schultz lab (Young
et al. 2010 and Xie et al. 2007). In addition to the above mutagenesis studies, PRMT1
was profiled against thirty-three kinase targets in order to determine possible kinases
responsible for phosphorylation. These experiments were done in collaboration with
Kinexus Bioinformatics Corporation.
Herein, we describe our efforts to decipher the means of regulation of PRMT1
activity. Site-directed mutagenesis and UAA incorporation was used to investigate the
consequence of phosphorylation on S102 and Y291. In addition, PRMT1 was profiled
against a variety of kinases to determine if the protein could be phosphorylated.
3.2 Materials and Methods
3.2.1 Chemicals
Iscove’s Modified Dulbecco’s Medium (IMDM) was purchased from (ATCC).
Acrylamide, ammonium persulfate, beta-mercaptoethanol, sodium dodecyl sulfate (SDS),
tetramethylethylenediamine (TEMED), and tris(hydroxymethyl)aminomethane (TRIS)
were purchased from Bio-Rad (Hercules, CA). Acetonitrile, (ethylenedinitrilo)tetraacetic
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acid (EDTA), dimethylformamide (DMF), Fmoc-protected amino acids, methanol,
phenylmethylsulfonyl fluoride (PMSF), trifluoroacetic acid (TFA), and Wang resin were
purchased from EMD (Gibbstown, NJ).

Dichloromethane, diethyl ether, sodium

chloride, triisopropylsilane were purchased from Fisher Scientific (Pittsburgh, PA).
Mutagenic primers were purchased from IDT Inc. (Coralville, IA). Fetal bovine serum
(FBS) was purchased from Mediatech Inc. (Manassas, VA). Dithiothreitol (DTT), 4-(2Hydroxyethyl)-1-piperazineethanesulfonic

acid

(HEPES),

isopropyl

β-D-1-

thiogalactopyranoside (IPTG), and tricine were purchased from RPI (Mt. Prospect, IL).
4-(bromomethyl)phenylacetic

acid,

trimethylsilyl-diazomethane

(TMSCH2N2),

(diphenylmethylene) glycine ethyl ester, benzyl trimethylammonium hydroxide, dimethyl
sulfoxide (DMSO), and piperidine were purchased from Sigma-Aldrich (St. Louis, MO).
14

C-labeled SAM and γ-33P-labeled ATP were purchased from Perkin-Elmer and

14

C-

labeled BSA from Sigma-Aldrich. Triton X-100 and sodium acetate were purchased
from VWR (West Chester, PA). Site-directed mutagenesis, the purification of PRMT1,
peptide synthesis, and the gel-based methylation assay were performed according to the
procedures outlined in Chapter 2.
3.2.1 Cell Culture Maintenance & Whole Cell Extract Preparation
K562 cells were grown in Iscove’s Modified Dulbecco’s Medium (IMDM)
supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic solution
(Mediatech Inc) at 37 °C and 5% CO2. For immunoprecipitation experiments, cells were
grown to confluency and either 10 µM MG132, 10 µM MG132 (Cayman Chemical10012628) plus 1 mM orthovanadate (NEB-P0758S), or DMSO as a control was added to
three separate flasks and incubated for 2 h at 37 °C and 5% CO2. Cells were removed

76

and centrifuged for 5 min at 225 x g and 4 °C. After three washes with PBS, cells were
lysed by a 30 min incubation at 4 °C in modified RIPA buffer (50 mM Tris pH 8, 150
mM sodium chloride, 1 mM EDTA, 1% NP-40) in the presence of complete protease
inhibitor cocktail (Roche-4693132), phosphatase inhibitor cocktail II (Sigma-P8465), and
1 mM orthovanadate. Lysed cells were centrifuged for 5 min at 3824 x g at 4 °C and the
supernatant was removed as the whole cell extract. Protein concentration was determined
by a DC™ Protein Assay (Bio-Rad).
3.2.2 Immunoprecipitation
K562 cell extracts were diluted to 4 µg/µL (1 mg total protein) in modified RIPA
buffer (50 mM Tris pH 8, 150 mM sodium chloride, 1 mM EDTA, 1% NP-40) in the
presence of cOmplete protease inhibitor cocktail (Roche), phosphatase inhibitor cocktail
II (Sigma), and 1 mM orthovanadate (NEB). Extracts and antibody control (dilution
buffer only) were incubated with 5 µL of 1 µg/µL anti-PRMT1 antibody (Bethyl – A300722A) for 2 h with rotation at 4 °C. A 50 µL slurry of Protein G Sepharose 4 Fast Flow
Beads (GE) in cell extract dilution buffer was added to each sample and incubated ON
with rotation at 4 °C. Beads were washed three times with 200 µL of modified RIPA
buffer. Proteins were eluted with 60 µL of SDS-loading dye and heated for 10 min at 95
°C. Samples and controls were separated by 12% SDS-PAGE. Proteins were transferred
to a nitrocellulose membrane and probed with anti-PRMT1 (Abcam – ab7027) or 4G10®
Platinum anti-phosphotyrosine antibodies followed by incubation with goat anti-mouse
HRP conjugate (Millipore – 12-349). Proteins were visualized using Pierce ECL western
blotting substrate (Thermo Scientific).
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3.2.5 Synthesis of p-carboxymethyl-L-phenylalanine (pCMF)
pCMF was synthesized by modification of an already established protocol (Xie et
al. 2007). A solution of 4 g (17 mmol) of 4-(bromomethyl)phenylacetic acid in 78.4 mL
of THF and 39.2 mL of methanol was cooled to 0 °C followed by the slow addition of 17
mL (34 mmol) of trimethylsilyl-diazomethane (TMSCH2N2). The reaction was stirred
for 25 min at 0 °C, then the solvent was evaporated in vacuo and the mass of the product
was verified by LCMS: expected = m/z 242.99 (M + H+), observed = m/z 243.0 (M + H+).
A solution of the product (17 mmol), 266 mg (1.6 mmol) of potassium iodide (KI), and
4.54 g (17 mmol) of (diphenylmethylene) glycine ethyl ester in 77.5 mL of dioxane was
cooled to 0 °C followed by the slow addition of 6.5 mL of benzyl trimethylammonium
hydroxide (40% in water). The reaction was stirred at rt for 1 h and then extracted with
dichloromethane (CH2Cl2) and washed with brine. Solvent was evaporated in vacuo and
the mass of the product was verified by LCMS: expected = m/z 430.19 (M + H+),
observed = m/z 430.2 (M + H+). Aqueous HCl (1N, 40 mL) was added to the product and
stirred for 1 h at rt. The pH was then adjusted 8 with solid NaHCO3 and the product was
extracted with dichlormethane (CH2Cl2) and washed with brine. Solvent was evaporated
in vacuo and the mass of the product was verified by LCMS: expected = m/z 266.13 (M +
H+), observed = m/z 266.1 (M + H+). The compound was then dissolved in 30 mL of
NaOH and 15 mL of THF and stirred overnight at rt. Solvent was evaporated in vacuo
and product was partitioned in ether and water. The aqueous portions were collected and
lyophilized to yield a sodium salt of the final product and the mass was verified by
LCMS: expected = m/z 224.08 (M + H+), observed = m/z 224.1 (M + H+).
compound was used in subsequent experiments without further purification.
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The

3.2.6 Incorporation of pCMF into PRMT1
Incorporation of pCMF was performed using methods adapted from previously
reported protocols (Xie et al. 2007 & Young et al. 2010). Y291 of PRMT1 was mutated
to a TAG stop codon using the site directed mutagenesis methods described in Chapter 1.
The pEVOL-pCMF plasmid, a generous gift from Peter Schultz, was co-transformed into
E. coli BL21(DE3) cells with the Y291TAG mutant. One colony was used to inoculate 5
mL of 2YT media containing 50 μg/mL kanamycin and 25 μg/mL chloramphenicol.
Two liters of 2YT media were inoculated with 20 mL of overnight culture containing 50
μg/mL kanamycin and and 25 μg/mL chloramphenicol and grown at 37 °C and 250 rpm
until OD600 = 0.8. The cells were supplemented with 1 mM pCMF before being induced
with 0.2% arabinose and 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG). The cells
were then incubated with shaking at 30 °C overnight and the mutant protein was purified
according to the established protocol for WT PRMT1 (see Chapter 2).
3.2.7 In-Gel Digest
The Y291pCMF mutant (5 µg) was separated by 12% SDS-PAGE. Coomassie
stained gel bands corresponding to labeled PRMT1 were excised and the resultant gel
pieces were washed and dehydrated two times. Existing disulfide bonds were reduced
with 10 mM DTT and the resulting thiols were alkylated with 54 mM N-ethylmaleimide.
Proteins were digested with trypsin (Promega – V5113), at a 1:10 (w:w)(trypsin:protein)
ratio, overnight at 37 °C. The enzymatic reaction was quenched with 1% TFA and the
resulting peptides were desalted and concentrated using C18 ZipTips (Millipore). Dried
peptides were reconstituted in 0.1 % formic acid. All samples were analyzed by liquid
chromatography-tandem MS (LC-MS/MS) using an EASY-nLC II system coupled to a
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LTQ linear ion trap mass spectrometer (Thermo-Finnigan, San Jose, CA). Briefly,
peptides were concentrated and desalted on an RP trapping column (0.31 x 20 mm,
ReproSil-Pur C18-AQ, ThermoScientific) and eluted on-line with an analytical RP
column (0.075 x 100 mm, ReproSil-Pur C18-AQ, ThermoScientific), operating at 300
nl/min and using a 40-min gradient from 0% to 40% solvent B [solvent A: 0.1% formic
acid (v/v), solvent B: 0.1% formic acid (v/v), and 80% acetonitrile (v/v)]. The LTQ was
programmed in the ‘selected MS/MS ion monitoring’ (SMIM) mode. The m/z 400-1600
survey scan was first performed in order to check for the presence of digested peptides as
well as peptide separation along the gradient. This survey scan is followed by dependent
MS/MS scans that fragment the six most intense ions to confirm the presence of the
protein of interest. Next, MS/MS spectra were programmed, focusing on m/z 641.64,
which

corresponds

to

the

triply-charged

precursor

ion

of

the

modified

RTGFSTSPESPY*THWK peptide, and on m/z 883.90, corresponding to the doublycharged precursor ion of the modified TGFSTSPESPY*THWK peptide. Note that the
quadruple charge stems from a possible charge on the fragmented C21 peptide and that
the MS/MS scans were repeated twice.
3.2.8 Protein Kinase Assays
Protein kinase assays with PRMT1 as the substrate were performed by Kinexus
Bioinformatics Corporation (Vancouver, B.C. Canada). Briefly, 5 µL of γ-33P-labeled
ATP (50 M, 0.8 Ci final) was added to a mixture of 10 µL of kinase assay buffer, 5 µL of
an active protein kinase (~10-50 nM final), and 5 µL of PRMT1 or control substrate (1-5
g) to start the reaction.

Samples were incubated at ambient temperature for 20-40

minutes (depending on the target). Assays were quenched by spotting 10 µL of the
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reaction mixture onto a Multiscreen phosphocellulose P81 plate, which was then washed
3 times for approximately 15 minutes each in a 1% phosphoric acid solution. The
radioactivity on the P81 plate was counted in the presence of scintillation fluid in a Trilux
scintillation counter.

A control assay for each kinase target included all assay

components except the appropriate substrate (replaced with equal volume of assay
dilution buffer). Both the sample and control assays were done in duplicate and the
corrected activity for each kinase target was determined by subtracting the blank control
value.
3.3 Results and Discussion
3.3.1 Effect of Phosphorylation of S102
Disruption of the interaction between the hydroxyl group of S102, a conserved
residue amongst the type I PRMTs, and the back backbone carbonyl of Y39, also a
conserved residue, by phosphorylation has been demonstrated to negatively regulate
CARM1 (Feng et al. 2009). To investigate whether phosphorylation of this residue may
be a mechanism of regulation for PRMT1, we generated the S102A mutant to determine
the importance of the hydroxyl group, and a S102E mutant to mimic phosphorylation. As
seen in Tables 3.2 and 3.3, the results show that neither mutant affects the kinetic
parameters of PRMT1 to the degree that was observed with CARM1, where mutations
appear to abolish activity. However, we did observe a ~ 4.5- and ~ 5.5-fold increase in
the Km values for AcH4-21 with the S102E and S102A mutant; there was essentially no
effect on kcat, and the kinetic parameters for SAM are identical to WT. These small but
significant increases can likely be attributed to the destabilization of the N-terminal helix,
which we speculate plays a role in substrate recognition and binding. Overall, these
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results show that it is highly unlikely that PRMT1 activity is regulated by
phosphorylation at S102, however, modification of this residue cannot be ruled out as
more dramatic effects on protein-protein interactions and cellular localization are
possible.
Table 3.2 Kinetic parameters of PRMT1 mutants for the AcH4-21 peptide
Mutant

Km
(µM)

Fold

kcat
(min-1)

Fold

kcat/Km
(M-1·min-1)

Fold

WTa

1.1 ± 0.5

-----

4.6 x 10-1 ± 2 x 10-2

-----

4.1 x 105

-----

S102Ea

5±1

4.5

5.7 x 10-1 ± 2 x 10-2

0.8

1.1 x 105

3.7

S102Aa

6±1

5.5

6.3 x 10-1 ± 2 x 10-2

0.7

1.1 x 105

3.7

a

[SAM] = 15 μM.

Table 3.3 Kinetic parameters of PRMT1 mutants for SAM
Mutant

Km
(µM)

Fold

kcat
(min-1)

Fold

kcat/Km
(M-1·min-1)

Fold

WTa

6±1

-----

5.8 x 10-1 ± 3 x 10-2

-----

1 x 105

-----

S102Ea

5.1 ± 0.7

0.9

5.1 x 10-1 ± 2 x 10-2

1.1

9.9 x 104

1.0

S102Aa

5.6 ± 0.6

0.9

5.2 x 10-1 ± 2 x 10-2

1.1

8.8 x 104

1.1

a

[AcH4-21] = 100 μM.

3.3.2 Probing for Phosphotyrosine in PRMT1
As mentioned above, PhosphoSitePlus® (www.phosphosite.org) lists tyrosine
phosphorylation as an observed modification to a variety of PRMT1 residues; this list is
compiled from curated mass spectrometry data (Hornbeck et al. 2012). In an attempt to
confirm these mass spectrometry results and determine a phenotype for the modification,
we immunoprecipitated PRMT1 from K562 cells, a cell line from which a subset of
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PhosphoSitePlus® data is derived. To aid in the enrichment of the phosphorylated
enzyme, the cells were incubated with either DMSO as a control, MG132, a proteasome
inhibitor, or MG132 and orthovanadate, a phosphatase inhibitor. MG132 was added
because phosphorylation can often be an upstream signal for degradation. Orthovanadate
was added to prevent the removal of the phosphate group and possibly lead to an
accumulation of the modified protein. The enzyme was immunoprecipitated with an antiPRMT1 antibody and the blots were probed with either an anti-PRMT1 or an antiphosphotyrosine antibody (Figure 3.3). Unfortunately, phosphorylated PRMT1 was not
detected under any of the conditions tested. Immunoprecipitations were also performed
with the anti-phosphotyrosine antibody, however, the results were the same.

IP: αPRMT1
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-

-
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+

-
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Figure 3.3 Immunoprecipitation of PRMT1. K562 cells were treated prior to
lysis with DMSO, MG132, or a combination of MG132 and orthovanadate, and
immunoprecipitation on cell extracts was performed with anti-PRMT1. The
resultant blots were probed with either an anti-PRMT1 or an antiphosphotyrosine antibody.
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3.3.3 Effect of Phosphorylation of Y291
Although tyrosine phosphorylation was not detected in cell extracts, we sought to
determine the effect that phosphorylation of Y291 could have on PRMT1 activity. We
generated the Y291F mutant to determine the importance of the hydroxyl group, and the
Y291E mutant to mimic phosphorylation. However, because of the size and electronic
difference between glutamate and phosphotyrosine (Figure 3.2), we decided to generate a

Figure 3.4 Synthesis of pCMF
better mimic. To do this, the Y291 position on PRMT1 was mutated to a TAG stop
codon and pCMF, a known stable mimic of phosphorylated tyrosine (Xie et al. 2007),
was synthesized according to the scheme outlined in Figure 3.4. pCMF was incorporated
into the protein using an orthogonal amber suppressor tRNA/aminoacyl-tRNA synthetase
pair. Figure 3.51 shows a comparison between the expression of WT PRMT1 and the
Y291pCMF mutant under the same conditions from a test expression in E. coli.
BL21(DE3) cells. The expression was then scaled up (Figure 3.6A) and the Y291pCMF
mutant was purified according to the WT PRMT1 protocol (Figure 3.6B). Note that the
Y291TAG truncation mutant did not co-purify with the Y291pCMF mutant, likely due to
the inability to fold properly. The presence of pCMF at this position was confirmed by
MS/MS (Figure 3.7).
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37

WB: αPRMT1

Figure 3.5 Incorporation of pCMF into
PRMT1. Test expressions were performed
with the WT enzyme and the Y291TAG
mutant in the presence of pCMF in E. coli.
A
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Induction

Y291pCMF
37

37

Y291TAG

Y291pCMF

WB: αPRMT1

Figure 3.6 Expression and purification of PRMT1(Y291pCMF). (A) Expression
conditions were scaled up to 2 L and incorporation of pCMF was consistent with the
test expressions. (B) The mutant was purified according to the WT PRMT1 protocol
and yielded only the full length enzyme.
The kinetic parameters for the Y291 mutants can be found in Tables 3.4 and 3.5.
In regards to AcH4-21, the Y291F and Y291E mutants yielded a ~ 2.0-fold and ~ 1.4fold decrease in kcat/Km, respectively, compared to the WT enzyme, and these observed
decreases were solely based on small increases in Km. The Y291pCMF mutant, however,
yielded a more significant decrease (~ 5.1-fold) in kcat/Km that was caused by an ~ 7.3fold increase in Km. These results suggest that the Y291 plays a small role in substrate
binding, but not catalysis, and thus phosphorylation of this residue would likely affect
substrate binding.

85

y9+
1186.62
2100

y12 y11 y10 y9 y8 y7 y6

y13+2

MS/MS spectrum
883.9

805.15

b80+

y12+2

789.39

731.45

y6*+

y3 y2

T G F S T S P E S P Y* T H W K

856.85

a 9+
866.28

y8
Intensity

b60+
563.28

y2+

b8

b12 b13 b14

y6+

b12+

873.49

1297.51

y90+

y110+
1356.65

y11+
1374.65

1168.62

594.11

y10+2
b 3+

y3+

306.08

470.31

b 4+

1089.57

942.54

y11+2

b130+

y8+

y70+

637.54

1416.64

y100+

y12+

1255.61

400

500

600

700

b13+

b14+

1434.67

1621.67

b140+

1602.70
1461.73

688.04

393.18

300

b6

0+

1273.64

y9+2

333.17

0

y10

960.57

545.26
1050

b3 b4
y7+

+2

b140+
1639.81

800

900

1000

1100

1200

1300

1400

1500

1600

1700

1800

m/z

Figure 3.7 MS/MS Analysis of PRMT1(Y291pCMF).
Table 3.4 Kinetic parameters of PRMT1 mutants for the AcH4-21 peptide
Mutant

Km
(µM)

Fold

kcat
(min-1)

Fold

kcat/Km
(M-1·min-1)

Fold

WTa

1.1 ± 0.5

-----

4.6 x 10-1 ± 2 x 10-2

-----

4.1 x 105

-----

Y291Fa

5 ± 1.8

4.6

1.03 ± 6 x 10-2

0.45

2.1 x 105

2.0

Y291Ea

4.4 ± 0.6

4.0

1.32 ± 3 x 10-2

0.35

3.0 x 105

1.4

Y291pCMFa

8 ± 1.8

7.3

6.4 x 10-1 ± 2 x 10-2

0.72

8.0 x 104

5.1

a

[SAM] = 15 μM.

Table 3.5 Kinetic parameters of PRMT1 mutants for SAM

a

Mutant

Km
(µM)

Fold

kcat
(min-1)

Fold

kcat/Km
(M-1·min-1)

Fold

WTa

6 ± 1.0

-----

5.8 x 10-1 ± 3 x 10-2

-----

1 x 105

-----

Y291Fa

8 ± 1.0

1.3

1.55 ± 6 x 10-2

0.37

1.8 x 105

0.56

Y291Ea

7 ± 1.5

1.2

1.6 ± 1 x 10-1

0.36

2.3 x 105

0.43

Y291pCMFa

6 ± 1.1

1.0

5.5 x 10-1 ± 3 x 10-2

1.1

9.1 x 104

1.1

[AcH4-21] = 100 μM.
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Surprisingly, the kinetic parameters for all three mutants matched those of the WT
enzyme. This was puzzling because, based on the crystal structure of PRMT1 and
previous studies with H293 (Figure 3.2A), we hypothesized that disruption of the Nterminal α-helix would greatly impact SAM binding. However, these results demonstrate
that the Y291 residue does not play a role in SAM binding and therefore phosphorylation
of this residue would like not affect SAM binding or catalysis.
3.3.4 Profiling of PRMT1 Against Select Kinases
Because we were unable to detect phosphorylated PRMT1 in vivo, we decided to
take a different approach by profiling PRMT1 against select kinases to determine if
PRMT1 can be phosphorylated in vitro. Radioactive kinase assays were performed by
Kinexus Bioinformatics Corporation with our PRMT1 enzyme. Thirty-three kinases
were assayed in total and the twenty-five kinases with the most activity towards PRMT1
can be found in Table 3.6. There are two different methods for comparing activity. The
first method is to examine the percent change from control (% CFC) with percentages >
5% being significant. This method suggests that PRMT1 is a likely substrate for cKIT,
KDR, ERK1, ERK5, JNK1, JNK2, JNK3, FLT1, and AXL.

This method can be

misleading, however, because the control substrates are often optimized for the particular
kinase and/or used in high concentrations. The second method only examines the CPM
counts for PRMT1 that pertain to each kinase, with counts >8000 being significant. Note
that the kinases displayed in Table 3.6 were chosen based on the second method. This
method suggests that PRMT1 is a likely substrate for AXL, KDR, FGR, FYN A, SRC,
YES1, FER, and LYN A, which are all tyrosine kinases. These results are promising in
that they provide a starting point for future in vitro and in vivo kinase experiments.
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Tab3. Table 3.6 Percent activity of select protein kinases with PRMT1
Kinase

Substrate CPM

PRMT1 CPM

% CFC

AXL

303327

27780

9

KDR

142513

14876

10

FGR

332996

13096

4

FYN A

341735

13058

4

SRC

305044

11629

4

YES1

389767

11474

3

FER

454478

8759

2

LYN A

347599

8751

3

FES

210964

7214

3

HCK

398546

6962

2

FLT1

111562

6032

5

LCK

146117

5646

4

FLT3

134185

5310

4

FGFR3

344175

5298

2

ERK5

43006

4934

11

JNK1

47712

4165

9

ERK1

78080

4047

5

MET

245282

3886

2

FRFR1 (FLT2)

215787

2841

1

JNK2

27479

2529

9

FGFR4

136640

2495

2

ITK

96295

2435

3

FGFR2

263187

2024

1

c-KIT

25199

1838

7

JNK3

25072

1653

7

p38a MAPK

248961

1011

0
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3.4 Conclusions
Post-translational modification of PRMT1 has yet to be characterized; therefore
we set out to investigate the regulation of the enzyme by PTMs, specifically
phosphorylation. Our research efforts focused on two residues, S102 and Y291. S102 is
conserved in Type I PRMTs and phosphorylation of this residue is a means of regulation
for CARM1. Two mutants, S102A and S102E, were made in PRMT1 and the kinetic
analysis of these mutants demonstrated that this residue is not important for substrate or
cofactor binding, or catalysis, and thus it is highly unlikely that PRMT1 is regulated by a
mechanism similar to CARM1.
The Y291 residue was chosen for investigation based on curated mass
spectrometry data from PhosphoSitePlus® (Hornbeck et al. 2012). Y291F and Y291E
mutants were generated, as well as the incorporation of pCMF into the protein, in an
attempt to properly mimic phosphotyrosine. The results showed that, in general, this
residue likely plays a minor role in substrate binding and that phosphorylation at this
position would likely disrupt substrate binding. However, to our surprise, no affect was
observed in regards to SAM, which was quite puzzling based on structural observations
and previous studies with H293. These results suggest that the interaction between H293
and D51 is likely enough to hold the main portion of the α-helix in place, despite the
addition of a phosphate group at Y291. Interestingly, based on structure analysis, the
interaction between histidine and aspartate appears to be conserved amongst Type I
PRMTs, and thus it is likely that this is a critical interaction for PRMT catalysis. In
addition, as mentioned in Chapter 1, PRMT1 has a variety of splice variants and these
variations at the N-terminus appear to play a role in substrate specificity (Goulet et al.
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2007). Therefore, it is possible that phosphorylation of Y291 could modulate substrate
specificity by affecting the position of the N-terminal tail. Note that the pCMF residue is
still lacking a negative charge compared to phosphotyrosine so it is possible that the
modification may have an even greater effect in vivo.
In collaboration with Kinexus Bioinformatics Company, we have profiled
PRMT1 against thirty-three different protein kinases to determine if the enzyme can be
phosphorylated in vitro. The results show that several tyrosine kinases (i.e., AXL, KDR,
FGR, FYN A, SRC, YES1, FER, and LYN A) are active against PRMT1. Future
experiments will include in vitro assays with the top purified kinases to attempt to
determine potential sites of modification. In vivo experiments will also be performed in
which stimuli will be added in order to activate signaling pathways that are particular for
the most active kinases, thus possibly increasing the concentration of phosphorylated
PRMT1.
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CHAPTER 4
Regulation of PRMT1 by Protein-Protein Interactions
4.1 Introduction
As discussed in Chapter 3, it is highly likely that the PRMTs are regulated by a
variety of mechanisms (i.e., the activation or repression of gene expression, PTMs, and/or
protein-protein interactions).

The role of PTMs in regards to PRMT1 activity was

discussed in Chapter 3, but we also were interested in determining how protein-protein
interactions regulate the activity of this enzyme because preliminary data indicates that
the PRMTs are regulated via this mechanism. For example, there is evidence that the
tumor suppressor protein DAL-1/4.1B enhances PRMT3-dependent methylation of MCF7 cell lysates (Singh et al. 2004), however, it both enhances and inhibits PRMT5
dependent methylation in a substrate specific manner (Jiang et al. 2005). In another
example, the substrate specificity of CARM1 is altered by BRG1, a component of the
nucleosomal methylation activator complex (NUMAC), which shifts CARM1-dependent
methylation towards nucleosomal histone H3 as opposed to the free histone (Xu et al.
2004). In addition, PRMT5 is regulated by its binding partner MEP50, as there is a
substantial difference in methyltransferase activity between the enzyme alone and the
enzyme in a complex with MEP50. PRMT5 is also active as part of a variety of multiprotein complexes, that include the 20S methylosome and the Swi/Snf complex, with
MEP50 being a common component (Antonysamy et al. 2012).
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Although still not fully understood, there is evidence that PRMT1 activity is
regulated by protein-protein interactions. The isozyme was originally identified due to its
interaction with the anti-proliferative proteins BTG1 and BTG2 (Lin et al. 1996) and
subsequent experiments suggested that these two proteins are capable of enhancing
PRMT1 activity (Lin et al. 1996 & Berthet et al. 2002). More recently, the deadenylase
CCR4 Associated Factor 1 (CAF1) was found to modulate enzyme activity in a substrate
specific manner by decreasing methylation of SAM68 and histone H4 but not affecting
hnRNPA1 methylation in vitro. These observations were validated in vivo using siRNA
knockouts of CAF1 in MCF-7 cells and probing for asymmetric dimethylation of SAM68
and histone H4.

The authors also showed that in vitro, BTG1 increases PRMT1-

dependent methylation of Histone H4 while decreasing methylation of SAM68.

In

addition, the authors were able to pull down CAF1 and BTG1 with GST-PRMT1 and
show that PRMT1 and CAF1 colocalize in the cell (Robin-Lespinasse et al. 2007).
Interestingly, BTG1 and CAF1 are binding partners (Rouault et al. 1998 and Bogdan et
al. 1998), thus providing further evidence for a likely regulatory mechanism involving all
three proteins.
Because the initial studies examining the effect of BTG1 and CAF1 on PRMT1
activity only looked at relative rates, we set out to perform a more in depth
characterization and thereby provide a molecular basis for the regulation afforded by
these interacting proteins. Using the PRMT1 catalyzed asymmetrical dimethylation of
histone H4 at R3 as a model (Figure 4.1A), at least two possible scenarios exist for the
regulation of PRMT1 by its interacting partners (Figure 4.1B).

In both cases, the

interacting protein (i.e., CAF1 or BTG1) could bind to PRMT1 or the substrate. In the
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case of CAF1, binding would prohibit methylation, however, in the case of BTG1,
binding would recruit PRMT1 to the target arginine, in this case on histone H4. The role
that both CAF1 and BTG1 play together in the regulation of PRMT1 has yet to be
determined. To probe the illustrated scenarios, PRMT1 activity assays were performed at
increasing concentrations of CAF1 and BTG1, individually and together, with low and
high concentrations of histone H4 and AcH4-21, a minimal peptide substrate of histone
H4. The results suggest that CAF1 can bind histone H4 and prevent methylation and/or it
can bind PRMT1 and target it to histone H4. In addition, it is likely that BTG1 binds to
both proteins as well; however, it appears to have less affinity for histone H4 compared to
CAF1.

Figure 4.1 Enzyme regulation scenarios of PRMT1 by CAF1 and BTG1. (A) PRMT1
asymmetrically dimethylates histone H4 at R3. (B) CAF1 and BTG1 can exhibit their
regulatory effects on PRMT1 by either binding the enzyme or binding the potential
substrate.
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4.2 Materials and Methods
4.2.1 Chemicals
Acrylamide, ammonium persulfate, beta-mercaptoethanol, sodium dodecyl sulfate
(SDS), tetramethylethylenediamine (TEMED), and tris(hydroxymethyl)aminomethane
(TRIS)

were

purchased

from

Bio-Rad

(Hercules,

CA).

Acetonitrile,

(ethylenedinitrilo)tetraacetic acid (EDTA), dimethylformamide (DMF), Fmoc-amino
acids, methanol, phenylmethylsulfonyl fluoride (PMSF), trifluoroacetic acid (TFA), and
Wang resin were purchased from EMD (Gibbstown, NJ). Dichloromethane, diethyl
ether, glutathione (reduced), imidazole, potassium phosphate monobasic, potassium
phosphate dibasic, sodium chloride, triisopropylsilane (TIS), and urea were purchased
from Fisher Scientific (Pittsburgh, PA). Dithiothreitol (DTT), 4-(2-Hydroxyethyl)-1piperazineethanesulfonic acid (HEPES), isopropyl β-D-1-thiogalactopyranoside (IPTG),
and tricine were purchased from RPI (Mt. Prospect, IL). Guanidinium hydrochloride,
and piperidine were purchased from Sigma-Aldrich (St. Louis, MO).

14

C-labeled SAM

was purchased from Perkin-Elmer and 14C-labeled BSA from Sigma-Aldrich. Triton X100 and sodium acetate were purchased from VWR (West Chester, PA). The purification
of PRMT1 and the synthesis of the AcH4-21 peptide are outlined in Chapter 2.
4.2.2 Purification of Histone H4
Recombinant histone H4 was purified with slight modification to an established
protocol (Thompson et al. 2001). A plasmid encoding histone H4 was transformed into
E. coli BL21(DE3) cells and starter cultures, prepared from single colonies in the
presence of 100 µg/mL ampicillin, were incubated overnight at 37 °C with rotation.
Overnight starter cultures were then used to inoculate 2 L of 2YT media plus ampicillin
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(32 g tryptone, 20 g yeast, 10 g NaCl, 100 µg/mL ampicillin) and the culture was grown
at 37 °C with shaking to an OD600 of 0.4. Protein expression was induced with 0.4 mM
IPTG for 1.5 h. Cells were harvested by centrifugation at 4400 x g for 10 min and the
pellet was resuspended in Wash Buffer (50 mM Tris pH 7.5, 100 mM NaCl, 1 mM
EDTA, 1 mM PMSF) followed by flash freezing in liquid nitrogen. The cell suspension
was thawed at 42 °C for 30 min and cells were lysed by 8 cycles of sonification (8 sec
pulse with 1 min rest at 100% amplitude). Lysed cells were centrifuged for 20 min at
23,000 RPM and the resulting pellet was washed with 50 mL of Wash Buffer plus 1%
Triton X-100.

The washed pellet was centrifuged for 10 min at 14,000 x g, the

supernatant was discarded, and a second round of washing and centrifugation was
performed. The final pellet was minced in 1 mL of DMSO and incubated at RT for 30
min followed by the addition of 10 mL of unfolding buffer (7 M guanidinium HCl, 20
mM Tris pH 7.5, 10 mM DTT). The resuspension was incubated for 1 h at RT with
stirring then centrifuged for 10 min at 13,000 x g and the supernatant was removed and
saved. The pellet was resuspended in 5 mL of unfolding buffer, incubated for another 10
min at RT with stirring, and centrifuged for 10 min at 13,000 x g.

The second

supernatant was combined with the first and dialyzed overnight against 4 L of ddH2O and
1 mM β-mercaptoethanol at 4 °C. The solution was lyophilized the following day and
the dried white powder was resuspended in 20 mM sodium acetate pH 5.2, 5 mM βmercaptoethanol, 1 mM EDTA, 7 M deionized urea and further purified using a CM
SepharoseTM Fast Flow (GE Healthcare) column on the FPLC, with a stationary phase of
20 mM sodium acetate pH 5.2, 5 mM β-mercaptoethanol, 1 mM EDTA, and 5 mM
deionized urea and a linear gradient mobile phase of 20 mM sodium acetate pH 5.2, 5
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mM β-mercaptoethanol, 1 mM EDTA, 5 mM deionized urea, and 2 M sodium chloride.
Fractions were checked by SDS-PAGE and pure fractions were dialyzed against 4 L of
ddH2O and 1 mM β-mercaptoethanol at 4 °C and subsequently lyophilized the next day.
The dried protein was dissolved in unfolding buffer to a concentration of 2 mg/mL and
incubated for 15 min at RT followed by a two-fold dilution in unfolding buffer and
incubation for 1 h at RT. Histone H4 was then dialyzed overnight against 10 mM Tris
pH 7.5, 250 mM sodium chloride, 1 mM EDTA, and 5 mM β-mercaptoethanol at 4 °C.
4.2.3 Purification of mCAF1, hBTG1, and Glutathione S-transferase
The mCAF1 and hBTG1 plasmids were a generous gift from Dr. Muriel Le
Romancer and were subcloned from their original pGEX-ET E. coli expression vectors
into pGEX-6P-1 (BamHI and SmaI restriction sites) and pGEX-6P-2 (EcoRI restriction
sites) E. coli expression vectors, respectively. The plasmids were separately transformed
into E. coli Rosetta cells and single colonies were used to inoculate starter cultures, in the
presence of 80 µg/mL ampicillin and 25 µg/mL chloramphenicol, that were grown
overnight at 37 °C. Starter cultures, in addition to 50 µg/mL ampicillin and 17.5 µg/mL
chloramphenicol, were added to 2 x 1 L of TB media (12 g tryptone, 24 g yeast, 0.4%
glycerol, 0.17 M KH2PO4, and 0.72 M K2HPO4 ) and grown at 37 °C with shaking until
an OD600 of 0.8-1.0 was achieved.

Protein expression was induced with 0.3 mM

isopropyl β-D-1-thiogalactopyranoside and cultures were incubated at 16 °C overnight.
Cells were harvested by centrifugation at 4,400 x g for 10 min at 4 °C. The pellet was
resuspended in 26 mL of lysis buffer (20 mM Tris pH 8, 5 mM EDTA, 20% glycerol, 400
mM sodium chloride, and 5 mM DTT) and 4 mL of protease inhibitor cocktail solution
(72 mg of Protease Inhibitor Cocktail (Sigma – P8465), 800 µL of dimethyl sulfoxide,
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3200 µL of ddH2O). The resuspended pellet was mixed slowly for 30 min at 4 °C
followed by 12 cycles of sonication (15 sec pulse with 1 min rest at 100% amplitude).
Lysed cells were centrifuged at 23,000 x g for 30 min at 4 °C. The supernatant was
applied to a Glutathione Sepharose® 4B (GE Healthcare) column followed by a low salt
wash (20 mM Tris pH 8, 1 mM EDTA, 20% glycerol, 200 mM sodium chloride, and 1
mM DTT) and a high salt wash (20 mM Tris pH 8, 1 mM EDTA, 20% glycerol, 500 mM
sodium chloride, and 1 mM DTT). The proteins were then eluted with glutathione buffer
(10 mM reduced glutathione, 50 mM Tris-HCl pH 8 and 1 mM DTT). Washes and
elution fractions were checked by SDS-PAGE and PreScission Protease (GE Healthcare)
was added to the fractions containing protein prior to overnight dialysis against 20 mM
Tris pH 8, 20 mM EDTA, 1 mM DTT, and 500 mM sodium chloride 4 °C. Dialyzed
protein was applied to a regenerated Glutathione Sepharose® 4B column and the flow
through was collected and dialyzed for 3 h against 20 mM Tris pH 8, 1 mM EDTA, and 1
mM DTT 4 °C. The protein was further purified using a HiTrap TM Q Fast Flow (GE
Healthcare) column on the FPLC, with a stationary phase of 20 mM Tris pH 8.5 and 2
mM DTT and a linear gradient mobile phase of 10 mM Tris pH 8.5, 2 mM DTT, and 1
mM sodium chloride. Fractions were checked by SDS-PAGEe and pure fractions were
dialyzed against 20 mM Hepes pH 8, 1 mM EDTA, 1 mM DTT, 10% glyercol, and 5
mM sodium chloride at 4 °C.
Glutathione S-transferase (GST) was purified using a modified mCAF1 and
hBTG1 protocol. The empty pGEX-6P-1 vector was used to express GST and the pure
protein was collected in the glutathione buffer fraction (10 mM reduced glutathione, 50
mM Tris-HCl pH 8 and 1 mM DTT) from the Glutathione Sepharose® 4B (GE
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Healthcare) column. The protein was then dialyzed against 20 mM HEPES pH 8, 1 mM
EDTA, 1 mM DTT, 10% glyercol, and 5 mM sodium chloride at 4 °C.
4.2.4 Gel-Based Methylation Assay
The gel-based PRMT1 methylation assay has been previously described (Osborne
et al. 2007). For percent activity experiments in which the enzyme was preincubated
with the interacting proteins, reaction mixtures of 50 mM HEPES pH 8.0, 1 mM EDTA,
50 mM sodium chloride, 0.5 mM dithiothreitol, 15 μM [14C]-labeled SAM, 0.2 μM
PRMT1 or 0.8 μM PRMT1, and varying concentrations of GST, mCAF1, hBTG1, or
mCAF1/hBTG1 (0-30 μM) were preincubated at 37 °C for 10 min. The reaction was
initiated with 25 μM AcH4-21, 3 μM histone H4, or 25 μM histone H4 and was quenched
after 15 min or 90 min. For percent activity experiments in which the substrate was
preincubated with the interacting proteins, the same reaction mixture was preincubated
with either 15 μM AcH4-21 or 3 μM histone H4 at 37 °C for 10 min. The reaction was
initiated with 0.8 μM PRMT1 and was quenched after 90 min. The samples were run on
tris-tricine gels and incorporated radioactivity was quantified using Image Quant
(Molecular Dynamics). The assays were done in duplicate and the standard deviation of
the raw data values agreed within ≤ 20%. Percent activity was determined by dividing
the rates at each particular interacting protein concentration by the acquired rate at 0 μM
interacting protein.
4.3 Results and Discussion
Previous studies have qualitatively determined that PRMT1 activity is affected by
CAF1 and BTG in a substrate specific manner (Lin et al. 1996, Berthet et al. 2002,
Robin-Lespinasse et al. 2007). In order to quantitatively analyze these effects, as well as
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Figure 4.2 Effect of interacting proteins on PRMT1 activity at high concentrations of
substrate. Enzyme was preincubated with the interacting protein(s) followed by
initiation of the methylation reaction with (A) histone H4 (25 µM) or (B) AcH4-21
(25 µM).
determine the possible mechanism of regulation (Figure 4.1), we performed in vitro
activity assays with PRMT1 in the presence of CAF1, BTG1, and a combination of the
two. These assays were done at low and high concentrations of both histone H4 and the
AcH4-21 peptide. Because the original studies demonstrated that CAF1 and BTG1 coimmunoprecipitate with PRMT1, the first assays that were performed involved
preincubating PRMT1 with the interacting protein(s) followed by initiation of the
methylation reaction with a high concentration of substrate (Figure 4.2). The results
show a general increase in activity in the presence of the interacting proteins, individually
and together, as well as for the GST control, for both histone H4 and the AcH4-21
peptide. These results were confusing as they do not agree with previously published
results, which show that CAF1 inhibits and BTG1 enhances methylation of histone H4.
Therefore, the assay was repeated in the same manner but with a lower concentration of
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histone H4, similar to that of the original study, to determine if substrate concentration
was a factor (Figure 4.3). Here, an increase in activity in the presence of CAF1, BTG1,
and a combination of both was observed, followed by a decrease starting at 10 µM, while
the GST control remained constant. Although inhibition was observed, these results were
still not consistent with previous findings and thus unsatisfying.
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Figure 4.3 Effect of interacting proteins on
PRMT1 activity at low concentrations of
substrate. Enzyme was preincubated with the
interacting protein(s) followed by initiation of
the methylation reaction with histone H4 (3
µM).
To determine if the two proteins affect PRMT activity by binding to the substrate
instead (Figure 4.1), assays were repeated except with preincubation of the interacting
proteins and the substrates followed by initiation of the reaction with PRMT1 (Figure
4.4). The results observed with histone H4 were more like the results that we expected,
with a decrease in activity in the presence of CAF1 and a slight increase with BTG1.

100

Quite surprisingly, however, there was generally no inhibition or activation with AcH421 as the substrate. This observation suggests that the interacting proteins likely bind to
the core of histone H4, which is absent from the peptide. In addition, the presence of
both CAF1 and BTG1 decreased PRMT1 activity, almost to the extent of CAF1.
Conclusions cannot yet be made from this observation however, as more experiments
will need to be done to probe this interaction.
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Figure 4.4 Effect of interacting proteins on PRMT1 activity at low concentrations of
substrate. (A) Histone H4 (3 µM) or (B) AcH4-21 (15 µM) was preincubated with the
interacting protein(s) followed by initiation of the methylation reaction with PRMT1.
A summary of the individual results with CAF1 and BTG1 can be found in Figure
4.5. It is obvious from these graphs that the preincubation conditions play a role in the
effect of CAF1 on PRMT1 activity, i.e., inhibition when preincubated with histone H4
and activation when preincubated with PRMT1. This further demonstrates the likelihood
that CAF1 can bind PRMT1, but may also be a histone binding protein, which has not
been previously observed.

The preincubation conditions only yield a very small
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difference in regards to BTG1, which suggests that if BTG1 binds to histone H4 it is
likely not a strong interaction.
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Figure 4.5 Summary of the effects of CAF1 and BTG1 on PRMT1 activity. The red bars
show results for the preincubation with histone H4 (3 µM) and the blue bars show for
preincubation with PRMT1 with increasing concentrations of (A) CAF1 and (B) BTG1.
4.4 Conclusions
Studies have shown that CAF1 and BTG1 are capable of inhibiting or enhancing
PRMT1 activity in a substrate dependent manner, although the exact mechanism of this
regulation is unknown (vide supra). Therefore, efforts were made to quantify these
effects and possibly determine the mechanism of inhibition or activation of PRMT1.
Activity assays were performed with low and high concentrations of histone H4 and
AcH4-21 and with varying concentrations of interacting proteins. The results show that
preincubation of PRMT1 with the interacting protein(s) followed by initiation with a high
concentration of substrate only enhances activity. The same assay repeated at lower
concentrations of substrate showed some inhibition but not to the degree described by
other groups. However, when histone H4 was preincubated with the interacting proteins,
the results were similar to the previously reported results with inhibition caused by CAF1
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and activation by BTG1. Surprisingly, there was no effect on activity when AcH4-21
was preincubated with the proteins, which suggests that the proteins likely bind to the
core of histone H4.
Looking at the possible scenarios for protein-protein interactions (Figure 4.1), the
results allude to a possible scenario where CAF1 can bind PRMT1 and target it to histone
H4, but can also bind histone H4 and prevent methylation. In the case of BTG1, it
appears as though it can bind both proteins but has a lower affinity for histone H4
compared to CAF1.

The lack of an effect with AcH4-21 further demonstrates the

likelihood that both of these proteins bind histone H4.
Overall, initial efforts have been made to characterize the regulation of PRMT1
by its interacting partners. There is still a lot of work that needs to be done to determine
their exact role in vivo. The fact that the effects on PRMT1 appear to be substrate
dependent (Robin-Lespinasse et al. 2007) suggests that interaction with the substrates is
critical for these observations. Therefore, studies with other substrates (e.g. SAM68) and
co-immunoprecipitation experiments may shed light on whether the observed effects are
mainly due to interactions with the substrate or with PRMT1. It would also be interesting
to examine if the PRMT1 splice variants yield different outcomes with these interacting
proteins.
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CHAPTER 5
Development of PRMT1 Inhibitors
5.1 Introduction
As described in detail in Chapter 1, dysregulation of PRMT1 likely plays a role in
breast cancer (Le Romancer et al. 2008 & Baldwin et al. 2012), leukemia (Cheung et al.
2007 & Shia et al. 2012), heart disease (Vallance et al. 2004), and ALS (Tradewell et al.
2012), thus suggesting that it may be a viable drug target. In addition, the precise roles
that PRMT1 plays in normal cells have yet to be fully characterized, further
demonstrating the usefulness of a specific inhibitor. The structural similarities between
the PRMT family members as well as between the PRMTs and protein lysine
methyltransferases (PKMTs), however, presents a difficult challenge when attempting to
develop a potent and selective inhibitor or inactivator for PRMT1, as there are currently
no cell permeable selective inhibitors to date. However, this shortcoming should not
overshadow the efforts that have been made by various groups in the last decade to solve
this predicament.
Arginine methyltransferase inhibitor 1, more commonly known as AMI-1, was
the first PRMT selective inhibitor to be described. This compound, along with several
less potent and/or selective compounds, was identified by screening a small molecule
library (Figure 5.1). With an IC50 value of 8.81 µM for PRMT1, the compound was
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found to reversibly inhibit all of the PRMTs tested, but not the PKMTs, and shown to be
cell permeable (Cheng et al. 2004). The lack of an effect on SAM binding in UV

Figure 5.1 Structures of selected PRMT inhibitors discovered from
library screenings.
crosslinking experiments suggested that AMI-1 likely binds in the arginine binding
pocket (Cheng et al.2004) and this hypothesis was confirmed by inhibition studies using a
fluorescence based assay (Feng et al. 2009). However, others have suggested that,
according to molecular models, it binds partially in the SAM binding pocket and partially
in the arginine binding pocket (Ragno et al. 2007). Centering on AMI-1 and several
other compounds identified in the original library screen (i.e., AMI-5, AMI-6, and AMI9) various groups have attempted to modify these structures in order to improve their
potency and selectivity towards the PRMTs (Ragno et al. 2007, Mai et al. 2007, Bonham
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et al. 2010, Castellano et al. 2010). These analogues include substitutions of carboxylic
groups for the sulfonic groups (e.g., 1b) (Castellano et al. 2010), substituted 1,5-diphenyl1,4-pentadien-3-ones (e.g., 8) (Mai et al. 2007), as well as combining parts of AMI-1,
AMI-6, and AMI-9 into one molecule (e.g., 4) (Bonham et al. 2010) (Figure 5.1).
Although some of these compounds were found to be more potent than the original
compounds, specificity was still lacking.

Figure 5.2 Structures of selected PRMT inhibitors discovered from virtual
screenings.
A second and more targeted approach has also been undertaken by way of virtual
screening using the structures of PRMT1, PRMT3, and CARM1 as guides (Spannhoff et
al. 2007, Spannhoff et al. 2007, Heinke et al. 2009). These screens have produced
compounds such as stilbamidine (Spannhoff et al. 2007), allantodapsone (Spannhoff et al.
2007), RM65 (Spannhoff et al. 2007), and C-7280948 (Heinke et al. 2009), as well as
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subsequent analogs of these original compounds such as 2e (Bissinger et al. 2011)
(Figure 5.2). In addition, a series of compounds, which possess the AMI-1 core, (e.g., 3)
were found that target the substrates of PRMT1 as opposed to the enzyme itself (Feng et
al. 2010) (Figure 5.2); this later finding raises questions regarding the inhibition
mechanism of the aforementioned sulfonylureas.

In spite of the fact that the

aforementioned compounds are suitable inhibitors, and in some cases are cell permeable,
their specificity amongst the members of the PRMT family has not been fully
investigated.

Figure 5.3 Structures of SAM analogues and selected bisubstrate PRMT inhibitors.
Although, library and virtual screenings are popular techniques for the discovery
of small molecule inhibitors, other groups have taken a more logical approach by
modifying SAM and/or peptide versions of PRMT substrates for use as inhibitors. In
support of this approach is the fact that S-adenosylhomocysteine (SAH), a product of
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PRMT-dependent methylation, and sinefungin, a SAM analog, are potent inhibitors of the
PRMTs, with specific IC50’s for PRMT1 at 19.8 ± 5.57 µM and 1.44 µM ± 0.41 µM,
respectively (Osborne et al. 2007) (Figure 5.3).

Several bisubstrate analogs that

incorporate both the SAM moiety and the target arginine residue have been characterized
(e.g., 17 (Dowden et al. 2010) and 19 (Dowden et al. 2011)), with both showing
specificity for the PRMTs over the PKTs and the latter showing specificity for PRMT1
over CARM1 (Figure 5.3). Another group has used a peptide based on the methylation
site of fibrilarin as scaffolding for inhibitor design (e.g., R1-4) (Figure 5.3). In this case,
substitutions were made at the Nη of the guanidinium group and the results show that
these inhibitors are selective for PRMT1 and PRMT6 over CARM1 with IC50 values less
than 80 µM (Lakowski et al. 2010).

Figure 5.4 Mechanism of PRMT1 inhibition by AAI.
Our lab has also been focused on developing inhibitors for the PRMTs,
specifically for PRMT1.

The first inhibitor developed in our lab was 5’-

(diaminobutyric acid)-N-iodoethyl-5’-deoxyadenosine ammonium hydrochloride
(AAI) (Figure 5.4), with an IC50 of 18.5 ± 4.2 µM in comparison to 350 ± 36 µM for
AMI-1 (Osborne et al. 2008). Note that the large difference in the IC50 values
between our studies and the original AMI-1 publication are likely due to differences
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in experimental conditions, (e.g., substrate identity and concentration), thus
demonstrating the error in comparing IC50 values stemming from different conditions.
Although more laborious and time consuming, the best method for comparing
inhibition potency is Ki or, in the case of irreversible inhibitors, kinact/KI.

Figure 5.5 Structures of haloacetamidine based inhibitors and inactivators.
Table 5.1 IC50 values for PRMT1 inhibitors and inactivatorsa

a

Enzyme

C21
(µM)

Cl-amidine
(µM)

F21
(µM)

F-amidine
(µM)

PRMT1

1.8 ± 0.1

225 ± 10

94 ± 17

>500

PRMT3

>500

>500

109 ± 28

>500

CARM1

>500

>500

>500

>500

PRMT6

8.8 ± 0.5

>500

>250

>500

PAD4

145 ± 20

5.9 ± 0.3

117 ± 14

21.6 ± 2.1

Values from Obianyo 2010.

Target based inhibitor design in our lab has not been limited to the PRMTs.
In fact, our lab previously described two potent inactivators, Cl-amidine and Famidine, for the PADs, a family of enzymes that convert arginine to citrulline in
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proteins (Figure 5.5) (Luo et al. 2006a and Luo et al. 2006b). Because the PADs and
the PRMTs both modify arginine residues, it was thought that these two compounds
might also inhibit the PRMTs. The IC50 values for the compounds with PRMT1 were
high (Table 5.1) (Obianyo et al. 2010), however, based on previous studies in our lab
that demonstrated that positively charged residues distal to the site of modification are
critical for substrate recognition (Osborne et al. 2007), it was likely that the lack of
substrate recognition elements was the cause of this high value as opposed to the
warhead.

To test this hypothesis, the Cl- and F-acetamidine moieties were

incorporated at the arginine 3 position of AcH4-21, a peptide substrate of PRMT1
that is based on the N-terminus of histone H4 (Figure 5.5) (Osborne et al. 2007).
Indeed, the potency of the peptide based inhibitors, termed C21 and F21, was greatly
increased and C21 was found to be selective for PRMT1 and PRMT6 over PRMT3
and CARM1 (Table 5.1). Interestingly, C21 was ~ 52-fold more potent than F21, and
subsequent dialysis experiments demonstrated that C21 is an irreversible inactivator,
however, F21 is a competitive reversible inhibitor. (Obianyo et al. 2010).

Figure 5.6 Possible mechanisms of inactivation of the PRMTs.
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Possible mechanisms of inactivation of the PRMTs with the haloacetamidinebased inhibitors are illustrated in Figure 5.6. Further kinetic studies with C21 and
PRMT1 revealed that inactivation for this isozyme is a two-step mechanism with Ki,
kinact, and kinact/Ki values of ≤ 0.8 ± 0.4 µM, 3.1 ± 0.4 min-1, and 4.6 x 106 min-1M-1,
respectively, thus making this the most potent PRMT1 inhibitor at this time (Obianyo
et al. 2010). Studies with C21 also demonstrated inhibition of PRMT1 in cellulo
(Obianyo et al. 2010), and the addition of a fluorescein or biotin tag, F-C21 and BC21 respectively, transforms the inactivator into an activity-based probe that can
selectively label or pull down PRMT1 from cell extracts (Obianyo et al. 2011).
Although C21 has been characterized extensively, the site of modification has
remained a mystery. Substrate protection experiments, however, have suggested that it is
likely an active site residue because the enzyme is protected from inactivation at higher
substrate concentrations (Obianyo et al. 2010). Cl-amidine and F-amidine modify an
active site cysteine residue in the PADs (Luo et al. 2006a and Luo et al. 2006b), however,
the residue modified in PRMT1 is unknown; although a cysteine residue (C101) is
present in the active site of PRMT1. Herein, we describe our efforts to determine the
residue in PRMT1 that is modified by both Cl-amidine and C-21. We also describe our
efforts to develop more potent and selective inhibitors for PRMT1 based on the site of
modification. The results of these studies have opened new doors for the rational design
of selective SAM-based inactivators of the PRMTs.
5.2 Materials and Methods
5.2.1 Chemicals
Acrylamide, ammonium persulfate, beta-mercaptoethanol, sodium dodecyl sulfate
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(SDS), tetramethylethylenediamine (TEMED), and tris(hydroxymethyl)aminomethane
(TRIS)

were

purchased

from

Bio-Rad

(Hercules,

CA).

Acetonitrile,

(ethylenedinitrilo)tetraacetic acid (EDTA), dimethylformamide (DMF), Fmoc-protected
amino acids, methanol, phenylmethylsulfonyl fluoride (PMSF), trifluoroacetic acid
(TFA), and Wang resin were purchased from EMD (Gibbstown, NJ). 6-chloropurine
riboside, dichloromethane, diethyl ether, N-ethylmaleimide, imidazole, sodium chloride,
and triisopropylsilane (TIS) were purchased from Fisher Scientific (Pittsburgh, PA).
Dithiothreitol (DTT), 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
isopropyl β-D-1-thiogalactopyranoside (IPTG), and tricine were purchased from RPI (Mt.
Prospect, IL). Piperidine was purchased from Sigma-Aldrich (St. Louis, MO).
labeled SAM was purchased from Perkin-Elmer and

14

14

C-

C-labeled BSA from Sigma-

Aldrich. The purification of PRMT1, site-directed mutagenesis, the synthesis of the
AcH4-21 peptide, and the gel-based activity assay are outlined in Chapter 2.

The

synthesis of Cl-amidine (Luo et al. 2006a) and C-21 (Obianyo et al. 2010) have been
previously described.
5.2.2 Labeling Reactions
For labeling of PRMT1 with Cl-amidine, a reaction mixture of 50 mM HEPES pH
8.0, 1 mM EDTA, 50 mM NaCl, 0.5 mM dithiothreitol, and 5 mM Cl-amidine was preincubated at 37 °C for 10 min. The reaction was initiated with 4.17 µM (5 µg) of
PRMT1 and the reaction was quenched after 15 min with 4x SDS-loading dye. The
entire reaction (5 µg of PRMT1) was separated by SDS-PAGE. For labeling of PRMT1
with C21, a reaction mixture of 50 mM HEPES pH 8.0, 1 mM EDTA, 50 mM NaCl, 0.5
mM dithiothreitol, and 8.33 µM C21 was pre-incubated at 37 °C for 10 min. The
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reaction was initiated with 8.33 µM (10 µg) of PRMT1 and the reaction was quenched
after 15 min with SDS-loading dye. Half of the reaction (5 µg of PRMT1) was separated
by SDS-PAGE.
5.2.3 In-Gel Digestion
Coomassie stained gel bands corresponding to labeled PRMT1 were excised and
the resultant gel pieces were washed and dehydrated two times. Existing disulfide bonds
were reduced with 10 mM DTT and the resulting thiols were alkylated with 54 mM Nethylmaleimide. Proteins were digested with trypsin (Promega – V5113), at a 1:10
(w:w)(trypsin:protein) ratio, overnight at 37 °C. The enzymatic reaction was quenched
with 1% TFA and the resulting peptides were desalted and concentrated using C18
ZipTips (Millipore). Dried peptides were reconstituted in 0.1 % formic acid. All samples
were analyzed by liquid chromatography-tandem MS (LC-MS/MS) using an EASY-nLC
II system coupled to an LTQ linear ion trap mass spectrometer (Thermo-Finnigan, San
Jose, CA). Briefly, peptides were concentrated and desalted on an RP trapping column
(0.31 x 20 mm, ReproSil-Pur C18-AQ, ThermoScientific) and eluted on-line with an
analytical RP column (0.075 x 100 mm, ReproSil-Pur C18-AQ, ThermoScientific),
operating at 300 nl/min and using a 40-min gradient from 0% to 40% solvent B [solvent
A: 0.1% formic acid (v/v), solvent B: 0.1% formic acid (v/v), and 80% acetonitrile (v/v)].
For analysis of PRMT1 labeled with Cl-amidine, a m/z 400-1600 survey scan was
performed followed by the fragmentation of the ten most intense ions. A database search
with the MS/MS results was performed using the SEQUEST algorithm to identify the
modified cysteine residue(s) (m/z 377.15). For analysis of PRMT1 labeled with C21, the
LTQ was programmed in the ‘selected MS/MS ion monitoring’ (SMIM) mode. The m/z
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400-1600 survey scan was first performed in order to check for the presence of digested
peptides as well as peptide separation along the gradient. This survey scan is followed by
dependent MS/MS scans that fragment the six most intense ions to confirm the presence
of the protein of interest. Next, MS/MS spectra were programmed, focusing on m/z
564.55, which corresponds to the quadruply-charged precursor ion of the modified
KVIGIEC*SSISDYAVK peptide, and on m/z 752.40, corresponding to the same
modified peptide but in its triply-charged state. Note that the quadruple charge stems
from a possible charge on the fragmented C21 peptide and that the MS/MS scans were
repeated twice.
5.2.4 IC50 Assay
IC50 values were determined using a gel-based radioactive assay with a reaction
mixture of 50 mM HEPES pH 8.0, 1 mM EDTA, 50 mM NaCl, 0.5 mM dithiothreitol, 25
µM AcH4-21, 0.2 µM PRMT1, and varying concentrations of inhibitor. Samples were
pre-incubated for 10 min at 37 °C and the reaction was then initiated with 15 μM [ 14C]labeled SAM. The reaction was quenched with tris-tricine gel loading dye after 15 min
and the samples were run on tris-tricine gels. Incorporated radioactivity was measured by
phosphorimage analysis (Molecular Dynamics). Each assay was done in duplicate and
the standard deviation of the duplicate raw data values agreed within ≤ 20%. The GraFit
version 5.0.11 software (Leatherbarrow 2004) was used to fit the data to eq. 1,
Fractional activity of PRMT1 = 1/(1 + ([I]/IC50))

(1),

in which the concentration of inhibitor equals [I] and the concentration of inhibitor that
yields half-maximal activity equals the IC50.
5.2.5 Dialysis Experiments

114

For C21, a reaction mixture of 50 mM HEPES pH 8.0, 1 mM EDTA, 50 mM
NaCl, 0.5 mM dithiothreitol, 125 µM C21, and 10 µM enzyme (WT PRMT1 or C101A
mutant) in a final volume of 150 µL was incubated for 1 h at 37 °C. Note that a control
reaction was also performed without C21. Samples were then dialyzed for 24 h at 4°C
against 100 mM HEPES, 200 mM NaCl, 1 mM DTT, 2 mM EDTA, and 10% glycerol in
a total volume of 2 L.

An aliquot was removed from all samples, before dialysis, and

activity was measured using the gel-based assay described in Chapter 2, with 15 µM 14CSAM, 25 µM AcH4-21, 125 µM C21, and 0.2 µM enzyme or enzyme-inhibitor complex
for 15 min at 37 °C, followed by quenching with tris-tricine gel loading dye. After
dialysis, protein concentration in each sample was determined by Bradford assay and
activity was measured with 15 µM

14

C-SAM, 25 µM AcH4-21, and 0.2 µM enzyme or

enzyme-inhibitor complex for 15 min at 37 °C, followed by quenching with tris-tricine
gel loading dye.

Samples were separated by tris-tricine gels and radioactivity was

measured using phosphorimage analysis (Molecular Dynamics). The product formed by
the control reactions was set to 100% and the percent activity of the other samples was
determined based on this number. The same procedure was repeated for Cl-acetamidinoN-ethyl-aminoadenosine, except the concentration of inhibitor was 1 mM and only the
WT enzyme was assayed.
5.2.6 Synthesis of N-ethyl-aminoadenosine
A solution of 100 mg (0.35 mmol) of 6-chloropurine riboside and 70 µL (1.1
mmol) of ethylene diamine in 3 mL of IPA was refluxed for 1 h at 83 °C. Ether was then
added to the reaction and the compound was purified by trituration. The ether was then
decanted and the product, N-ethyl-aminoadenosine, was dried in vacuo and the mass was
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verified by LC-MS: expected = m/z 311.14 (M + H+), observed = m/z 311.1 (M + H+).
N-ethyl-aminoadenosine was used in subsequent experiments without further
purification.
5.2.7 Synthesis of Cl-acetamidino-N-ethyl-aminoadenosine
A solution of 39 mg (0.126 mmol) of the N-ethyl-aminoadenosine, 30 mg (0.189
mmol) of ethylchloroacetimidate hydrochloride, and 71.7 µL (0.377 mmol) of potassium
carbonate in 5 mL of methanol was then rocked overnight at rt. The solvents were
evaporated in vacuo and the product was purified by RP-HPLC with a linear gradient of
water (0.05% TFA)/acetonitrile (0.05% TFA). The mass of the product was verified by
LC-MS: expected = m/z 386.13 (M + H+), observed = m/z 386.1 (M + H+).
5.3 Results and Discussion
5.3.1 Identifying the Site of Modification of Haloacetamidine-Based Inactivators
Our lab previously described two irreversible inactivators of PRMT1, i.e., Clamidine and C21, with the latter of the two being the most potent PRMT1 inhibitor
described to date (Obianyo et al. 2010). Cl-amidine was originally described as a potent
PAD inhibitor (Luo et al. 2006a and Luo et al. 2006b) and because both families of
enzymes modify arginine residues, it was thought that it might inhibit the PRMTs as well,
which proved to be true. The site of modification of the PADs is an active site cysteine
residue that is critical for activity (Luo et al. 2006a and Luo et al. 2006b); however, it has
been unclear as to the identity of the site of modification for PRMT1, as a cysteine
residue is not important for catalysis. Discovery of the site of modification would aid in
the development of more potent and selective inhibitors by allowing for modification of
the current inhibitors or by creation of new inhibitors.
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Figure 5.7 MS/MS of the site of modification of PRMT1 with (A) Cl-amidine and (B)
C21. For both inactivators, KVIGIECSSISDYAVK was identified as the modified
peptide, with C101 as the modified residue.
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Because C21 is peptide based, which can complicate the MS/MS analysis,
PRMT1 was first labeled with Cl-amidine and then an in-gel trypsin digest was
performed followed by MS/MS analysis. The results show that C101, an active site
cysteine residue, is the site of modification (Figure 5.7A). The experiment was then
repeated with C21 and the results revealed that C101 is the site of modification for this
inactivator as well (Figure 5.7B).
5.3.2 Characterization of the C101A Mutant
To characterize the role of C101 in PRMT1 catalysis, an alanine mutant was made
and the kinetic parameters were determined (Tables 5.2 and 5.3). Unlike the modified
Table 5.2 Kinetic parameters of PRMT1 mutants for the AcH4-21 peptide
Mutant

Km
(µM)

Fold

kcat
(min-1)

Fold

kcat/Km
(M-1·min-1)

Fold

WTa

1.1 ± 0.5

-----

4.6 x 10-1 ± 2 x 10-2

-----

4.1 x 105

-----

C101Aa

0.8 ± 0.57

0.73

1.03 x 10-1 ± 4 x 10-2

0.45

1.3 x 106

0.32

a

[SAM] = 15 μM.

Table 5.3 Kinetic parameters of PRMT1 mutants for SAM
Mutant

Km
(µM)

Fold

kcat
(min-1)

Fold

kcat/Km
(M-1·min-1)

Fold

WTa

6±1

-----

5.8 x 10-1 ± 3 x 10-2

-----

1 x 105

-----

C101Aa

10 ± 3

1.7

1.3 ± 1 x 10-1

0.45

1.3 x 105

0.8

a

[AcH4-21] = 100 μM.

cysteine in the PADs, mutation of this cysteine residue confirmed previous observations
(Zhang et al. 2003) that it does not play a role in substrate binding or catalysis, as
demonstrated by the similar Km, kcat, and kcat/Km values. In fact, based on kcat/Km, it is a
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slightly better enzyme. We then hypothesized that the C101A mutant would likely not be
inhibited by C21, due to the fact that the enzyme can no longer be covalently
modified. The results show, however, that the C101A mutant is still inhibited by C21,
but the IC50 value is increased by ~ 18-fold (Table 5.4). These results suggest that C21
may be a reversible inhibitor for C101A, while an irreversible inactivator of the WT
enzyme. Dialysis experiments were performed to confirm this hypothesis and the results
Table 5.4 IC50 values for C21

Enzyme

C21
(µM)

Fold

PRMT1

1.8 ± 0.1

-----

C101A

32 ± 6

18

100

Percent Activity (%)

80

60

40

20

0
(WT) Pre-

(WT) Post-

(C101A) Pre- (C101A) Post-

Dialysis
Control

125 µM C-21

Figure 5.8 Dialysis experiments of WT PRMT1 and the
C101A mutant with C21. The WT enzyme remains
inactivated after dialysis, thus demonstrating that C21 is an
irreversible inactivator towards the enzyme. The C101A
mutant regains activity after dialysis, thus showing that C21
is only a reversible inhibitor for the mutant enzyme.
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showed that the C101A mutant regained activity after dialysis (Figure 5.8). The WT
enzyme, however, remained inactivated, thus suggesting that C21, is a reversible
inhibitor for C101A.

These results also confirm that C101 is the relevant site of

modification.
5.3.3 Design of SAM Analogues as PRMT1 Inactivators
The fact that PRMT1 is modified at C101 by C21 would suggest that the residue
is located in the substrate binding pocket. Surprisingly however, examination of the
crystal structure shows that C101 faces the SAM binding pocket instead and is only 3.9 Å
from the adenine rings and 4.1 Å from the ribose of SAH (Figure 5.9). Based on these

4.1 Å

C101
3.9 Å

5.1 Å

SAH

Figure 5.9 Structure of PRMT1 showing the
position of the C101 residue in relation to SAH.
This figure was prepared with UCSF Chimera
using the coordinates from PRMT1 (PDBID
1ORI).
structural observations, as well as the fact that SAM analogues (i.e. SAH and sinefungin)
are potent inhibitors of the PRMTs, vide supra, we hypothesized that we could create
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more potent inactivators for PRMT1 by designing analogues of SAH that contain
warheads that react with cysteine (i.e., chloroacetamidine, fluoromethylketone, and
acrylamide). As a starting point for inhibitor development, only the adenosine portion of
SAH was used for the first SAM analogue, i.e., Cl-acetamidino-N-ethyl-aminoadenosine.
The synthetic scheme for this compound can be found in Figure 5.10. Briefly, ethylene
diamine

was

coupled

to

6-chloropurine

riboside

followed

by

coupling

of

ethylchloroacetamidate to yield the final product.

Figure 5.10 Synthesis of N-ethyl-aminoadenosine and Cl-acetamidino-N-ethylaminoadenosine.
IC50 values were determined for adenosine, N-ethyl-aminoadenosine, and Clacetamidino-N-ethyl-aminoadenosine and can be shown in comparison to C21 in Table
5.5. The results show that the chloroacetamidine warhead is critical for inhibition, as
demonstrated by the large IC50 values, i.e., >2000 µM, for adenosine and N-ethylaminoadenosine; in comparison, the IC50 of Cl-acetamidino-N-ethyl-aminoadenosine is 200 ±
109 µM.

The high value for the C101A mutant, >1000 µM, further suggests that

covalent modification of this residue by Cl-acetamidino-N-ethyl-aminoadenosine is
critical for inhibition. To confirm that this SAM analogue is an irreversible inhibitor,
dialysis experiments were performed and the results show that, although not as potent as
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C21 (Figure 5.8), activity is not regained after dialysis and therefore it too is an
irreversible inhibitor (Figure 5.11).

Table 5.5. IC50 Values for PRMT1 & mutant with inhibitors & inactivators

Compound

Structure

Mutant

IC50
(µM)

Fold

WTab

1.8 ± 0.1

-----

C101Aab

32 ± 6

18

WTab

200 ± 109

111

C101Aab

>1000

> 556

WTab

>2000

> 1111

C101Aab

>2000

> 1111

WTab

>2000

> 1111

C101Aab

>2000

> 1111

C-21

Cl-acetamidinoN-ethylaminoadenosine

N-ethylaminoadenosine

Adenosine

a

AcH4-21 = 25 μM; bSAM = 15 μM
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Figure 5.11 Dialysis experiments of WT
PRMT1
with
Cl-acetamidino-N-ethylaminoadenosine. The WT enzyme remains
inactivated after dialysis, thus demonstrating
that Cl-acetamidino-N-ethyl-aminoadenosine
is an irreversible inactivator.
5.4 Conclusions
The development of potent, selective, and cell permeable inhibitors of the PRMTs
has been a challenge due to the structural similarities between the family members. Our
lab has previously described the most potent inactivator to date, C21 (Obianyo et al.
2010), however, the site of modification was a mystery.

To identify the site of

modification, PRMT1 was first labeled with Cl-amidine, a potent inhibitor for the PADs,
and the MS/MS analysis revealed that C101 was modified. The same experiment was
performed with C21 and C101 was once again identified as the modified residue. A
C101A mutant was created to determine if this residue is important for catalysis, and the
kinetic parameters demonstrated that it is not. Although the C101A mutant is still
inhibited by C21, dialysis experiments determined that the inhibitor was reversible
compared to its irreversibility with the WT enzyme.
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Interestingly, this residue has

previously been described as a hyper-reactive cysteine residue (Weerapana et al. 2010),
thus making it a good target for covalent modification. In fact, examination of the
structure of PRMT1 revealed that C101 is in the SAM binding pocket. Therefore, we
hypothesized that SAM analogues containing warheads that react with cysteine would be
potent inhibitors of PRMT1.

To test our hypothesis, a SAM analogue, i.e., Cl-

acetamidino-N-ethyl-aminoadenosine, was synthesized. IC50 values were determined for
not only the inhibitor, but for its precursors, adenosine, and N-ethyl-aminoadenosine, and
the results show that the warhead is critical for inhibition. Comparison of the values for
the WT enzyme and the C101A mutant suggests that C101 is the site of modification and
important for inhibition with the analogue. In addition, dialysis experiments confirmed
that Cl-acetamidino-N-ethyl-aminoadenosine is an irreversible inhibitor of the WT
enzyme.
Interestingly, a cysteine residue as this position is only found in PRMT1 and
PRMT8 (Figure 5.9A). This observation may explain why C21 is selective for PRMT1
over PRMT3 and CARM1, who each contain a cysteine residue that is buried away from
the active site (Figure 5.9B-C). It is thus surprising that C21 is also quite potent for
PRMT6, even though an active site cysteine residue is not present in the crystal structure.
However, a cysteine residue is located on the N-terminal tail of this isozyme, which looks
as though it may be in a position to react with C21 after it is bound, based on the crystal
structures of other PRMTs.
Of most interest is a cysteine residue in the active site of PRMT5 that is opposite
the position of C101 in PRMT1 (Figure 5.9D). Although the reactivity of this cysteine
residue is unknown, this observation suggests that it may be possible to develop SAM
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analogues that are individually selective for PRMT1 and PRMT5 by varying the position
of the warhead.

Figure 5.12 Structural representation of PRMT cysteine
residues around the active site for (A) PRMT1, (B) PRMT3,
(C) CARM1, and (D) PRMT5. Note that the transparent
spheres (B and C) are facing away from the active site. This
figure was prepared with UCSF Chimera using the coordinates
from PRMT1 (PDBID 1ORI), PRMT3 (PDBID 3SMQ),
CARM1 (PDBID 3B3F), and PRMT5 (PDBID 4GQB).
Overall, the results described in this chapter have opened up a new door for our
efforts to develop potent and selective inhibitors and inactivators of not only PRMT1, but
other isozymes as well. Future studies will include the synthesis of SAM analogues with
SAH as the backbone and a variety of different linkers and warheads. We hypothesize
that our newly designed inhibitors will be the most potent and selective PRMT inhibitors
to date.
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CHAPTER 6
Crosstalk Between Methylation and Phosphorylation3
6.1 Introduction
As mentioned in Chapter 1, the best characterized examples of crosstalk between
two or more different post-translational modifications (PTMs) occur with respect to
histones. These examples demonstrate the critical roles that crosstalk plays in regulating
cell signaling pathways. Recently, however, non-histone crosstalk has been observed
between serine/threonine phosphorylation and the modification of arginine residues
within kinase consensus sequences.

We hypothesize that crosstalk between

serine/threonine phosphorylation and arginine modifications (Figure 6.1) is a general
mechanism to regulate eukaryotic cell signaling, given that these neighboring arginine
residues are key substrate recognition elements for many protein kinases (Figure 6.2).

Figure 6.1 Potential model for crosstalk between arginine
methylation and phosphorylation.

3

Adapted with permission from Rust, H.L.; Thompson, P.R., Kinase consensus sequences: a breeding
ground for crosstalk. ACS chemical biology 6(9), 881-892. Copyright 2013 American Chemical Society.
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Figure 6.2 Serine/Threonine Protein Kinase consensus sequences. A number of
serine/threonine protein kinases recognize protein sequences that contain positively
charged arginine and lysine residues adjacent to the site of phosphorylation. For
example, Akt, prefers substrates that have two arginines (or lysines) at positions -3 and -5
with respect to the modification site that are separated by a variant residue. Each box
represents one residue’s position and multiple single letter amino acid codes demonstrate
variability within that position. Adapted from (Kinexus 2011).
6.1.1 Arginine Methylation Blocks Phosphorylation
Four examples of direct, adjacent cis crosstalk (see Chapter 1) have emerged
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involving arginine methylation and serine phosphorylation.

First, Yamagata et al.

demonstrated that FOXO1 (forkhead box O1) is methylated in vitro and in vivo by
PRMT1 (Protein Arginine Methyltransferase 1) (Yamagata et al. 2008). FOXO1 is a
member of the FOXO family of transcription factors, which play essential roles in cell
cycle regulation, apoptosis, the oxidative stress response, and overall cell survival (Greer
et al. 2005). The sites of FOXO1 modification, R248 and R250, are conserved across
family members and species.

Interestingly, the FOXO family members are

phosphorylated by Akt at three conserved residues, one of which, i.e., S253 in FOXO1
(Brunet et al. 1999), lies adjacent to R248 and R250 (mouse numbering). The authors
then demonstrated that methylation of these two arginine residues inhibited
phosphorylation of S253, a clear example of cis crosstalk. However, the converse was
not observed – phosphorylation does not prevent methylation (Yamagata et al. 2008).
Functionally, methylation of R248 and R250 blocks the phosphorylation of S253,
thereby preventing the phosphorylation dependent nuclear export of FOXO1 (Zhang et al.
2002). Additional experiments indicated that it is the lack of phosphorylation, and not
the presence of methylated arginine residues, that is responsible for inhibiting FOXO1
export (Yamagata et al. 2008). Because the phosphorylation and nuclear export of
FOXO1 is associated with its polyubiquitination and degradation by the proteasome
(Matsuzaki et al. 2003 and Huang et al. 2005), the authors tested the effects of PRMT1
knockdown on FOXO ubiquitination and stability. The results indicated that PRMT1
knockdown enhanced the polyubiquitination of FOXO1, which promoted its degradation
by the proteasome (Yamagata et al. 2008).

128

Since it is well established that FOXO family members control the response to
oxidative stress (Greer et al. 2005), the authors further hypothesized that the methylation
of FOXO1 would affect this pathway. As expected, hydrogen peroxide led to an increase
in the PRMT1-dependent methylation of FOXO1, which in turn blocked the
phosphorylation of S253, and nuclear export. As a result, the transcription of a number
of FOXO1-dependent genes was increased including, BIM (BCL-2-interacting mediator),
an apoptosis inducing protein (Yamagata et al. 2008). Consistent with this model, when
either PRMT1 or FOXO1 were knocked down by siRNA, no increase in BIM
transcription was observed.

Although PRMT1 knockdown inhibited apoptosis in

response to oxidative stress, inhibition of PI3K-Akt signaling has the reverse effect
(Yamagata et al. 2008). Taken together, these results demonstrate a functional crosstalk
between the methylation of R248 and R250 and phosphorylation of S253 of FOXO1.
This mechanism of crosstalk appears to be evolutionarily conserved because methylation
of the FOXO1 orthologue in C. elegans, DAF-16, also inhibits its phosphorylation by
Akt. Interestingly, this activity in C. elegans appears to play a role in life span extension,
as PRMT1 knockouts died significantly earlier than wild type worms, thereby suggesting
that PRMT1 inhibition may exert pleiotropic off target effects (Takahashi et al. 2011).
Recently, Sakamaki et al. published a second example of cis crosstalk between
PRMT1 and Akt. Specifically, the authors investigated whether the phosphorylation of
other proteins that contain an Akt consensus sequence (i.e., RXRXXS/T) are modulated
by the methylation of adjacent arginine residues (Sakamaki et al. 2011). Several known
Akt substrates (i.e., BAD, PGC-1, eNOS, p27, GSK3, and MDM2) were tested as
PRMT1 substrates.

Only PGC-1 (peroxisome proliferator-activated receptor-γ
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coactivator) (Yamagata et al. 2008) and BAD (BCL-2 antagonist of cell death)
(Sakamaki et al. 2011), were shown to be methylated by PRMT1. The fact that eNOS,
p27, GSK3, and MDM2 were not methylated (Sakamaki et al. 2011) suggests that
additional PRMT1 recognition elements are required for substrate methylation (vide
infra). In BAD, the sites of modification were identified as R94 and R96, and, as was the
case with FOXO1 (Yamagata et al. 2008), arginine methylation prevented
phosphorylation of an adjacent serine residue (i.e., S99), but prior phosphorylation did
not affect BAD methylation by PRMT1 (Sakamaki et al. 2011).
Due to the functional role of a methylation/phosphorylation switch in regulating
FOXO1 activity (Yamagata et al. 2008), it was probable that crosstalk would also affect
the physiological activity of BAD. BAD is a pro-apoptotic member of the BCL-2 protein
family and plays a major role in regulating cellular apoptosis (Danial et al. 2008).
Previous studies have demonstrated that several kinases and phosphatases are responsible
for altering the phosphorylation state of BAD and thus dictating its location and activity
(Danial et al. 2008, Yang et al. 1995, Datta et al. 1997, Harada et al. 1999, Bonni et al.
1999, Datta et al. 2000, Tan et al. 2000, Virdee et al. 2000, Ayllon et al. 2000, Chiang et
al. 2001, Wang et al. 1999). For example, when BAD is dephosphorylated, it binds to the
pro-survival proteins BCL-XL/BCL-2 and displaces the pro-apoptotic proteins BAK
and/or BAX (from BCL-XL/BCL-2) to create activated homodimers that form a pore in
the mitochondria, which ultimately leads to apoptosis (Danial et al. 2008, Yang et al.
1995, Dewson et al. 2009).

However, in response to cellular stress, BAD is

phosphorylated at S75, S99, and S118. Once phosphorylated, BAD binds to a 14-3-3
protein and is subsequently removed from the mitochondria and sequestered in the
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cytoplasm. As a consequence, the pro-apoptotic function of BAD is muted (Datta et al.
1997, Harada et al. 1999, Bonni et al. 1999, Datta et al. 2000, Tan et al. 2000, Virdee et
al. 2000, Zha et al. 1996, del Peso et al. 1997). Based on this model, one would expect
that decreased methylation of BAD by PRMT1 would increase phospho-BAD levels,
which would lead to enhanced 14-3-3 binding, sequesteration in the cytoplasm, decreased
caspase activity, and consequently an increase in cell viability, all of which were
observed when PRMT1 was knocked down by siRNA (Sakamaki et al. 2011). In contrast
to the situation with FOXO1, methylation of BAD was not triggered by oxidative stress
or known BAD activators. Thus it is unclear whether BAD methylation is constitutive or
occurs in response to an unknown stimulant (Sakamaki et al. 2011). In any case, these
observations demonstrate that the methyltransferase activity of PRMT1 is critical for the
pro-apoptotic function of BAD through its prevention of Akt mediated phosphorylation
of S99 (Sakamaki et al. 2011).
The previous two examples involved PRMT1, a Type I PRMT that catalyzes the
asymmetric dimethylation of arginine residues in proteins. In the third example of direct
adjacent cis crosstalk, PRMT5, a Type II PRMT that symmetrically dimethylates
arginines, is the responsible enzyme. Specifically, Guo et al. show that FEN1 (flap
endonuclease 1) is methylated at R192 by PRMT5 and that methylation of this particular
arginine inhibits the phosphorylation of S187 by Cdk2-cyclin E (cyclin dependent kinase2).

As with the previous examples, the reverse scenario was not observed, i.e.,

phosphorylation does not prevent methylation (Guo et al. 2010).

Since FEN1

phosphorylation prevents its binding to PCNA (proliferating cell nuclear antigen)
(Henneke et al. 2003), it is unsurprising that by preventing phosphorylation, methylation
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promotes the PCNA and FEN1 interaction.

However, methylation occurring after

phosphorylation did not re-establish this protein complex, confirming that the inhibition
of phosphorylation, and not methylation alone, is responsible for the observed effect
(Guo et al. 2010). The interaction between PCNA and FEN1 is responsible for localizing
FEN1 to the site of replication. This interaction is important because FEN1 is an exoand endonuclease involved in essential DNA processes, such as replication and repair
(Shen et al. 2005). A R192K mutant, which cannot be methylated, abrogated both the
PCNA/FEN1 interaction and the localization of FEN1 to the site of replication. As a
consequence, a buildup of DNA double-stranded breaks was detected, followed by
slower progression through the cell cycle, and ultimately mitotic arrest (Guo et al. 2010).
Because other studies have shown that PRMT1 plays a role in the oxidative stress
response (Yamagata et al. 2008), the authors also investigated the effect of hydrogen
peroxide on the methylation of FEN1. The results showed that oxidative stress results in
localization of methylated FEN1 to the nucleus. FEN1 that lacked methylation resulted
in a decrease in cell survival and an increase in mutations, thus demonstrating a
correlation between arginine methylation and DNA repair (Guo et al. 2010). These
observations demonstrate that PRMT5 dependent methylation of the R192 residue of
FEN1 plays a critical role in preventing Cdk2-cyclinE dependent phosphorylation of
S187 and subsequently allows for proper DNA replication and repair. With respect to
human disease, these results suggest that PRMT5 inhibition would synergize with DNA
damaging agents as a way to treat cancer.
6.1.2 Phosphorylation Blocks Arginine Methylation
The above crosstalk examples demonstrate a functional role for the inhibition of
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serine phosphorylation by arginine methylation, but not the inverse. More recently, Sims
et al. uncovered such an example of direct adjacent cis crosstalk, where phosphorylation
of RNA polymerase II (RNAPII) prevents its methylation at R1810 (Sims et al. 2011).
The CTD (carboxy terminal domain) of RNAPII contains a series of heptad repeats
whose consensus sequence is YSPTSPS (Egloff et al. 2008), however, several of these
repeats contain arginine or lysine substitutions in the last position (i.e., YSPTSP[R/K])
(Sims et al. 2011). It is known that S2 and S5 of these sequences can be phosphorylated
by P-TEFb (positive transcription elongation factor

b) and CAK, (CDK activating

kinase), respectively (Sims et al. 2011). Phosphorylation of these residues activates
RNAPII and aids in the recruitment of essential proteins (Fong et al. 2001 & Misteli et al.
1999) that are important for gene transcription (Egloff et al. 2008). Due to the unique
nature of the arginine and lysine substitutions, the authors investigated whether they were
specifically modified. The only PTM to be identified was methylation of R1810 by
CARM1 (co-activator-associated protein arginine methyltransferases 1) or PRMT4.
Interestingly, phosphorylation of S2 and S5 prevented methylation of R1810 but
methylation did not prevent phosphorylation. Also, the presence of both methylation and
phosphorylation was observed in vivo suggesting that methylation occurs before
phosphorylation (Sims et al. 2011). The functional consequence of a lack of methylation
of R1810 is downregulated transcription of small nuclear RNA (snRNA) and small
nucleolar RNA (snoRNA) (Sims et al. 2011).
6.1.3 Distal Crosstalk Between Arginine Methylation and Phosphorylation
Although the main focus of this chapter is direct adjacent cis crosstalk within
kinase consensus sequences, it is worth noting two additional examples involving distal
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non-histone crosstalk between arginine methylation and phosphorylation.

The first

example involves an interesting interplay between the CARM1 dependent methylation of
R3 in C/EBP (CCAAT/enhancer-binding protein ) (Kowenz-Leutz et al. 2010), a
transcription factor, and the phosphorylation of T253 by MAPK (Nakajima et al. 1993).
Here, phosphorylation of T253 abrogates the interaction between C/EBP and CARM1,
which abolishes the methylation of R3 (Kowenz-Leutz et al. 2010).

Unmethylated

C/EBP is then free to bind to the SWI/SNF nucleosome remodeling and the Mediator
transcriptional co-activator complexes to facilitate the increased transcription of C/EBPdependent genes.

Thus, R3 methylation inhibits interactions between C/EBP,

SWI/SNF, and Mediator, and as a consequence, down regulates the transcription of genes
under the control of C/EBP.
A second example of distal crosstalk involves the members of the STAT (signal
transducer and activator of transcription) family of proteins, which play important roles
in cell differentiation, survival, and apoptosis (Calo et al. 2003). Given that STAT1 is
methylated by PRMT1 at R31, a conserved arginine residue (Mowen et al. 2001), Chen et
al. investigated whether the corresponding arginine in STAT6, R27, was also modified,
and found that this was the case. However, the responsible methyltransferase was not
identified (Chen et al. 2004).

Nevertheless, the authors did show that the lack of

methylation prevented phosphorylation of a distal tyrosine residue (i.e., Y641) and
consequently inhibited nuclear translocation, abrogated DNA binding, and decreased
protein stability. It was shown that this crosstalk was not due to the activation of tyrosine
phosphatases. Overall, the results demonstrated that arginine methylation of STAT6 is
required for phosphorylation of an essential tyrosine residue, which ultimately effects the
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location of the protein, its DNA binding capabilities, and protein stability (Chen et al.
2004).
6.1.4 Structural Basis for Crosstalk
Protein kinases typically bind and phosphorylate serine, threonine, or tyrosine
residues within a distinct consensus sequence. Of these kinases, Akt is a perfect example
of how PTMs within a consensus sequence can alter substrate binding. For Akt, the
consensus sequence (i.e., RXR[S/T/A][S/T/A][S/T][F/L]) contains two positively
charged arginine residues at the -3 and -5 positions relative to the phosphorylation site
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Figure 6.3 Structural basis for crosstalk. A structure of Akt (white)
bound to a GSK3 (cyan) derived peptide demonstrates that
arginine residues in the -5 and -3 positions are critical for Akt
substrate recognition. R-5 forms direct and indirect hydrogen
bonds with several key residues (i.e. E279, Y316, E342), as well
as, with T-2 on the peptide. This residue is also capable of
forming a salt bridge with E279. R-3 forms both a hydrogen bond
and salt bride with E236. The methylation of both R-5 and R-3
would disrupt these key interactions and thus result in the observed
inhibition of serine phosphorylation, which is demonstrated in
several examples presented in this review (i.e., FOXO1 (Yamagata
et al. 2008) and BAD (Sakamaki et al. 2011). This figure was
prepared with UCSF Chimera using the coordinates for the
Akt•GSK3 peptide complex (PDBID 1O6L).
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(Figure 6.2). Based on the structure of Akt bound to a peptide whose sequence is derived
from GSK3Yang et al. 2002) (Figure 6.3), it is apparent that R-5 forms several direct
and indirect hydrogen bonds with surrounding Akt residues, including E279, Y316, and
E342, as well as T-2 on the peptide itself. In addition, the positive charge of R-5 and the
negative charge of E279 are likely capable of forming a salt bridge. R-3 also forms a
hydrogen bond and salt bridge with E236, and, although the distance between R-3 and
D440 is too great for a hydrogen bond interaction, it is also possible that there are
electrostatic attractions between these two residues. In the examples described above,
both R-3 and R-5 were methylated and this prevented the phosphorylation of the targeted
serine residue (Yamagata et al. 2008 & Sakamaki et al. 2011). The structural basis for
this crosstalk is easily discerned. For example, while the formation of an asymmetrically
dimethylated arginine would not alter the charge of the residue, it would undoubtedly
create steric bulk. This added steric bulk would prevent the formation of key hydrogen
bonds, with for example E279 and Y316 in the substrate binding cleft, which would
result in an inability to properly bind the substrate and thereby inhibit phosphorylation.
Similar effects would be expected for the methylation of R-3. One could imagine that
deimination of these two arginine residues by the PADs would likely yield the same
result. However, instead of adding steric bulk, abrogation of protein binding would be
due to the neutralization of the positively charged arginine residue and the disruption of
proper hydrogen bonding. Although the conversion to citrulline would still allow for a
lower degree of hydrogen bond formation, the carbonyl oxygen would only be a
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hydrogen bond acceptor, thus terminating the bidentate interactions between R-3 and
E236 and R-5 and E279.
Interestingly, phosphorylation does not block methylation by PRMT1 and
PRMT5. Based on the crystal structure of PRMT1 (Zhang et al. 2003), as well as work
from our own lab (Osborne et al. 2007), this observation is easily rationalized. For
example, while the surface of PRMT1 is highly negatively charged (Zhang et al. 2003),
which would suggest that the introduction of a phosphate group would lead to
electrostatic repulsions, we have shown that the residues between the site of methylation
and distal positively charged residues are relatively unimportant for substrate recognition
(Osborne et al. 2007). Although a similar explanation is likely for PRMT5, detailed
substrate specificity studies have not been performed on this isozyme. In contrast to the
situation with PRMTs 1 and 5, phosphorylation of S2 and S5 in RNAPII blocked the
methylation of R1810 by CARM1 (Sims et al. 2011). Given that detailed substrate
specificity studies have also not been performed for this enzyme and no structures of
CARM1 bound to cognate peptide substrates are available, it is difficult to speculate on
why phosphorylation blocks methylation. Nevertheless, the addition of two phosphate
groups adjacent to the site of methylation would likely not only cause a perturbation in
the peptide structure itself, due to repulsion between the two phosphate groups, but would
also likely disrupt key interactions within the substrate binding cleft.
6.1.5 Role of Additional Modifications
Although the discussion so far has focused mainly on arginine methylation, this
residue is also subject to deamination and it is likely that this additional modification will
exhibit crosstalk with protein phosphorylation. In support of this notion, the Coonrod
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group recently showed that Elk-1 (ETS like gene 1), a member of the ETS family of
transcription factors, is deiminated by PAD4 and that this modification increases Elk-1
phosphorylation by ERK2.

Although it has yet to be established that these two

modifications occur in the same consensus sequence, it is known that phosphorylation
facilitates a tight interaction between Elk-1 and p300 leading to increased histone
acetylation and ultimately the activation of c-Fos (Zhang et al. 2011).
One final layer of complexity is the role of antagonistic PTMs. For example, we
and others have shown that deimination/citrullination of an arginine residue can
antagonize/prevent the methylation of that same arginine residue (Hidaka et al. 2005,
Kearney et al. 2005, Thompson et al. 2006, Raijmakers et al. 2007, Cuthbert et al. 2004,
Guo et al. 2011). In addition, serine O-GlcNAcylation has been shown to antagonize
phosphorylation of the same serine residue (Hart et al. 2010 & Wang et al. 2010).
Overall, these individual observations suggest that crosstalk within kinase consensus
sequences is potentially quite complex, has multiple levels, and that eukaryotic cell
signaling is not well represented by the linear pathways often depicted in textbooks.
6.1.6 Crosstalk and Disease
Crosstalk between protein phosphorylation and modification of arginine residues
within kinase consensus sequences potentially has significant relevance to human
disease. This is the case because the modification of these basic residues can potentially
have either growth promoting or growth suppressing effects. For example, in the two
examples of Akt crosstalk, PRMT1 opposes the effects of Akt-mediated phosphorylation
(Yamagata et al. 2008 & Sakamaki et al. 2011). Given that PI3K-Akt signaling is
overactive in multiple cancers, these results suggest that the inhibition of PRMT1 would
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further stimulate the growth promoting and cell survival effects of Akt signaling.
Nevertheless, PRMT1 has been shown to be required for the growth promoting effects of
estrogen signaling and siRNA knockdown of PRMT1 has been shown to suppress the
growth of MCF7 cells (Le Romancer et al. 2008). As such, it is unclear whether PRMT1
represents a valid target for the development of an anticancer therapeutic, thereby
highlighting the critical need for developing bioavailable PRMT1 inhibitors that can be
used to specifically address this question. Additionally, the putative role of arginine
modifying enzymes in regulating kinase signaling highlight the possibility that the effects
of inhibitors targeting these enzymes may be due not only to effects on gene transcription
but also to effects on kinase signaling pathways. Again, this highlights the need for
additional research to examine the links between consensus crosstalk and human disease.
Finally, the fact that the mutation of K303 to an arginine residue in ERα is present in onethird of patients with premalignant hyperplasias (Fuqua et al. 2000) is highly interesting
because it suggest that cancer associated mutations can impinge on crosstalk. Given the
numerous PRMTs, PADs, and kinases, research in this area is undoubtedly an untapped
treasure waiting to be discovered.
6.1.7 Predicting Crosstalk
Given that protein kinase substrates can be readily predicted based on the
presence/absence of a particular consensus sequence, the most obvious question is
whether it is possible to predict crosstalk. The answer appears to be yes. Below we
predict potential crosstalk between Akt substrates and PRMT1-mediated methylation.
Note that we focused on these two enzymes because of prior precedents with Akt (see
above) and our own expertise in predicting PRMT1 substrates (Osborne et al. 2007).
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Additionally, PRMT1 is responsible for 85% of all PRMT activity in vivo (Tang et al.
2000 & Nicholson et al. 2009), thus it is likely that, if kinase consensus crosstalk is a
global mechanism for cellular regulation, PRMT1 would be the principal isozyme
involved. Nevertheless, it should be recognized that the same approach could be taken to
predict crosstalk between any given kinase with a known consensus sequence and a
lysine or arginine modifying enzyme whose substrate specificity determinants are known.
In contrast to kinases, the distinct substrate recognition sequences for PRMT1,
and the PRMTs in general, are relatively unknown. In an effort to determine a minimal
peptide substrate, based on the N-terminus of histone H4, our lab discovered that
positively charged residues distal to the site of methylation are important for substrate
recognition and catalysis (Osborne et al. 2007). This makes sense because the surface of
PRMT1 is negatively charged and therefore electrostatic interactions between the protein
and the substrate are likely present (Zhang et al. 2003 & Osborne et al. 2007). With this
knowledge, we investigated whether similarities are present between histone H4 and the
recently discovered PRMT1 substrates described above. As shown in Table 6.1, for
histone H4, BAD, and the FOXO family members, two arginine residues, in close
proximity to each other, are present distal to the site of methylation in addition to a
number of other positively charged residues.

This observation coincides with our

previous findings (Osborne et al. 2007). Closer examination of Akt substrates that failed
to be methylated by the PRMTs, (e.g., eNOS, p27, and GSK3) (Sakamaki et al. 2011)
shows that they lack distal positively charged residues throughout the intervening
sequences (Table 6.1). The one exception is MDM2. However in this case, the presence
of several negatively charged glutamates likely masks the presence of distal positively
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Table 6.1. Tested Substrates for PRMT1 and Akt
Protein

ab

Sequence

Function

3-RGKGGKGLGKGGAKRHRKVLRD-24
transcriptional regulation
Histone H4
a
94-RGRSRSAPPNLWAAQRYGRELRRM-117
pro-apoptotic
BAD
251-RRRAASMDNNSKFAKSRSRAAKKK-274
transcription (pro-apoptotic)
FOXO1ac
566-RSRSRSFSRHRSCSRSPYSRSRSR-589
gluconeogenesis
PGC-1ad
e
1172-RIRTQSFSLQERQLRGAVPWAFEP-1195
vasodilation, angiogenesis
e-NOS
e
4-RPRTTSFAESCKPVQQPSAFGSMK-27
cell cycle, apoptosis
GSK3-
152-RKRPATDDSSTQNKRANRTEENVS-175
cell cycle
p27e
161-RRRAISETEENSDELSGERQRKRH-184
proteolysis
MDM2e
181-RKRHKSDSISLSFDESLALCVIRE-204
proteolysis
MDM2e
a
Known PRMT1 substrate. bNot known to be an Akt Substrate. cNumbers correspond to human
FOXO1. Mouse FOXO1 begins at 248. dSites of methylation have not been identified. eNot a
PRMT1 Substrate. The light blue represents sites of methylationde. The red represents known sites
of Akt phosphorylation. The purple represents positively charged residues. The orange represents
negatively charged residues.

charged residues. In light of this analysis, we hypothesized that novel Akt/PRMT1
substrates can be predicted based on the identity of residues downstream from the kinase
consensus sequences (Table 6.2). Note that we have stratified the Akt substrates into
three groups, i.e., highly probable, likely, and unlikely PRMT1 substrates.

Highly

probable substrates were selected based on the presence of at least two distal arginine
residues separated by one or two variable residue(s), as these RXR and RXXR motifs are
a common theme among the known PRMT substrates. These predictions also include at
least one other distal positively charged residue in addition to these motifs. Likely
substrates include those Akt substrates that possess a number of positively charged
residues distal from the predicted sites of methylation, but do not possess the RXR or
RXXR motifs, or do not contain an additional positively charged residue. Note that
further studies will need to be conducted to determine whether lysine can substitute for
arginine in these positions or if the presence of several nonspecific positively charged
residues alone is enough for efficient substrate recognition and catalysis. The effect of
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Table 6.2. PRMT1 and Akt Crosstalk Predictions
A. Known PRMT1 & Akt Substrates
Protein
Sequence
Histone H4ab
BADa
FOXO1aa
FOXO3aa
FOXO4a
PGC-1ac

3-RGKGGKGLGKGGA----KRHRKVLRD-24
94-RGRSRSAPPNLWAAQ----RYGRELRRM-117
251-RRRAASMDNNSKFA-----KSRSRAAKKK-274
248-RRRAVSMDNSNKYT-----KSRGRAAKKK-271
192-RRRAASMDSSSKLL-----RGRSKAPKKK-215
566-RSRSRSFSRHRSCS-----RSPYSRSRSR-589

B. Highly Probable PRMT1 Substrates
Protein
Sequence
Acinus
B-Raf
Cot (Tpl2)
eIF4B
EZH2
FOXG1
HMOX1
PFKFB2
TERT
Tuberin
Tuberin

1175-RSRSRSRD-----------RRRKERAKSKEKKS-1198
424-RERKSSSSSED--------RNRMKTLGRRDSD-447
397-RCQSLDSALLE------RKRLLSREKEL-418
417-RSRTGSESSQTGTSTTSS-RNARRR-440
16-RKRVKSEYM----------RLRQLKRFRRADEVK-39
274-RRRSTTSRAKLAF------KRGARLTSTGL-107
183-RSRMNSLEMTPAV------RQRVIEEAKTA-206
461-RMRRNSFTPLSSSNTI---RRPRNYSV-484
222-RRRGGSASRSLPLP-----KRPRRGAAPE-245
934-RARSTSLNERPKSL-----RIARPPKQGL-957
1457-RPRGYTISDSAPS------RRGKRVERDAL-1480

C. Likely PRMT1 Substrates
Protein
Sequence
Arfaptin
Ataxin
CK1-D
GATA-1
GATA-2
p21
PDE3A
PRAS40
Skp2
TBC1D4
Tuberin

255-RGRLESAQATFQAH-----RDKYEKLRGD-278
771-RKRRWSAPES---------RKLEKSEDEPPLTL-794
365-RERKVSM------------RLHRGAPVNISSSD-388
305-RNRKASG------------KGKKKRGSSLGGTG-328
396-RNRKMSN------------KSKKSKKGAECFEE-419
140-RKRRQTSMTDFYHS-----KRRLIFSKRK-163
288-RRRRSSSVVSAEMSGCSS-KSHRRT-311
241-RPRLNTSDFQ---------KLKRKY-256
67-RKRLKSKGSDKDFVIV---RRPKLNRE-90
637-RRRAHTFSHPPSST-----KRKLNLQDGR-660
976-RCRSISVSEHVV-------RSRIQTSLTSAS-999

D. Unlikely PRMT1 Substrates
Protein
Sequence
AR
AR
BIM
IRS-1
mTOR
Nur77
p300
Rac1

208-RAREASGAPTSSKDYNLGGTSTIS-231
786-RMRHLSQEFGQLQITPQEFLCMKA-809
84-RRSSLLSRSSSGYFSFDTDRSP-105
522-RKRTHSAGTSPTITHQKTPSQSSV-545
2443-RTRTDSYSAGQSVEILDGVELGEP-2466
346-RGRLPSKPKQPPDASPANLLTSLV-369
1829-RRRMASMQRTGVVGQQQGLPSPTP-1852
66-RLRPLSYPQTDVFLICFSLVSPAS-89

Function
transcriptional regulation
pro-apoptotic
transcription (pro-apoptotic)
transcription (pro-apoptotic)
transcription (pro-apoptotic)
gluconeogenesis

Function
apoptosis
Erk1/2 pathway
oncogene
translation initiation
methyltransferases
transcription
heme oxigenase
glycolysis
telomerase reverse transcriptase
tumor suppressor
tumor suppressor

Function
cell survival
neurodegeneration
circadian clock
transcription factor
transcription factor
cell cycle
regulates cAMP and cGMP
insulin signaling
E3 ubiquitin ligase
Glut4 trafficking
tumor suppressor

Function
nuclear receptor
nuclear receptor
pro-apoptotic
insulin receptor signaling
cell growth
nuclear receptor
transcriptional coactivator
Rho-GTPase

a

Known PRMT1 substrate. bNot known to be an Akt Substrate. cNumbers correspond to human
FOXO1. Mouse FOXO1 begins at 248. dSites of methylation have not been identified. eNot a PRMT1
Substrate. The light blue represents sites of methylationde. The red represents known sites of Akt
phosphorylation. The purple represents positively charged residues. The orange represents negatively
charged residues.

the presence and position of negatively charged residues on substrate recognition also
will need further investigation because, as mentioned above, they likely mask the
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positively charged residues. Validation of the predicted PRMT1 and Akt substrates
would indicate that consensus crosstalk is a general mechanism to control eukaryotic cell
signaling.
6.1.8 Research Overview
Herein we describe our initial efforts toward proving that crosstalk between
arginine methylation and phosphorylation of serine/threonine residues exists and is
possible to predict.

Although studies by other groups have already demonstrated

crosstalk between PRMT1 and Akt in regards to FOXO1 (see Section 6.1.1), our results
with this model will be used as a proof of concept before moving on to our predicted
models (i.e., EZH22 & B-Raf). The determination of a minimal peptide substrate for
FOXO1, the effect of serine phosphorylation on substrate recognition by PRMT1,
processivity experiments, as well as initial efforts to investigate crosstalk between
phosphorylation and deminination will be described.
6.2 Materials and Methods
6.2.1 Chemicals
Sodium

dodecyl

sulfate

(SDS), tris(hydroxymethyl)aminomethane

(TRIS),

tetramethylethylenediamine, acrylamide, and ammonium persulfate were purchased from
Bio-Rad (Hercules, CA). 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
Tricine, dithiothreitol (DTT) were purchased from RPI (Mt. Prospect, IL). Acetonitrile
and methanol were purchased from Fisher Scientific (Pittsburgh, PA). Sodium chloride
and dimethylformamide (DMF) were purchased from Alfa Aesar (Ward Hill, MA).
Piperidine was purchased from Sigma-Aldrich (St. Louis, MO). Fmoc-protected amino
acids, (ethylenedinitrilo)tetraacetic acid (EDTA), and trifluoroacetic acid (TFA) were
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purchased from EMD (Gibbstown, NJ).
Elmer and

14

14

C-labeled SAM was purchased from Perkin-

C-labeled BSA from Sigma-Aldrich. The purification of PRMT1 and the

synthesis of the AcH4-21, FOXO1-21, FOXO1-22, and FOXO-30 peptides are outlined
in Chapter 2.
6.2.2 Purification of PAD4
The purification of PAD4 has been described (Knuckley et al. 2007). In brief, a
pGEX-6P-1 construct (Nakashima et al. 1999) containing the PAD4 gene and an Nterminal GST tag was transformed into E. coli Rosetta cells. One colony was used to
inoculate 5 mL starter cultures containing 50 μg/mL ampicillin and 20 μg/mL
chloramphenicol and incubated overnight with shaking at 37 °C. One liter of TB media
was inoculated with 10 mL of overnight culture containing 50 μg/mL ampicillin and 20
μg/mL chloramphenicol and grown at 37 °C and 250 rpm until OD600 = 0.8-1.0. Protein
expression was then induced with 0.3 mM isopropyl-β-D-thiogalactopyranoside and the
cells were incubated with shaking at 16 °C overnight. The next day the cells were
harvested by centrifugation at 5000 rpm (4400 g) for 10 min. The pellet was resuspended
in 30 mL of Lysis Buffer (20 mM Tris-HCl pH 8, 1 mM EDTA, 1 mM DTT, 400 mM
NaCl, 20% glycerol) plus 2 mL of protease inhibitor cocktail (Sigma-P8465). Cells were
mixed slowly for 30 min at 4 °C before being lysed by sonication (13 cycles of 15 sec
burst with 1 min rest at output of 10 and a constant duty cycle). The lysate was
centrifuged at 14,000 rpm (21,808 g) for 30 min and the supernatant was applied to a
Glutathione Sepharose 4B (GE Healthcare) column. The column was washed with 50
mL of a low salt buffer (20 mM Tris-HCl pH 8, 1 mM EDTA, 1 mM DTT, 250 mM
NaCl, and 10% glycerol), 50 mL of a high salt buffer (20 mM Tris-HCl pH 8, 1 mM
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EDTA, 1 mM DTT, 500 mM NaCl, and 10% glycerol), and eluted with two 25 mL
washes of glutathione buffer (50 mM Tris-HCl pH 8.0, 1 mM DTT, and 10 mM reduced
glutathione pH 8.0). Fractions were screened on a 12% SDS-PAGE gel and 10 µL of
Prescission Protease (GE Healthcare) was added to fractions containing protein followed
by dialysis overnight in 20 mM Tris-HCl pH 7.6, 1 mM EDTA, 2 mM DTT, and 500 mM
NaCl. Dialysis buffer was exchanged 3x to remove excess glutathione. The next day the
protein was re-applied to the Glutathione Sepharose 4B column and collected followed
by a 50 mL column wash of glutathione buffer (see above). The flow through was
dialyzed against 20 mM Tris-HCl pH 8.0, 1 mM EDTA, 50 mM NaCl, and 2 mM DTT
for 3 h. The dialyzed protein was additionally purified by FPLC using a HiTrap Q Fast
Flow column (GE Healthcare) with 20 mM Tris-HCl pH 8.5 and 2 mM DTT as buffer A
and a linear gradient from 0-100% of buffer B (20 mM Tris-HCl pH 8.5, 2 mM DTT, and
1 M NaCl). Fractions were screened on a 12% SDS-PAGE gel and by a COLDER
activity assay. Fractions containing pure and active protein were dialyzed overnight in 20
mM Tris-HCl pH 8.0, 1 mM EDTA, 2 mM DTT, 500 mM NaCl, and 10% glycerol. The
next day the protein was concentrated using a 10 kDa Amicon Centriplus centrifugal
filter and the concentration was determined using a Bradford assay. The enzyme was
flash frozen in liquid nitrogen and stored at -80 °C.
6.2.3 Gel-Based Activity Assay
A gel-based activity assay was used to acquire the steady state kinetic parameters
of PRMT1 and has been previously described. (Osborne et al. 2007). Assays were
performed in a reaction mixture of 50 mM HEPES pH 8.0, 1 mM EDTA, 50 mM NaCl,
0.5 mM dithiothreitol, 15 μM [14C]-labeled SAM, and a varying concentration of peptide
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(0-1000 μM final). Reactions were pre-incubated at 37 °C for 10 min before the addition
of PRMT1. Assays with AcH4-21 were quenched after 15 min and assays with the
FOXO1 peptides were quenched after 1 h. Each assay was done in duplicate and the
standard deviation of the duplicate raw data values agreed within ≤ 20%. The GraFit
version

5.0.11

software

(Leatherbarrow

2004)

was

used

to

fit

the

data

to eq 1,
υ = Vmax[S]/(Km+[S])

(1),

6.2.4 COLDER Based Activity Assay
Reaction mixtures of 100 mM Tris-HCl pH 7.6, 10 mM CaCl2, 50 mM NaCl, 2
mM dithiothreitol, and a varying concentrations of benzoyl arginine ethyl ester (BAEE)
(0-10 mM) or peptide substrates (0-1mM final) were pre-incubated at 37 °C for 10 min.
The reactions were initiated by the addition of PAD4 (0.2 µM final), giving a total
volume of 60 µL. Reactions were incubated for 6 min at 37 °C before being quenched by
liquid nitrogen. Color development was accomplished by the addition of 200 µL of
COLDER Solution (2.25 M H3PO4, 4.5 M H2SO4, 1.5 mM NH4Fe(SO4), 20 mM diacetyl
monoxime, and 1.5 mM thiosemicarbazide), followed by vortexing and incubation at 95
°C for 30 min. The absorbance for each reaction was measured at 540 nm and the
amount of citrulline produced was determined using a citrulline standard curve. Each
assay was done in duplicate and the standard deviation of the duplicate raw data values
agreed to within ≤ 20%. The GraFit version 5.0.11 software (Leatherbarrow 2004) was
used to fit the data to eq 1.
6.2.7 MALDI-MS Based Activity Assay
The processivity of PRMT1 was determined using a matrix assisted laser
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desorption/ionization (MALDI) MS based assay that was previously described (Osborne
et al. 2007). Assays were performed in a reaction mixture of 50 mM HEPES pH 8.0, 1
mM EDTA, 50 mM NaCl, 500 μM SAM, and 20 μM AcH4-21 or FOXO1-22. Reactions
were then pre-incubated at 37 °C for 10 min followed by the addition of PRMT1 (500
nM final).

The reaction was quenched with 3 μL of 50% TFA in ddH2O at the

appropriate time point. Spectra were acquired on an Applied Biosystems 4800 Plus
MALDI TOF/TOF MS and analyzed using Data Explorer® software.

The percent

turnover was determined by dividing the intensity of the modified peptide by the sum of
the intensities of the unmodified and modified substrates times 100%.
For the PAD4 activity assay, a reaction mixture of 100 mM Tris-HCl pH 7.6, 10
mM CaCl2, 50 mM NaCl, 2 mM dithiothreitol, and 1 mM FOXO1-22 were pre-incubated
at 37 °C for 10 min. The reactions were initiated by the addition of PAD4 (0.2 µM final),
incubated for 0 min and 60 min at 37 °C, and then quenched by liquid nitrogen.
Reactions were desalted using a C18 ZipTip and spectra were acquired using an Applied
Biosystems 4800 Plus MALDI TOF/TOF MS. The spectra were analyzed using Data
Explorer® software.
6.3 Results and Discussion
6.3.1 Identifying a Minimal Peptide Substrate
FOXO1 is methylated by PRMT1 at R251 and R253 (human numbering)
(Yamagata et al. 2008); the original numbers (R248 and R250) are for mouse FOXO1.
Because we have previously demonstrated that peptides can be used in place of full
proteins for kinetic studies (Osborne et al. 2007), we first sought to identify a minimal
peptide substrate for FOXO1. The use of peptides in place of proteins has several
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advantages, i.e., the ability to achieve higher concentrations for use in determining kinetic
parameters, as well as the ability to easily mimic different post translational
modifications. The sequences of the peptides tested against PRMT1 can be found in
Table 6.3. Note that AcH4-21 is the minimal peptide substrate previously determined for
Histone H4 and was used for kinetic comparison because it is an excellent substrate for
PRMT1. All three FOXO1 sequences contain the sites of methylation with variation at
the N- and C-termini. The kinetic parameters for these four peptides can be found in
Table 6.4.
Table 6.3 Peptide Sequences
Peptide

Sequence
Ac-1SGRGKGGKGLGKGGAKRHRKV21

AcH4-21
FOXO1-21

Ac-245KSGKSPRRRAASMDNNSKFAK265

FOXO1-22

Ac-249SPRRRAASMDNNSKFAKSRSRA265

FOXO1-30

Ac-245KSGKSPRRRAASMDNNSKFAKSRSRAAKKK265

Table 6.4 Kinetic parameters of PRMT1 for the FOXO1 peptide substrates
Km

Fold

kcat

Fold

AcH4-21a

1.1 ± 0.5

-----

4.6 x 10-1 ± 2 x 10-2

FOXO1-21a

110 ± 20

100

FOXO1-22a

23 ± 8.5

FOXO1-30a

20 ± 13

Peptide

a

(µM)

kcat/Km

Fold

-----

4.1 x 105

-----

4.3 x 10-2 ± 2 x 10-3

11

3.8 x 102

1079

20

1.46 x 10-1 ± 9 x 10-3

3.2

6.4 x 103

64

18

2.0 x 10-1 ± 2 x 10-2

2.3

8.6 x 103

48

(min-1)

(M-1·min-1)

[SAM] = 15 μM.

Based on the observed kinetic parameters, the results clearly show that positively
charged residues distal to the site of methylation are important for substrate recognition.
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For example, there is a ~ 5-fold decrease in Km between FOXO1-21 and the two longer
peptides, which each contain 2 or more additional positively charged residues at their Ctermini. This observation is consistent with our hypothesis (see Section 6.1.7) that
PRMT1 substrates can be predicted based on the sequence C-terminal to the site of
methylation (Table 6.2). Note that while FOXO1-30 has the lowest fold decrease in
kcat/Km (~ 48-fold) relative to AcH4-21, longer peptides tend to be more difficult to
synthesize. Additionally, the ~1.3-fold difference in the kcat/Km values for FOXO1-30
and FOXO1-22 is not significant. Therefore, FOXO1-22 was chosen as the minimal
peptide substrate for use in future studies.
6.3.2 Processivity of PRMT1 with FOXO1-22
Although previous studies utilized an antibody that was raised towards a FOXO1
peptide that contained asymmetric dimethylarginine at R251 and R253 (Yamagata et al.
2008), the total extent of methylation at these positions (i.e., ω-MMA, ADMA, or a
mixture of both) has not been confirmed. It is also uncertain as to whether PRMT1 uses a
processive or distributive mechanism with this substrate, i.e., the production of ω-MMA
and ADMA before substrate release versus substrate release after ω-MMA formation
followed by rebinding of the substrate and SAM for the formation of ADMA. Note that
it was previously determined that with the AcH4-21 peptide, PRMT1 uses a partially
processive mechanism (Osborne et al. 2007) (Figure 6.4A).

The presence of two

potentially methylated arginine residues in FOXO1-22, compared to one in AcH4-21,
adds an additional level of complexity, because processivity can result from the
formation of ω-MMA and ADMA on a single residue or it can also describe whether both
arginine

residues

are

sequentially

methylated
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Figure 6.4 Processivity of PRMT1. (A) With AcH4-21 as a substrate, PRMT1
utilizes a partially processive mechanism in which a second molecule of SAM can
rebind to form ADMA prior to release of ω-MMA, but ω-MMA can also be released
prior to rebinding of SAM. (B) The FOXO1-22 peptide contains the addition of up
to four methyl groups, however, the majority of methylated peptides contain only 2
methyl groups.
Nevertheless, as an initial effort to better characterize the mechanism of methylation of
FOXO1, a MALDI-based mass spectrometry assay was used to assess the formation of
the methylation products over time (Figure 6.4). The results show up to four methylation
events, which is consistent with two arginine residues being dimethylated. However,
methylation appears to be quite slow, with the majority of peptides only containing one
or two methyl groups. In order to determine the order of methylation, i.e., whether these
two methylation events takes place on the same arginine residue or if ω-MMA is present
on both R251 and R253, further analysis using MS/MS will need to be performed.
6.3.3 Effect of Serine Phosphorylation on PRMT1-Dependent Methylation
FOXO1 is phosphorylated by Akt at S256 (human numbering).

As stated

previously, studies have shown that methylation by PRMT1 prevents phosphorylation but
the reverse is not observed (Yamagata et al. 2008).
150

To determine the effect of

phosphorylation on methylation in our peptide model, S256 of FOXO1-22 was
substituted with glutamate to mimic phosphoserine (FOXO1-22(S256E)). The kinetic
parameters of PRMT1 with this mutant can be seen in Table 6.5. The results show a ~
3.1-fold increase in Km compared to the WT FOXO1-22 peptide and a ~ 4.9-fold decrease
in kcat/Km, thus demonstrating that phosphorylation likely has a small but significant
effect on methylation. The discrepancy between our study and Yamagata et al. may lie in
the fact that the authors only made a visual observation and thus the conclusion was only
relative and not based on quantification. It is also possible that other residues in FOXO1
are critical for methylation, thus demonstrating the need for kinetic analysis with the full
length protein to determine if our peptide model is relevant.
Table 6.5 Kinetic parameters of PRMT1 for the FOXO1 peptide substrates
Km

Fold

FOXO1-22a

23 ± 8.5

FOXO1-22
(S256E)a

72 ± 13

Peptide

a

(µM)

kcat

Fold

-----

1.46 x 10-1 ± 9 x 10-3

3.1

9.8 x 10-2 ± 4 x 10-3

(min-1)

kcat/Km

Fold

-----

6.4 x 103

-----

1.5

1.3 x 103

4.9

(M-1·min-1)

[SAM] = 15 μM.

6.3.4 FOXO1 as a PAD4 Substrate
As mentioned previously, because the PAD family of enzymes also modifies
arginine residues, there is the possibility for crosstalk between deimination and
phosphorylation. To test whether FOXO1 is a potential substrate for PAD4, kinetic
parameters were determined with the FOXO1 peptides. Benzoyl arginine ethyl ester
(BAEE), an excellent PAD4 substrate, is used for comparison (Table 6.6). The data show
that all three FOXO1 peptides are good substrates for PAD4. Previous studies in our lab
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Table 6.6 Kinetic parameters of PAD4 for the FOXO1 peptide substrates
Km

Fold

kcat

Fold

BAEE

0.4 ± 0.10

-----

6.2 ± 3 x 10-1

FOXO1-21

0.2 ± 0.08

0.5

FOXO1-22

0.2 ± 0.03

FOXO1-30

0.4 ± 0.07

Peptide

(mM)

kcat/Km

Fold

-----

1.6 x 104

-----

6.8 x 10-1 ± 9 x 10-2

9.1

3.3 x 103

4.7

0.5

4.5 ± 3 x 10-1

1.3

2.3 x 104

0.7

1

2.8 ± 2 x 10-1

2.2

6.3 x 103

2.5

(min-1)

(M-1·min-1)

with PAD4 have demonstrated that the enzyme is capable of deiminating multiple
arginine residues on a single peptide, thus the slower kcat values for FOXO1-22 may be
due to the lack of two additional arginine residues compared to the other peptides. To
determine the number of arginine residues that are converted to citrulline on FOXO1-22
by PAD4, the enzyme was reacted with the peptide for 1 h before being analyzed by

% Intensity

MALDI-MS (Figure 6.5). A mass shift of 3 Da indicates that three arginine residues are
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Figure 6.5 Mass spectrometric analysis of the deimination of FOXO1-22 by PAD4.
A 3 Da shift is observed between (A) the control reaction minus PAD4 and (B) plus
PAD4, thus demonstrating the conversion of three arginine residues to citrulline.
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converted to citrulline, as this modification adds 1 Da to the residue mass. Because all
three peptides contain at least three arginine residues, it remains uncertain as to whether
the slower catalysis observed with FOXO1-21 is due to a smaller number of arginine
residues or a difference in substrate recognition elements.
6.3.5 Effect of Serine Phosphorylation on PAD4-Dependent Deimination
Because FOXO1 is a potential substrate for PAD4 based on our peptide model,
we next wanted to investigate the effect of phosphorylation on deimination. As with
PRMT1, the kinetic parameters were determined for PAD4 with the S256E mutant (Table
6.7). Interestingly, the results show that phosphorylation has a very similar effect on
PAD4-dependent deimination as it did with PRMT1-dependent methylation with an ~
4.7-fold decrease in kcat/Km that can be attributed to an increase in Km. These results
suggest that the presence of a negatively charged residue or residues C-terminal to the
potentially modified arginine residue(s) has a negative effect on substrate recognition for
both PRMT1 and PAD4.
Table 6.7 Kinetic parameters of PAD4 for the FOXO1 peptide substrates
Km

Fold

FOXO122a

0.2 ± 0.03

FOXO1-22
(S256E)a

0.87 ± 0.09

Peptide

a

(mM)

kcat

Fold

-----

4.5 ± 3 x 10-1

4.4

4.3 ± 4 x 10-1

(min-1)

kcat/Km

Fold

-----

2.3 x 104

1.1

1

4.9 x 103

4.7

(M-1·min-1)

[SAM] = 15 μM.

6.4 Conclusions
There are currently several examples of crosstalk between arginine methylation
and serine/threonine phosphorylation (vide supra). Based on these examples and our
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knowledge of PRMT1 catalysis, we have hypothesized that this form of crosstalk is a
common mechanism of regulation in cell signaling pathways and that it can likely be
predicted based on the sequence surrounding an Akt consensus motif (Table 6.2). Before
exploring our theory, we first wanted to better characterize an already known crosstalk
model, specifically that of FOXO1, to use as a basis for subsequent studies.
In vitro and in vivo studies have demonstrated that FOXO1 is methylated at R251
and R253. These sites of methylation have only been confirmed by mutation to lysine
residues and the use of an antibody that was raised towards a peptide that contained
asymmetric dimethylarginine at these positions (Yamagata et al. 2008).

Therefore,

confirmation by mass spectrometry is still needed and is currently underway in our lab.
To further characterize the mechanism of PRMT1-dependent methylation of FOXO1,
initial studies were conducted to determine a minimal peptide substrate (because of the
ease of working with peptides in comparison to full length proteins) and the fact that the
peptide models have worked well for other PRMT1 substrates (i.e., histone H4).
FOXO1-22 was determined to be a sufficient peptide substrate, although kinetic studies
still need to be conducted with the full length protein to confirm that this model works for
this particular substrate. However, the observed results could aid in defining a possible
consensus sequence for PRMT1-dependent methylation.
Because the exact methylation products (i.e., ω-MMA, ADMA, or a mixture of
both) at R251 and R253 have also not been confirmed by mass spectrometry, initial
studies were done to further characterize methylation of these residues. Although a
degree of complication exists because there are two potentially methylated residues as
opposed to one, a MALDI-based assay was used to quantify the transfer of methyl groups
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to FOXO1-22. The data show that up to four methyl groups are added to the peptide,
however, the addition of only one or two methyl groups is predominant. Further studies,
such as MS/MS, will be needed to confirm the processivity of PRMT1 towards FOXO1.
FOXO1 is phosphorylated at S256 and this phosphorylation event is inhibited by
arginine methylation of R251 and R253, however, phosphorylation did not affect
methylation (Yamagata et al. 2008). However, the latter conclusion was only based on
relative amounts, therefore, we sought to confirm this observation using our peptide
substrate. The S256 residue of the FOXO1-22 peptide was exchanged for a glutamate to
mimic phosphoserine. Although small, the observed decrease in kcat/Km (~ 4.9-fold) is
significant, suggesting that phosphorylation can subtly modulate PRMT1 activity. This
result will need to be confirmed with the full length protein to determine if other residues
surrounding the site of methylation compensate for the addition of a phosphate group.
Since PAD4 also modifies arginine residues within proteins, we examined
whether our FOXO-22 peptide was a substrate for PAD4. The results show that all three
of the FOXO1 peptides are substrates for the enzyme. The PAD4-FOXO1 reaction was
also analyzed by mass spectrometry, which showed that three arginine residues are
deiminated on the FOXO1-22 peptide.

A similar effect was observed with PAD4

compared to PRMT1 in regards to the FOXO1-22(S256E) peptide, thus suggesting a
common link between the consensus sequences of arginine modifying enzymes. Future
studies will involve trying to confirm if FOXO1 is actually deiminated in vivo.
Overall, the aforementioned studies are only our initial efforts towards proving
our crosstalk hypothesis, as much more work needs to be done. Future efforts will
include kinetic studies with the full length protein, to confirm that FOXO1-22 can be
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used to study the PRMT1-FOXO1 mechanism, and confirmation of the methylation sites
by mass spectrometry. Our PRMT1 inactivator, C21, will be used to to examine the
crosstalk mechanism between methylation and phosphorylation of FOXO1 in vivo. We
will then proceed in the same manner with other predicted substrates.
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CHAPTER 7
Conclusions & Future Directions
Protein post-translational modifications (PTMs) play a variety of roles in the cell
by affecting protein-protein interactions, the cellular location of proteins, and protein
stability. Due to their importance in normal cellular function, dysregulation of a variety
of PTMs has been linked to a plethora of diseases (e.g., cancer and autoimmune
diseases), therefore making them effective drug targets. Our lab is focused on arginine
modifying enzymes, more specifically the Protein Arginine Methyltransferases (PRMTs).
This family of nine isozymes catalyzes the transfer of a methyl group from Sadenosylmethionine (SAM) to the guanidinium moiety of arginine residues in proteins,
generating an ω-monomethylarginine residue (ω-MMA), which can then be further
methylated to produce either an asymmetrically dimethylated arginine residue (ADMA)
or a symmetrically dimethylated arginine (SDMA) residue. Of the nine family members,
we are most interested in PRMT1 because it is thought to be responsible for the majority
of asymmetrically dimethylated arginine residues in the cell (Tang et al. 2000 & Pawlak
et al. 2000). In addition, a variety of studies have suggested that the enzyme plays an
important role in the onset of diseases such cancer, heart disease, and ALS.
In order to begin to better understand the roles that PRMT1 plays in healthy and
diseased cells, we first investigated the catalytic mechanism of the enzyme. Using sitedirected mutagenesis, we confirmed the importance of several active site residues to
catalysis (i.e., E153 and H293) and substrate/cofactor binding (i.e., M155 & H293). We
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also determined that H293 likely does not act as a general base in the mechanism.
Finally, our results suggest that prior deprotonation of the guanidinium is not required
and the reaction is simply catalyzed by bringing the cofactor and substrate into close
proximity.
We next set out to probe the means by which PRMT1 activity is regulated.
Although several of the PRMT family members have been found to be regulated by
PTMs, the regulation of PRMT1 by this method has yet to be revealed. According to
curated mass spectrometry data from PhosphoSitePlus® (www.phosphosite.org), PRMT1
is potentially phosphorylated, ubiquitylated, and acetylated in the cell (Hornbeck et al.
2012). As a starting point, we investigated two possibly phosphorylated residues, i.e.,
S102 and Y291. Using site-directed mutagenesis and the incorporation of pCMF, a
stable phosphotyrosine mimic, we determined the effect that phosphorylation of these
individual residues would have on activity.

The S102 residue, which is conserved

amongst Type I PRMTs, is important for CARM1 activity and phosphorylation of this
residue prevents SAM binding and abolishes activity. The results show, however, that
phosphorylation of S102 does not affect PRMT1 activity and thus modification of this
residue is likely not a mechanism for regulating this enzyme. The Y291 residue, which
was chosen based on PhosphoSitePlus® (www.phosphosite.org) data, appears to play a
role in substrate binding, as demonstrated by increases in the Km values for the Y291A,
Y291E, and Y291pCMF mutants. Although we hypothesized that phosphorylation of
this residue would greatly affect overall activity, especially SAM binding, the results
suggest that the interaction between H293 and D51 is enough to hold the N-terminal αhelix in place for proper SAM binding. It is also possible that pCMF does not fully
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mimic phosphotyrosine because it is lacking a negative charge and a greater effect on
SAM binding would be observed in vivo. However, based on studies showing that the Nterminal splice variants of PRMT1 have different substrate specificities, we hypothesize
that phosphorylation of this residue may destabilize the N-terminal tail and alter the
substrate specificity. Future studies will involve, not only further investigation into the
effect of phosphorylation of Y291, but also the effect of other potentially phosphorylated
PRMT1 residues, and a search for the responsible kinases.
PTMs are not the only means of enzyme regulation, as protein-protein interactions
have also been found to affect the activity of the PRMTs. PRMT1 has two known
interacting proteins, CAF1 and BTG1, which appear to inhibit and/or enhance activity in
a substrate specific manner (Lin et al. 1996, Berthet et al. 2002, Robin-Lespinasse et al.
2007). To characterize the effects of these two proteins from a mechanistic point of
view, we performed assays in vitro with increasing concentrations of CAF1 or BTG1.
The results suggest that CAF1 binds to histone H4 and inhibits methylation, but it can
also bind PRMT1 and target it to the histone. On the other hand, BTG1 appears to bind
both PRMT1 and histone H4, but does not inhibit activity. Future studies will involve
examining the effects of these two proteins in regards to other histones, as well as,
immunoprecipitation experiments to confirm that they can interact with PRMT
substrates.
PRMT1 appears to be involved in a variety of diseases, and thus one of our main
goals is to develop potent and selective inhibitors and inactivators for the enzyme. We
have previously described C21, the most potent PRMT1 inhibitor to date (Obianyo et al.
2010); however, it was not known which residue was covalently modified. MS/MS was
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used to identify an active site cysteine, C101, as the site of modification. Although this
residue is not important for catalysis, as demonstrated by the fact that the kinetic
parameters are similar to the WT enzyme, other studies have shown that it is a hyperreactive cysteine (Weerapana et al. 2010). Interestingly, only PRMT1 and PRMT8 have
an active site cysteine residue as this position, as PRMT3 and CARM1 each have a
cysteine residue that is buried away from the active site. In an attempt to target C101 and
potentially develop a new PRMT1 selective inhibitor, we coupled a chloroacetamidine
warhead to the adenosine portion of SAM to create Cl-acetamidino-N-ethylaminoadenosine. Although it is not nearly as potent as C21, it is irreversible, and
comparison of the IC50 for the compound with N-ethyl-aminoadenosine and adenosine
show that the warhead is essential for inhibition. As this is only a first generation
inhibitor, future studies will involve designing and synthesizing SAM analogues based on
SAH with a warhead attached. In addition, PRMT5 has an active site cysteine residue
that is in the SAM binding pocket but on the opposite side of C101. We hypothesize that
we will be able to create selective inhibitors for both of these enzymes by fine tuning the
position of a warhead on SAH.
Finally, there are several examples that demonstrate crosstalk between arginine
methylation and phosphorylation within kinase consensus sequences, more specifically
between PRMT1 and Akt. In the case of FOXO1, studies have shown that methylation of
R251 and R253 prevents the phosphorylation of S256 by Akt, however, prior
phosphorylation does not affect methylation (Yamagata et al. 2008). Based on this
example, and several others, and examination of the sequences of Akt substrates, we
hypothesize that we can predict crosstalk between these two modifications. We have
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previously shown that positively charged residues C-terminal and distal to the site of
methylation are important for substrate recognition (Osborne et al. 2007). Therefore, the
presence of positively charged residues C-terminal to arginine residues within kinase
consensus sequences are likely an indicator that the substrate can be methylated by
PRMT1 and that this methylation inhibits phosphorylation. Before testing predicted
substrates, we first set out to characterize crosstalk in regards to FOXO1. Analysis of the
kinetic parameters of PRMT1 with peptides based on the methylated sequence of FOXO1
confirmed our suspicion that positively charged residues are critical. The results also
showed that prior phosphorylation does have a small effect on substrate binding. In
addition, the FOXO1 peptides were found to be good substrates for PAD4, an enzyme
which converts arginine to citrulline in proteins. Future studies will be focused on
confirming the sites of methylation with the full length FOXO1 protein, examining
crosstalk between methylation and phosphorylation of FOXO1 in vivo with C21, our
PRMT1 inhibitor, attempting to identify deiminated FOXO1 in vivo. We will also use
these same methods to attempt to identify crosstalk within our predicted PRMT1
substrates.
In conclusion, the results presented in the previous chapters have given us further
insight into the catalytic mechanism of PRMT1-dependent methylation and the regulation
of enzyme activity by phosphorylation and protein-protein interactions. They have also
laid the groundwork for the development of more potent and selective inhibitors for
PRMT1 and PRMT5, as well as, the prediction of crosstalk between arginine methylation
and phosphorylation.
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